Compositions and methods for inhibiting expression of the PCSK9 gene

Information

  • Patent Grant
  • 9822365
  • Patent Number
    9,822,365
  • Date Filed
    Monday, January 25, 2016
    8 years ago
  • Date Issued
    Tuesday, November 21, 2017
    6 years ago
Abstract
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
Description
SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 21, 2015, is named 32851US_sequencelisting.txt, includes 1505 sequences (see <160>), and is 563 KB in size.


FIELD OF THE INVENTION

This invention relates to double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference to inhibit the expression of the PCSK9 gene and the use of the dsRNA to treat pathological processes which can be mediated by down regulating PCSK9, such as hyperlipidemia.


BACKGROUND OF THE INVENTION

Proprotein convertase subtilisin kexin 9 (PCSK9) is a member of the subtilisin serine protease family. The other eight mammalian subtilisin proteases, PCSK1-PCSK8 (also called PC1/3, PC2, furin, PC4, PC5/6, PACE4, PC7, and SIP/SKI-1) are proprotein convertases that process a wide variety of proteins in the secretory pathway and play roles in diverse biological processes (Bergeron, F. (2000) J. Mol. Endocrinol. 24, 1-22, Gensberg, K., (1998) Semin. Cell Dev. Biol. 9, 11-17, Seidah, N. G. (1999) Brain Res. 848, 45-62, Taylor, N. A., (2003) FASEB J. 17, 1215-1227, and Zhou, A., (1999) J. Biol. Chem. 274, 20745-20748). PCSK9 has been proposed to play a role in cholesterol metabolism. PCSK9 mRNA expression is down-regulated by dietary cholesterol feeding in mice (Maxwell, K. N., (2003) J. Lipid Res. 44, 2109-2119), up-regulated by statins in HepG2 cells (Dubuc, G., (2004) Arterioscler. Thromb. Vasc. Biol. 24, 1454-1459), and up-regulated in sterol regulatory element binding protein (SREBP) transgenic mice (Horton, J. D., (2003) Proc. Natl. Acad. Sci. USA 100, 12027-12032), similar to the cholesterol biosynthetic enzymes and the low-density lipoprotein receptor (LDLR). Furthermore, PCSK9 missense mutations have been found to be associated with a form of autosomal dominant hypercholesterolemia (Hchola3) (Abifadel, M., et al. (2003) Nat. Genet. 34, 154-156, Timnms, K. M., (2004) Hum. Genet. 114, 349-353, Leren, T. P. (2004) Clin. Genet. 65, 419-422). PCSK9 may also play a role in determining LDL cholesterol levels in the general population, because single-nucleotide polymorphisms (SNPs) have been associated with cholesterol levels in a Japanese population (Shioji, K., (2004) J. Hum. Genet. 49, 109-114).


Autosomal dominant hypercholesterolemias (ADHs) are monogenic diseases in which patients exhibit elevated total and LDL cholesterol levels, tendon xanthomas, and premature atherosclerosis (Rader, D. J., (2003) J. Clin. Invest. 111, 1795-1803). The pathogenesis of ADHs and a recessive form, autosomal recessive hypercholesterolemia (ARH) (Cohen, J. C., (2003) Curr. Opin. Lipidol. 14, 121-127), is due to defects in LDL uptake by the liver. ADH may be caused by LDLR mutations, which prevent LDL uptake, or by mutations in the protein on LDL, apolipoprotein B, which binds to the LDLR. ARH is caused by mutations in the ARH protein that are necessary for endocytosis of the LDLR-LDL complex via its interaction with clathrin. Therefore, if PCSK9 mutations are causative in Hchola3 families, it seems likely that PCSK9 plays a role in receptor-mediated LDL uptake.


Overexpression studies point to a role for PCSK9 in controlling LDLR levels and, hence, LDL uptake by the liver (Maxwell, K. N. (2004) Proc. Natl. Acad. Sci. USA 101, 7100-7105, Benjannet, S., et al. (2004) J. Biol. Chem. 279, 48865-48875, Park, S. W., (2004) J. Biol. Chem. 279, 50630-50638). Adenoviral-mediated overexpression of mouse or human PCSK9 for 3 or 4 days in mice results in elevated total and LDL cholesterol levels; this effect is not seen in LDLR knockout animals (Maxwell, K. N. (2004) Proc. Natl. Acad. Sci. USA 101, 7100-7105, Benjannet, S., et al. (2004) J. Biol. Chem. 279, 48865-48875, Park, S. W., (2004) J. Biol. Chem. 279, 50630-50638). In addition, PCSK9 overexpression results in a severe reduction in hepatic LDLR protein, without affecting LDLR mRNA levels, SREBP protein levels, or SREBP protein nuclear to cytoplasmic ratio. These results indicate that PCSK9, either directly or indirectly, reduces LDLR protein levels by a posttranscriptional mechanism


Loss of function mutations in PCSK9 have been designed in mouse models (Rashid et. al., (2005) PNAS, 102, 5374-5379., and identified in human individuals Cohen et al., (2005), Nature Genetics., 37, 161-165. In both cases loss of PCSK9 function lead to lowering of total and LDLc cholesterol. In a retrospective outcome study over 15 years, loss of one copy of PCSK9 was shown to shift LDLc lower and to lead to an increased risk-benefit protection from developing cardiovascular heart disease (Cohen et. al., 2006 N. Engl. J. Med., 354., 1264-1272.). Clearly the evidence to date indicates that lowering of PCSK9 levels will lower LDLc.


Recently, double-stranded RNA molecules (dsRNA) have been shown to block gene expression in a highly conserved regulatory mechanism known as RNA interference (RNAi). WO 99/32619 (Fire et al.) discloses the use of a dsRNA of at least 25 nucleotides in length to inhibit the expression of genes in C. elegans. dsRNA has also been shown to degrade target RNA in other organisms, including plants (see, e.g., WO 99/53050, Waterhouse et al.; and WO 99/61631, Heifetz et al.), Drosophila (see, e.g., Yang, D., et al., Curr. Biol. (2000) 10:1191-1200), and mammals (see WO 00/44895, Limmer; and DE 101 00 586.5, Kreutzer et al.). This natural mechanism has now become the focus for the development of a new class of pharmaceutical agents for treating disorders that are caused by the aberrant or unwanted regulation of a gene.


Despite significant advances in the field of RNAi and advances in the treatment of pathological processes which can be mediated by down regulating PCSK9 gene expression, there remains a need for agents that can inhibit PCSK9 gene expression and that can treat diseases associated with PCSK9 gene expression such as hyperlipidemia.


SUMMARY OF THE INVENTION

The invention provides a solution to the problem of treating diseases that can be modulated by down regulating the proprotein convertase subtilisin kexin 9 (PCSK9) by using double-stranded ribonucleic acid (dsRNA) to silence PCSK9 expression.


The invention provides double-stranded ribonucleic acid (dsRNA), as well as compositions and methods for inhibiting the expression of the PCSK9 gene in a cell or mammal using such dsRNA. The invention also provides compositions and methods for treating pathological conditions that can modulated by down regulating the expression of the PCSK9 gene, such as hyperlipidemia. The dsRNA of the invention comprises an RNA strand (the antisense strand) having a region which is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and is substantially complementary to at least part of an mRNA transcript of the PCSK9 gene.


In one embodiment, the invention provides double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of the PCSK9 gene. The dsRNA comprises at least two sequences that are complementary to each other. The dsRNA comprises a sense strand comprising a first sequence and an antisense strand comprising a second sequence. The antisense strand comprises a nucleotide sequence which is substantially complementary to at least part of an mRNA encoding PCSK9, and the region of complementarity is less than 30 nucleotides in length, generally 19-24 nucleotides in length. The dsRNA, upon contacting with a cell expressing the PCSK9, inhibits the expression of the PCSK9 gene by at least 40%.


For example, the dsRNA molecules of the invention can be comprised of a first sequence of the dsRNA that is selected from the group consisting of the sense sequences of Table 1 and Table 2 the second sequence is selected from the group consisting of the antisense sequences of Tables 1 and Table 2. The dsRNA molecules of the invention can be comprised of naturally occurring nucleotides or can be comprised of at least one modified nucleotide, such as a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative. Alternatively, the modified nucleotide may be chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. Generally, such modified sequence will be based on a first sequence of the dsRNA selected from the group consisting of the sense sequences of Tables 1 and Table 2 and a second sequence selected from the group consisting of the antisense sequences of Tables 1, and Table 2.


In another embodiment, the invention provides a cell comprising one of the dsRNAs of the invention. The cell is generally a mammalian cell, such as a human cell.


In another embodiment, the invention provides a pharmaceutical composition for inhibiting the expression of the PCSK9 gene in an organism, generally a human subject, comprising one or more of the dsRNA of the invention and a pharmaceutically acceptable carrier or delivery vehicle.


In another embodiment, the invention provides a method for inhibiting the expression of the PCSK9 gene in a cell, comprising the following steps:

    • (a) introducing into the cell a double-stranded ribonucleic acid (dsRNA), wherein the dsRNA comprises at least two sequences that are complementary to each other. The dsRNA comprises a sense strand comprising a first sequence and an antisense strand comprising a second sequence. The antisense strand comprises a region of complementarity which is substantially complementary to at least a part of a mRNA encoding PCSK9, and wherein the region of complementarity is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and wherein the dsRNA, upon contact with a cell expressing the PCSK9, inhibits expression of the PCSK9 gene by at least 40%; and
    • (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the PCSK9 gene, thereby inhibiting expression of the PCSK9 gene in the cell.


In another embodiment, the invention provides methods for treating, preventing or managing pathological processes which can be mediated by down regulating PCSK9 gene expression, e.g. hyperlipidemia, comprising administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of one or more of the dsRNAs of the invention.


In another embodiment, the invention provides vectors for inhibiting the expression of the PCSK9 gene in a cell, comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of one of the dsRNA of the invention.


In another embodiment, the invention provides a cell comprising a vector for inhibiting the expression of the PCSK9 gene in a cell. The vector comprises a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of one of the dsRNA of the invention.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows the structure of the ND-98 lipid.



FIG. 2 shows the results of the in vivo screen of 16 mouse specific (AL-DP-9327 through AL-DP-9342) PCSK9 siRNAs directed against different ORF regions of PCSK9 mRNA (having the first nucleotide corresponding to the ORF position indicated on the graph) in C57/BL6 mice (5 animals/group). The ratio of PCSK9 mRNA to GAPDH mRNA in liver lysates was averaged over each treatment group and compared to a control group treated with PBS or a control group treated with an unrelated siRNA (blood coagulation factor VII).



FIG. 3 shows the results of the in vivo screen of 16 human/mouse/rat crossreactive (AL-DP-9311 through AL-DP-9326) PCSK9 siRNAs directed against different ORF regions of PCSK9 mRNA (having the first nucleotide corresponding to the ORF position indicated on the graph) in C57/BL6 mice (5 animals/group). The ratio of PCSK9 mRNA to GAPDH mRNA in liver lysates was averaged over each treatment group and compared to a control group treated with PBS or a control group treated with an unrelated siRNA (blood coagulation factor VII).


Silencing of PCSK9 mRNA resulted in lowering total serum cholesterol levels.


The most efficacious in terms of knocking down PSCK9 message siRNAs showed the most pronounced cholesterol lowering effect (around 20-30%).



FIG. 4 shows the results of the in vivo screen of 16 mouse specific (AL-DP-9327 through AL-DP-9342) PCSK9 siRNAs in C57/BL6 mice (5 animals/group). Total serum cholesterol levels were averaged over each treatment group and compared to a control group treated with PBS or a control group treated with an unrelated siRNA (blood coagulation factor VII).



FIG. 5 shows the results of the in vivo screen of 16 human/mouse/rat crossreactive (AL-DP-9311 through AL-DP-9326) PCSK9 siRNAs in C57/BL6 mice (5 animals/group). Total serum cholesterol levels were averaged over each treatment group and compared to a control group treated with PBS or a control group treated with an unrelated siRNA (blood coagulation factor VII).



FIG. 6A and FIG. 6B. shows a comparison of the in vitro and in vivo results for silencing PCSK9.



FIG. 7A and FIG. 7B show in vitro results for silencing PCSK9 using monkey primary hepatocytes.



FIG. 8 shows in vivo activity of LNP-01 formulated siRNAs to pcsk-9.



FIG. 9 shows in vivo activity of LNP-01 Formulated chemically modified 9314 and 10792 parent molecules at different times. Clearly modified versions of 10792 display in vivo silencing activity.





DETAILED DESCRIPTION OF THE INVENTION

The invention provides a solution to the problem of treating diseases that can be modulated by the down regulation of the PCSK9 gene, by using double-stranded ribonucleic acid (dsRNA) to silence the PCSK9 gene thus providing treatment for diseases such as hyperlipidemia.


The invention provides double-stranded ribonucleic acid (dsRNA), as well as compositions and methods for inhibiting the expression of the PCSK9 gene in a cell or mammal using the dsRNA. The invention also provides compositions and methods for treating pathological conditions and diseases that can be modulated by down regulating the expression of the PCSK9 gene. dsRNA directs the sequence-specific degradation ofmRNA through a process known as RNA interference (RNAi).


The dsRNA of the invention comprises an RNA strand (the antisense strand) having a region which is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and is substantially complementary to at least part of an mRNA transcript of the PCSK9 gene. The use of these dsRNAs enables the targeted degradation of an mRNA that is involved in sodium transport. Using cell-based and animal assays, the present inventors have demonstrated that very low dosages of these dsRNA can specifically and efficiently mediate RNAi, resulting in significant inhibition of expression of the PCSK9 gene. Thus, the methods and compositions of the invention comprising these dsRNAs are useful for treating pathological processes which can be mediated by down regulating PCSK9, such as in the treatment of hyperlipidemia.


The following detailed description discloses how to make and use the dsRNA and compositions containing dsRNA to inhibit the expression of the target PCSK9 gene, as well as compositions and methods for treating diseases that can be modulated by down regulating the expression of PCSK9, such as hyperlipidemia. The pharmaceutical compositions of the invention comprise a dsRNA having an antisense strand comprising a region of complementarity which is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and is substantially complementary to at least part of an RNA transcript of the PCSK9 gene, together with a pharmaceutically acceptable carrier.


Accordingly, certain aspects of the invention provide pharmaceutical compositions comprising the dsRNA of the invention together with a pharmaceutically acceptable carrier, methods of using the compositions to inhibit expression of the PCSK9 gene, and methods of using the pharmaceutical compositions to treat diseases that can be modulated by down regulating the expression of PCSK9.


I. Definitions


For convenience, the meaning of certain terms and phrases used in the specification, examples, and appended claims, are provided below. If there is an apparent discrepancy between the usage of a term in other parts of this specification and its definition provided in this section, the definition in this section shall prevail.


“G,” “C,” “A” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil may be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base may base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine may be replaced in the nucleotide sequences of the invention by a nucleotide containing, for example, inosine. Sequences comprising such replacement moieties are embodiments of the invention.


As used herein, “PCSK9” refers to the proprotein convertase subtilisin kexin 9 gene or protein (also known as FH3, HCHOLA3, NARC-1, NARC1). mRNA sequences to PCSK9 are provided as human: NM_174936; mouse: NM_153565, and rat: NM_199253.


As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of the PCSK9 gene, including mRNA that is a product of RNA processing of a primary transcription product.


As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.


As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions may include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50° C. or 70° C. for 12-16 hours followed by washing. Other conditions, such as physiologically relevant conditions as may be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.


This includes base-pairing of the oligonucleotide or polynucleotide comprising the first nucleotide sequence to the oligonucleotide or polynucleotide comprising the second nucleotide sequence over the entire length of the first and second nucleotide sequence. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they may form one or more, but generally not more than 4, 3 or 2 mismatched base pairs upon hybridization, while retaining the ability to hybridize under the conditions most relevant to their ultimate application. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, may yet be referred to as “fully complementary” for the purposes of the invention.


“Complementary” sequences, as used herein, may also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified nucleotides, in as far as the above requirements with respect to their ability to hybridize are fulfilled.


The terms “complementary”, “fully complementary” and “substantially complementary” herein may be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of a dsRNA and a target sequence, as will be understood from the context of their use.


As used herein, a polynucleotide which is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide which is substantially complementary to a contiguous portion of the mRNA of interest (e.g., encoding PCSK9). For example, a polynucleotide is complementary to at least a part of a PCSK9 mRNA if the sequence is substantially complementary to a non-interrupted portion of a mRNA encoding PCSK9.


The term “double-stranded RNA” or “dsRNA”, as used herein, refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary, as defined above, nucleic acid strands. The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where separate RNA molecules, such dsRNA are often referred to in the literature as siRNA (“short interfering RNA”). Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′ end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop”, “short hairpin RNA” or “shRNA”. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′ end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker”. The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, a dsRNA may comprise one or more nucleotide overhangs. In addition, as used in this specification, “dsRNA” may include chemical modifications to ribonucleotides, including substantial modifications at multiple nucleotides and including all types of modifications disclosed herein or known in the art. Any such modifications, as used in an siRNA type molecule, are encompassed by “dsRNA” for the purposes of this specification and claims.


As used herein, a “nucleotide overhang” refers to the unpaired nucleotide or nucleotides that protrude from the duplex structure of a dsRNA when a 3′-end of one strand of the dsRNA extends beyond the 5′-end of the other strand, or vice versa. “Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the dsRNA, i.e., no nucleotide overhang. A “blunt ended” dsRNA is a dsRNA that is double-stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule. For clarity, chemical caps or non-nucleotide chemical moieties conjugated to the 3′ end or 5′ end of an siRNA are not considered in determining whether an siRNA has an overhang or is blunt ended.


The term “antisense strand” refers to the strand of a dsRNA which includes a region that is substantially complementary to a target sequence. As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches are most tolerated in the terminal regions and, if present, are generally in a terminal region or regions, e.g., within 6, 5, 4, 3, or 2 nucleotides of the 5′ and/or 3′ terminus.


The term “sense strand,” as used herein, refers to the strand of a dsRNA that includes a region that is substantially complementary to a region of the antisense strand.


“Introducing into a cell”, when referring to a dsRNA, means facilitating uptake or absorption into the cell, as is understood by those skilled in the art. Absorption or uptake of dsRNA can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. The meaning of this term is not limited to cells in vitro; a dsRNA may also be “introduced into a cell”, wherein the cell is part of a living organism. In such instance, introduction into the cell will include the delivery to the organism. For example, for in vivo delivery, dsRNA can be injected into a tissue site or administered systemically. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection.


The terms “silence” and “inhibit the expression of”, in as far as they refer to the PCSK9 gene, herein refer to the at least partial suppression of the expression of the PCSK9 gene, as manifested by a reduction of the amount of mRNA transcribed from the PCSK9 gene which may be isolated from a first cell or group of cells in which the PCSK9 gene is transcribed and which has or have been treated such that the expression of the PCSK9 gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has or have not been so treated (control cells). The degree of inhibition is usually expressed in terms of










(

mRNA





in





control





cells

)

-

(

mRNA





in





treated





cells

)



(

mRNA





in





control





cells

)


·
100


%




Alternatively, the degree of inhibition may be given in terms of a reduction of a parameter that is functionally linked to PCSK9 gene transcription, e.g. the amount of protein encoded by the PCSK9 gene which is secreted by a cell, or the number of cells displaying a certain phenotype, e.g apoptosis. In principle, PCSK9 gene silencing may be determined in any cell expressing the target, either constitutively or by genomic engineering, and by any appropriate assay. However, when a reference is needed in order to determine whether a given dsRNA inhibits the expression of the PCSK9 gene by a certain degree and therefore is encompassed by the instant invention, the assay provided in the Examples below shall serve as such reference.


For example, in certain instances, expression of the PCSK9 gene is suppressed by at least about 20%, 25%, 35%, or 50% by administration of the double-stranded oligonucleotide of the invention. In some embodiment, the PCSK9 gene is suppressed by at least about 60%, 70%, or 80% by administration of the double-stranded oligonucleotide of the invention. In some embodiments, the PCSK9 gene is suppressed by at least about 85%, 90%, or 95% by administration of the double-stranded oligonucleotide of the invention. Tables 1, 2, provides a wide range of values for inhibition of expression obtained in an in vitro assay using various PCSK9 dsRNA molecules at various concentrations.


As used herein in the context of PCSK9 expression, the terms “treat”, “treatment”, and the like, refer to relief from or alleviation of pathological processes which can be mediated by down regulating PCSK9 gene. In the context of the present invention insofar as it relates to any of the other conditions recited herein below (other than pathological processes which can be mediated by down regulating the PCSK9 gene), the terms “treat”, “treatment”, and the like mean to relieve or alleviate at least one symptom associated with such condition, or to slow or reverse the progression of such condition. For example, in the context of hyperlipidemia, treatment will involve a decrease in serum lipid levels.


As used herein, the phrases “therapeutically effective amount” and “prophylactically effective amount” refer to an amount that provides a therapeutic benefit in the treatment, prevention, or management of pathological processes which can be mediated by down regulating the PCSK9 gene on or an overt symptom of pathological processes which can be mediated by down regulating the PCSK9 gene. The specific amount that is therapeutically effective can be readily determined by ordinary medical practitioner, and may vary depending on factors known in the art, such as, e.g. the type of pathological processes which can be mediated by down regulating the PCSK9 gene, the patient's history and age, the stage of pathological processes which can be mediated by down regulating PCSK9 gene expression, and the administration of other anti-pathological processes which can be mediated by down regulating PCSK9 gene expression.


As used herein, a “pharmaceutical composition” comprises a pharmacologically effective amount of a dsRNA and a pharmaceutically acceptable carrier. As used herein, “pharmacologically effective amount,” “therapeutically effective amount” or simply “effective amount” refers to that amount of an RNA effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 25% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 25% reduction in that parameter.


The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof and are described in more detail below. The term specifically excludes cell culture medium.


As used herein, a “transformed cell” is a cell into which a vector has been introduced from which a dsRNA molecule may be expressed.


II. Double-stranded ribonucleic acid (dsRNA)


In one embodiment, the invention provides double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of the PCSK9 gene in a cell or mammal, wherein the dsRNA comprises an antisense strand comprising a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of the PCSK9 gene, and wherein the region of complementarity is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and wherein the dsRNA, upon contact with a cell expressing the PCSK9 gene, inhibits the expression of the PCSK9 gene by at least 40%. The dsRNA comprises two RNA strands that are sufficiently complementary to hybridize to form a duplex structure. One strand of the dsRNA (the antisense strand) comprises a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence, derived from the sequence of an mRNA formed during the expression of the PCSK9 gene, the other strand (the sense strand) comprises a region which is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. Generally, the duplex structure is between 15 and 30, more generally between 18 and 25, yet more generally between 19 and 24, and most generally between 19 and 21 base pairs in length. Similarly, the region of complementarity to the target sequence is between 15 and 30, more generally between 18 and 25, yet more generally between 19 and 24, and most generally between 19 and 21 nucleotides in length. The dsRNA of the invention may further comprise one or more single-stranded nucleotide overhang(s). The dsRNA can be synthesized by standard methods known in the art as further discussed below, e.g., by use of an automated DNA synthesizer, such as are commercially available from, for example, Biosearch, Applied Biosystems, Inc. In a preferred embodiment, the PCSK9 gene is the human PCSK9 gene. In specific embodiments, the antisense strand of the dsRNA comprises a strand selected from the sense sequences of Tables 1 and 2, and a second sequence selected from the group consisting of the antisense sequences of Tables 1 and 2. Alternative antisense agents that target elsewhere in the target sequence provided in Tables 1 and 2, can readily be determined using the target sequence and the flanking PCSK9 sequence.


In further embodiments, the dsRNA comprises at least one nucleotide sequence selected from the groups of sequences provided in Tables 1 and 2. In other embodiments, the dsRNA comprises at least two sequences selected from this group, wherein one of the at least two sequences is complementary to another of the at least two sequences, and one of the at least two sequences is substantially complementary to a sequence of an mRNA generated in the expression of the PCSK9 gene. Generally, the dsRNA comprises two oligonucleotides, wherein one oligonucleotide is described as the sense strand in Tables 1 and 2 and the second oligonucleotide is described as the antisense strand in Tables 1 and 2


The skilled person is well aware that dsRNAs comprising a duplex structure of between 20 and 23, but specifically 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer dsRNAs can be effective as well. In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in Tables 1 and 2, the dsRNAs of the invention can comprise at least one strand of a length of minimally 21 nt. It can be reasonably expected that shorter dsRNAs comprising one of the sequences of Tables 1 and 2 minus only a few nucleotides on one or both ends may be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs comprising a partial sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from one of the sequences of Tables 1 and 2, and differing in their ability to inhibit the expression of the PCSK9 gene in a FACS assay as described herein below by not more than 5, 10, 15, 20, 25, or 30% inhibition from a dsRNA comprising the full sequence, are contemplated by the invention. Further dsRNAs that cleave within the target sequence provided in Tables 1 and 2 can readily be made using the PCSK9 sequence and the target sequence provided.


In addition, the RNAi agents provided in Tables 1 and 2 identify a site in the PCSK9 mRNA that is susceptible to RNAi based cleavage. As such the present invention further includes RNAi agents that target within the sequence targeted by one of the agents of the present invention. As used herein a second RNAi agent is the to target within the sequence of a first RNAi agent if the second RNAi agent cleaves the message anywhere within the mRNA that is complementary to the antisense strand of the first RNAi agent. Such a second agent will generally consist of at least 15 contiguous nucleotides from one of the sequences provided in Tables 1 and 2 coupled to additional nucleotide sequences taken from the region contiguous to the selected sequence in the PCSK9 gene. For example, the last 15 nucleotides of SEQ ID NO:1 (minus the added AA sequences) combined with the next 6 nucleotides from the target PCSK9 gene produces a single strand agent of 21 nucleotides that is based on one of the sequences provided in Tables 1 and 2.


The dsRNA of the invention can contain one or more mismatches to the target sequence. In a preferred embodiment, the dsRNA of the invention contains no more than 3 mismatches. If the antisense strand of the dsRNA contains mismatches to a target sequence, it is preferable that the area of mismatch not be located in the center of the region of complementarity. If the antisense strand of the dsRNA contains mismatches to the target sequence, it is preferable that the mismatch be restricted to 5 nucleotides from either end, for example 5, 4, 3, 2, or 1 nucleotide from either the 5′ or 3′ end of the region of complementarity. For example, for a 23 nucleotide dsRNA strand which is complementary to a region of the PCSK9 gene, the dsRNA generally does not contain any mismatch within the central 13 nucleotides. The methods described within the invention can be used to determine whether a dsRNA containing a mismatch to a target sequence is effective in inhibiting the expression of the PCSK9 gene. Consideration of the efficacy of dsRNAs with mismatches in inhibiting expression of the PCSK9 gene is important, especially if the particular region of complementarity in the PCSK9 gene is known to have polymorphic sequence variation within the population.


In one embodiment, at least one end of the dsRNA has a single-stranded nucleotide overhang of 1 to 4, generally 1 or 2 nucleotides. dsRNAs having at least one nucleotide overhang have unexpectedly superior inhibitory properties than their blunt-ended counterparts. Moreover, the present inventors have discovered that the presence of only one nucleotide overhang strengthens the interference activity of the dsRNA, without affecting its overall stability. dsRNA having only one overhang has proven particularly stable and effective in vivo, as well as in a variety of cells, cell culture mediums, blood, and serum. Generally, the single-stranded overhang is located at the 3′-terminal end of the antisense strand or, alternatively, at the 3′-terminal end of the sense strand. The dsRNA may also have a blunt end, generally located at the 5′-end of the antisense strand. Such dsRNAs have improved stability and inhibitory activity, thus allowing administration at low dosages, i.e., less than 5 mg/kg body weight of the recipient per day. Generally, the antisense strand of the dsRNA has a nucleotide overhang at the 3′-end, and the 5′-end is blunt. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.


In yet another embodiment, the dsRNA is chemically modified to enhance stability. The nucleic acids of the invention may be synthesized and/or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry”, Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Chemical modifications may include, but are not limited to 2′ modifications, modifications at other sites of the sugar or base of an oligonucleotide, introduction of non-natural bases into the olibonucleotide chain, covalent attachment to a ligand or chemical moiety, and replacement of intemucleotide phosphate linkages with alternate linkages such as thiophosphates. More than one such modification may be employed.


Chemical linking of the two separate dsRNA strands may be achieved by any of a variety of well-known techniques, for example by introducing covalent, ionic or hydrogen bonds; hydrophobic interactions, van der Waals or stacking interactions; by means of metal-ion coordination, or through use of purine analogues. Generally, the chemical groups that can be used to modify the dsRNA include, without limitation, methylene blue; bifunctional groups, generally bis-(2-chloroethyl)amine; N-acetyl-N′-(p-glyoxylbenzoyl)cystamine; 4-thiouracil; and psoralen. In one embodiment, the linker is a hexa-ethylene glycol linker. In this case, the dsRNA are produced by solid phase synthesis and the hexa-ethylene glycol linker is incorporated according to standard methods (e.g., Williams, D. J., and K. B. Hall, Biochem. (1996) 35:14665-14670). In a particular embodiment, the 5′-end of the antisense strand and the 3′-end of the sense strand are chemically linked via a hexaethylene glycol linker. In another embodiment, at least one nucleotide of the dsRNA comprises a phosphorothioate or phosphorodithioate groups. The chemical bond at the ends of the dsRNA is generally formed by triple-helix bonds. Tables 1 and 2 provides examples of modified RNAi agents of the invention.


In yet another embodiment, the nucleotides at one or both of the two single strands may be modified to prevent or inhibit the degradation activities of cellular enzymes, such as, for example, without limitation, certain nucleases. Techniques for inhibiting the degradation activity of cellular enzymes against nucleic acids are known in the art including, but not limited to, 2′-amino modifications, 2′-amino sugar modifications, 2′-F sugar modifications, 2′-F modifications, 2′-alkyl sugar modifications, uncharged backbone modifications, morpholino modifications, 2′-O-methyl modifications, and phosphoramidate (see, e.g., Wagner, Nat. Med. (1995) 1:1116-8). Thus, at least one 2′-hydroxyl group of the nucleotides on a dsRNA is replaced by a chemical group, generally by a 2′-amino or a 2′-methyl group. Also, at least one nucleotide may be modified to form a locked nucleotide. Such locked nucleotide contains a methylene bridge that connects the 2′-oxygen of ribose with the 4′-carbon of ribose. Oligonucleotides containing the locked nucleotide are described in Koshkin, A. A., et al., Tetrahedron (1998), 54: 3607-3630) and Obika, S. et al., Tetrahedron Lett. (1998), 39: 5401-5404). Introduction of a locked nucleotide into an oligonucleotide improves the affinity for complementary sequences and increases the melting temperature by several degrees (Braasch, D. A. and D. R. Corey, Chem. Biol. (2001), 8:1-7).


Conjugating a ligand to a dsRNA can enhance its cellular absorption as well as targeting to a particular tissue or uptake by specific types of cells such as liver cells. In certain instances, a hydrophobic ligand is conjugated to the dsRNA to facilitate direct permeation of the cellular membrane and or uptake across the liver cells. Alternatively, the ligand conjugated to the dsRNA is a substrate for receptor-mediated endocytosis. These approaches have been used to facilitate cell permeation of antisense oligonucleotides as well as dsRNA agents. For example, cholesterol has been conjugated to various antisense oligonucleotides resulting in compounds that are substantially more active compared to their non-conjugated analogs. See M. Manoharan Antisense & Nucleic Acid Drug Development 2002, 12, 103. Other lipophilic compounds that have been conjugated to oligonucleotides include 1-pyrene butyric acid, 1,3-bis-O-(hexadecyl)glycerol, and menthol. One example of a ligand for receptor-mediated endocytosis is folic acid. Folic acid enters the cell by folate-receptor-mediated endocytosis. dsRNA compounds bearing folic acid would be efficiently transported into the cell via the folate-receptor-mediated endocytosis. Li and coworkers report that attachment of folic acid to the 3′-terminus of an oligonucleotide resulted in an 8-fold increase in cellular uptake of the oligonucleotide. Li, S.; Deshmukh, H. M.; Huang, L. Pharm. Res. 1998, 15, 1540. Other ligands that have been conjugated to oligonucleotides include polyethylene glycols, carbohydrate clusters, cross-linking agents, porphyrin conjugates, delivery peptides and lipids such as cholesterol.


In certain instances, conjugation of a cationic ligand to oligonucleotides results in improved resistance to nucleases. Representative examples of cationic ligands are propylammonium and dimethylpropylammonium. Interestingly, antisense oligonucleotides were reported to retain their high binding affinity to mRNA when the cationic ligand was dispersed throughout the oligonucleotide. See M. Manoharan Antisense & Nucleic Acid Drug Development 2002, 12, 103 and references therein.


The ligand-conjugated dsRNA of the invention may be synthesized by the use of a dsRNA that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the dsRNA. This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto. The methods of the invention facilitate the synthesis of ligand-conjugated dsRNA by the use of, in some preferred embodiments, nucleoside monomers that have been appropriately conjugated with ligands and that may further be attached to a solid-support material. Such ligand-nucleoside conjugates, optionally attached to a solid-support material, are prepared according to some preferred embodiments of the methods of the invention via reaction of a selected serum-binding ligand with a linking moiety located on the 5′ position of a nucleoside or oligonucleotide. In certain instances, an dsRNA bearing an aralkyl ligand attached to the 3′-terminus of the dsRNA is prepared by first covalently attaching a monomer building block to a controlled-pore-glass support via a long-chain aminoalkyl group. Then, nucleotides are bonded via standard solid-phase synthesis techniques to the monomer building-block bound to the solid support. The monomer building block may be a nucleoside or other organic compound that is compatible with solid-phase synthesis.


The dsRNA used in the conjugates of the invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.


Teachings regarding the synthesis of particular modified oligonucleotides may be found in the following U.S. patents: U.S. Pat. Nos. 5,138,045 and 5,218,105, drawn to polyamine conjugated oligonucleotides; U.S. Pat. No. 5,212,295, drawn to monomers for the preparation of oligonucleotides having chiral phosphorus linkages; U.S. Pat. Nos. 5,378,825 and 5,541,307, drawn to oligonucleotides having modified backbones; U.S. Pat. No. 5,386,023, drawn to backbone-modified oligonucleotides and the preparation thereof through reductive coupling; U.S. Pat. No. 5,457,191, drawn to modified nucleobases based on the 3-deazapurine ring system and methods of synthesis thereof; U.S. Pat. No. 5,459,255, drawn to modified nucleobases based on N-2 substituted purines; U.S. Pat. No. 5,521,302, drawn to processes for preparing oligonucleotides having chiral phosphorus linkages; U.S. Pat. No. 5,539,082, drawn to peptide nucleic acids; U.S. Pat. No. 5,554,746, drawn to oligonucleotides having β-lactam backbones; U.S. Pat. No. 5,571,902, drawn to methods and materials for the synthesis of oligonucleotides; U.S. Pat. No. 5,578,718, drawn to nucleosides having alkylthio groups, wherein such groups may be used as linkers to other moieties attached at any of a variety of positions of the nucleoside; U.S. Pat. Nos. 5,587,361 and 5,599,797, drawn to oligonucleotides having phosphorothioate linkages of high chiral purity; U.S. Pat. No. 5,506,351, drawn to processes for the preparation of 2′-O-alkyl guanosine and related compounds, including 2,6-diaminopurine compounds; U.S. Pat. No. 5,587,469, drawn to oligonucleotides having N-2 substituted purines; U.S. Pat. No. 5,587,470, drawn to oligonucleotides having 3-deazapurines; U.S. Pat. No. 5,223,168, and U.S. Pat. No. 5,608,046, both drawn to conjugated 4′-desmethyl nucleoside analogs; U.S. Pat. Nos. 5,602,240, and 5,610,289, drawn to backbone-modified oligonucleotide analogs; U.S. Pat. Nos. 6,262,241, and 5,459,255, drawn to, inter alia, methods of synthesizing 2′-fluoro-oligonucleotides.


In the ligand-conjugated dsRNA and ligand-molecule bearing sequence-specific linked nucleosides of the invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.


When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. Oligonucleotide conjugates bearing a variety of molecules such as steroids, vitamins, lipids and reporter molecules, has previously been described (see Manoharan et al., PCT Application WO 93/07883). In a preferred embodiment, the oligonucleotides or linked nucleosides of the invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.


The incorporation of a 2′-O-methyl, 2′-O-ethyl, 2′-O-propyl, 2′-O-allyl, 2′-O-aminoalkyl or 2′-deoxy-2′-fluoro group in nucleosides of an oligonucleotide confers enhanced hybridization properties to the oligonucleotide. Further, oligonucleotides containing phosphorothioate backbones have enhanced nuclease stability. Thus, functionalized, linked nucleosides of the invention can be augmented to include either or both a phosphorothioate backbone or a 2′-O-methyl, 2′-O-ethyl, 2′-O-propyl, 2′-O-aminoalkyl, 2′-O-allyl or 2′-deoxy-2′-fluoro group. A summary listing of some of the oligonucleotide modifications known in the art is found at, for example, PCT Publication WO 200370918.


In some embodiments, functionalized nucleoside sequences of the invention possessing an amino group at the 5′-terminus are prepared using a DNA synthesizer, and then reacted with an active ester derivative of a selected ligand. Active ester derivatives are well known to those skilled in the art. Representative active esters include N-hydrosuccinimide esters, tetrafluorophenolic esters, pentafluorophenolic esters and pentachlorophenolic esters. The reaction of the amino group and the active ester produces an oligonucleotide in which the selected ligand is attached to the 5′-position through a linking group. The amino group at the 5′-terminus can be prepared utilizing a 5′-Amino-Modifier C6 reagent. In one embodiment, ligand molecules may be conjugated to oligonucleotides at the 5′-position by the use of a ligand-nucleoside phosphoramidite wherein the ligand is linked to the 5′-hydroxy group directly or indirectly via a linker. Such ligand-nucleoside phosphoramidites are typically used at the end of an automated synthesis procedure to provide a ligand-conjugated oligonucleotide bearing the ligand at the 5′-terminus.


Examples of modified intemucleoside linkages or backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free-acid forms are also included.


Representative United States patents relating to the preparation of the above phosphorus-atom-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; and 5,697,248, each of which is herein incorporated by reference.


Examples of modified intemucleoside linkages or backbones that do not include a phosphorus atom therein (i.e., oligonucleosides) have backbones that are formed by short chain alkyl or cycloalkyl intersugar linkages, mixed heteroatom and alkyl or cycloalkyl intersugar linkages, or one or more short chain heteroatomic or heterocyclic intersugar linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts.


Representative United States patents relating to the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.


In certain instances, the oligonucleotide may be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to oligonucleotides in order to enhance the activity, cellular distribution or cellular uptake of the oligonucleotide, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such oligonucleotide conjugates have been listed above. Typical conjugation protocols involve the synthesis of oligonucleotides bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction may be performed either with the oligonucleotide still bound to the solid support or following cleavage of the oligonucleotide in solution phase. Purification of the oligonucleotide conjugate by HPLC typically affords the pure conjugate. The use of a cholesterol conjugate is particularly preferred since such a moiety can increase targeting liver cells cells, a site of PCSK9 expression.


Vector Encoded RNAi Agents


The dsRNA of the invention can also be expressed from recombinant viral vectors intracellularly in vivo. The recombinant viral vectors of the invention comprise sequences encoding the dsRNA of the invention and any suitable promoter for expressing the dsRNA sequences. Suitable promoters include, for example, the U6 or H1 RNA pol III promoter sequences and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the dsRNA in a particular tissue or in a particular intracellular environment. The use of recombinant viral vectors to deliver dsRNA of the invention to cells in vivo is discussed in more detail below.


dsRNA of the invention can be expressed from a recombinant viral vector either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.


Any viral vector capable of accepting the coding sequences for the dsRNA molecule(s) to be expressed can be used, for example vectors derived from adenovirus (AV); adeno-associated virus (AAV); retroviruses (e.g, lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like. The tropism of viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate.


For example, lentiviral vectors of the invention can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors of the invention can be made to target different cells by engineering the vectors to express different capsid protein serotypes. For example, an AAV vector expressing a serotype 2 capsid on a serotype 2 genome is called AAV 2/2. This serotype 2 capsid gene in the AAV 2/2 vector can be replaced by a serotype 5 capsid gene to produce an AAV 2/5 vector. Techniques for constructing AAV vectors which express different capsid protein serotypes are within the skill in the art; see, e.g., Rabinowitz J E et al. (2002), J Virol 76:791-801, the entire disclosure of which is herein incorporated by reference.


Selection of recombinant viral vectors suitable for use in the invention, methods for inserting nucleic acid sequences for expressing the dsRNA into the vector, and methods of delivering the viral vector to the cells of interest are within the skill in the art. See, for example, Domburg R (1995), Gene Therap. 2: 301-310; Eglitis M A (1988), Biotechniques 6: 608-614; Miller A D (1990), Hum Gene Therap. 1: 5-14; Anderson W F (1998), Nature 392: 25-30; and Rubinson D A et al., Nat. Genet. 33: 401-406, the entire disclosures of which are herein incorporated by reference.


Preferred viral vectors are those derived from AV and AAV. In a particularly preferred embodiment, the dsRNA of the invention is expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector comprising, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter.


A suitable AV vector for expressing the dsRNA of the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H et al. (2002), Nat. Biotech. 20: 1006-1010.


Suitable AAV vectors for expressing the dsRNA of the invention, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R et al. (1987), J. Virol. 61: 3096-3101; Fisher K J et al. (1996), J. Virol, 70: 520-532; Samulski R et al. (1989), J. Virol. 63: 3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.


III. Pharmaceutical Compositions Comprising dsRNA


In one embodiment, the invention provides pharmaceutical compositions comprising a dsRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical composition comprising the dsRNA is useful for treating a disease or disorder associated with the expression or activity of the PCSK9 gene, such as pathological processes which can be mediated by down regulating PCSK9 gene expression, such as hyperlipidemia. Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for delivery to the liver via parenteral delivery.


The pharmaceutical compositions of the invention are administered in dosages sufficient to inhibit expression of the PCSK9 gene. The present inventors have found that, because of their improved efficiency, compositions comprising the dsRNA of the invention can be administered at surprisingly low dosages. A dosage of 5 mg dsRNA per kilogram body weight of recipient per day is sufficient to inhibit or suppress expression of the PCSK9 gene and may be administered systemically to the patient.


In general, a suitable dose of dsRNA will be in the range of 0.01 to 5.0 milligrams per kilogram body weight of the recipient per day, generally in the range of 1 microgram to 1 mg per kilogram body weight per day. The pharmaceutical composition may be administered once daily, or the dsRNA may be administered as two, three, or more sub-doses at appropriate intervals throughout the day or even using continuous infusion or delivery through a controlled release formulation. In that case, the dsRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage. The dosage unit can also be compounded for delivery over several days, e.g., using a conventional sustained release formulation which provides sustained release of the dsRNA over a several day period. Sustained release formulations are well known in the art.


The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the individual dsRNAs encompassed by the invention can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein.


Advances in mouse genetics have generated a number of mouse models for the study of various human diseases, such as pathological processes which can be mediated by down regulating PCSK9 gene expression. Such models are used for in vivo testing of dsRNA, as well as for determining a therapeutically effective dose.


Any method can be used to administer a dsRNA of the present invention to a mammal. For example, administration can be direct; oral; or parenteral (e.g., by subcutaneous, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip). Administration can be rapid (e.g., by injection), or can occur over a period of time (e.g., by slow infusion or administration of slow release formulations).


Typically, when treating a mammal with hyperlipidemia, the dsRNA molecules are administered systemically via parental means. For example, dsRNAs, conjugated or unconjugate or formulated with or without liposomes, can be administered intravenously to a patient. For such, a dsRNA molecule can be formulated into compositions such as sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions in liquid or solid oil bases. Such solutions also can contain buffers, diluents, and other suitable additives. For parenteral, intrathecal, or intraventricular administration, a dsRNA molecule can be formulated into compositions such as sterile aqueous solutions, which also can contain buffers, diluents, and other suitable additives (e.g., penetration enhancers, carrier compounds, and other pharmaceutically acceptable carriers).


In addition, dsRNA molecules can be administered to a mammal as biologic or abiologic means as described in, for example, U.S. Pat. No. 6,271,359. Abiologic delivery can be accomplished by a variety of methods including, without limitation, (1) loading liposomes with a dsRNA acid molecule provided herein and (2) complexing a dsRNA molecule with lipids or liposomes to form nucleic acid-lipid or nucleic acid-liposome complexes. The liposome can be composed of cationic and neutral lipids commonly used to transfect cells in vitro. Cationic lipids can complex (e.g., charge-associate) with negatively charged nucleic acids to form liposomes. Examples of cationic liposomes include, without limitation, lipofectin, lipofectamine, lipofectace, and DOTAP. Procedures for forming liposomes are well known in the art. Liposome compositions can be formed, for example, from phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, or dioleoyl phosphatidylethanolamine. Numerous lipophilic agents are commercially available, including Lipofectin® (Invitrogen/Life Technologies, Carlsbad, Calif.) and Effectene™ (Qiagen, Valencia, Calif.). In addition, systemic delivery methods can be optimized using commercially available cationic lipids such as DDAB or DOTAP, each of which can be mixed with a neutral lipid such as DOPE or cholesterol. In some cases, liposomes such as those described by Templeton et al. (Nature Biotechnology, 15: 647-652 (1997)) can be used. In other embodiments, polycations such as polyethyleneimine can be used to achieve delivery in vivo and ex vivo (Boletta et al., J. Am Soc. Nephrol. 7: 1728 (1996)). Additional information regarding the use of liposomes to deliver nucleic acids can be found in U.S. Pat. No. 6,271,359, PCT Publication WO 96/40964 and Morrissey, D. et al. 2005. Nat Biotechnol. 23(8): 1002-7.


Biologic delivery can be accomplished by a variety of methods including, without limitation, the use of viral vectors. For example, viral vectors (e.g., adenovirus and herpesvirus vectors) can be used to deliver dsRNA molecules to liver cells. Standard molecular biology techniques can be used to introduce one or more of the dsRNAs provided herein into one of the many different viral vectors previously developed to deliver nucleic acid to cells. These resulting viral vectors can be used to deliver the one or more dsRNAs to cells by, for example, infection.


dsRNAs of the present invention can be formulated in a pharmaceutically acceptable carrier or diluent. A “pharmaceutically acceptable carrier” (also referred to herein as an “excipient”) is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle. Pharmaceutically acceptable carriers can be liquid or solid, and can be selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, and other pertinent transport and chemical properties. Typical pharmaceutically acceptable carriers include, by way of example and not limitation: water; saline solution; binding agents (e.g., polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose and other sugars, gelatin, or calcium sulfate); lubricants (e.g., starch, polyethylene glycol, or sodium acetate); disintegrates (e.g., starch or sodium starch glycolate); and wetting agents (e.g., sodium lauryl sulfate).


In addition, dsRNA that target the PCSK9 gene can be formulated into compositions containing the dsRNA admixed, encapsulated, conjugated, or otherwise associated with other molecules, molecular structures, or mixtures of nucleic acids. For example, a composition containing one or more dsRNA agents that target the PCSK9 gene can contain other therapeutic agents such as other lipid lowering agents (e.g., statins).


Methods for Treating Diseases that can be Modulated by Down Regulating the Expression of PCSK9


The methods and compositions described herein can be used to treat diseases and conditions that can be modulated by down regulating PCSK9 gene expression. For example, the compositions described herein can be used to treat hyperlipidemia and other forms of lipid imbalance such as hypercholesterolemia, hypertriglyceridemia and the pathological conditions associated with these disorders such as heart and circulatory diseases.


Methods for Inhibiting Expression of the PCSK9 Gene


In yet another aspect, the invention provides a method for inhibiting the expression of the PCSK9 gene in a mammal. The method comprises administering a composition of the invention to the mammal such that expression of the target PCSK9 gene is silenced. Because of their high specificity, the dsRNAs of the invention specifically target RNAs (primary or processed) of the target PCSK9 gene. Compositions and methods for inhibiting the expression of these PCSK9 genes using dsRNAs can be performed as described elsewhere herein.


In one embodiment, the method comprises administering a composition comprising a dsRNA, wherein the dsRNA comprises a nucleotide sequence which is complementary to at least a part of an RNA transcript of the PCSK9 gene of the mammal to be treated. When the organism to be treated is a mammal such as a human, the composition may be administered by any means known in the art including, but not limited to oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol) administration. In preferred embodiments, the compositions are administered by intravenous infusion or injection.


Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.


EXAMPLES

Gene Walking of the PCSK9 Gene


siRNA design was carried out to identify in two separate selections


a) siRNAs targeting PCSK9 human and either mouse or rat mRNA and


b) all human reactive siRNAs with predicted specificity to the target gene PCSK9.


mRNA sequences to human, mouse and rat PCSK9 were used: Human sequence NM_174936.2 was used as reference sequence during the complete siRNA selection procedure.


19 mer stretches conserved in human and mouse, and human and rat PCSK9 mRNA sequences were identified in the first step, resulting in the selection of siRNAs crossreactive to human and mouse, and siRNAs crossreactive to human and rat targets


SiRNAs specifically targeting human PCSK9 were identified in a second selection. All potential 19 mer sequences of human PCSK9 were extracted and defined as candidate target sequences. Sequences cross-reactive to human, monkey, and those cross-reactive to mouse, rat, human and monkey are all listed in Tables 1 and 2. Chemically modified versions of those sequences and their activity in both in vitro and in vivo assays are also listed in tables 1 and 2 and examples given in FIGS. 2-8.


In order to rank candidate target sequences and their corresponding siRNAs and select appropriate ones, their predicted potential for interacting with irrelevant targets (off-target potential) was taken as a ranking parameter. siRNAs with low off-target potential were defined as preferable and assumed to be more specific in vivo.


For predicting siRNA-specific off-target potential, the following assumptions were made:


1) positions 2 to 9 (counting 5′ to 3′) of a strand (seed region) may contribute more to off-target potential than rest of sequence (non-seed and cleavage site region)


2) positions 10 and 11 (counting 5′ to 3′) of a strand (cleavage site region) may contribute more to off-target potential than non-seed region


3) positions 1 and 19 of each strand are not relevant for off-target interactions


4) an off-target score can be calculated for each gene and each strand, based on complementarity of siRNA strand sequence to the gene's sequence and position of mismatches


5) number of predicted off-targets as well as highest off-target score must be considered for off-target potential


6) off-target scores are to be considered more relevant for off-target potential than numbers of off-targets


7) assuming potential abortion of sense strand activity by internal modifications introduced, only off-target potential of antisense strand will be relevant


To identify potential off-target genes, 19 mer candidate sequences were subjected to a homology search against publically available human mRNA sequences.


The following off-target properties for each 19 mer input sequence were extracted for each off-target gene to calculate the off-target score:


Number of mismatches in non-seed region


Number of mismatches in seed region


Number of mismatches in cleavage site region


The off-target score was calculated for considering assumption 1 to 3 as follows:


Off-target score=number of seed mismatches*10+number of cleavage site mismatches*1.2+number of non-seed mismatches*1


The most relevant off-target gene for each siRNA corresponding to the input 19 mer sequence was defined as the gene with the lowest off-target score. Accordingly, the lowest off-target score was defined as the relevant off-target score for each siRNA.


dsRNA Synthesis


Source of Reagents


Where the source of a reagent is not specifically given herein, such reagent may be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.


siRNA Synthesis


Single-stranded RNAs were produced by solid phase synthesis on a scale of 1 μmole using an Expedite 8909 synthesizer (Applied Biosystems, Applera Deutschland GmbH, Darmstadt, Germany) and controlled pore glass (CPG, 500 Å, Proligo Biochemie GmbH, Hamburg, Germany) as solid support. RNA and RNA containing 2′-O-methyl nucleotides were generated by solid phase synthesis employing the corresponding phosphoramidites and 2′-O-methyl phosphoramidites, respectively (Proligo Biochemie GmbH, Hamburg, Germany). These building blocks were incorporated at selected sites within the sequence of the oligoribonucleotide chain using standard nucleoside phosphoramidite chemistry such as described in Current protocols in nucleic acid chemistry, Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA. Phosphorothioate linkages were introduced by replacement of the iodine oxidizer solution with a solution of the Beaucage reagent (Chruachem Ltd, Glasgow, UK) in acetonitrile (1%). Further ancillary reagents were obtained from Mallinckrodt Baker (Griesheim, Germany).


Deprotection and purification of the crude oligoribonucleotides by anion exchange HPLC were carried out according to established procedures. Yields and concentrations were determined by UV absorption of a solution of the respective RNA at a wavelength of 260 nm using a spectral photometer (DU 640B, Beckman Coulter GmbH, Unterschleiβheim, Germany). Double stranded RNA was generated by mixing an equimolar solution of complementary strands in annealing buffer (20 mM sodium phosphate, pH 6.8; 100 mM sodium chloride), heated in a water bath at 85-90° C. for 3 minutes and cooled to room temperature over a period of 3-4 hours. The annealed RNA solution was stored at −20° C. until use.


For the synthesis of 3′-cholesterol-conjugated siRNAs (herein referred to as -Chol-3′), an appropriately modified solid support was used for RNA synthesis. The modified solid support was prepared as follows:


Diethyl-2-azabutane-1,4-dicarboxylate AA




embedded image


A 4.7 M aqueous solution of sodium hydroxide (50 mL) was added into a stirred, ice-cooled solution of ethyl glycinate hydrochloride (32.19 g, 0.23 mole) in water (50 mL). Then, ethyl acrylate (23.1 g, 0.23 mole) was added and the mixture was stirred at room temperature until completion of the reaction was ascertained by TLC. After 19 h the solution was partitioned with dichloromethane (3×100 mL). The organic layer was dried with anhydrous sodium sulfate, filtered and evaporated. The residue was distilled to afford AA (28.8 g, 61%).


3-{Ethoxycarbonylmethyl-[6-(9H-fluoren-9-ylmethoxycarbonyl-amino)-hexanoyl]-amino}-propionic acid ethyl ester AB




embedded image


Fmoc-6-amino-hexanoic acid (9.12 g, 25.83 mmol) was dissolved in dichloromethane (50 mL) and cooled with ice. Diisopropylcarbodiimde (3.25 g, 3.99 mL, 25.83 mmol) was added to the solution at 0° C. It was then followed by the addition of Diethyl-azabutane-1,4-dicarboxylate (5 g, 24.6 mmol) and dimethylamino pyridine (0.305 g, 2.5 mmol). The solution was brought to room temperature and stirred further for 6 h. Completion of the reaction was ascertained by TLC. The reaction mixture was concentrated under vacuum and ethyl acetate was added to precipitate diisopropyl urea. The suspension was filtered. The filtrate was washed with 5% aqueous hydrochloric acid, 5% sodium bicarbonate and water. The combined organic layer was dried over sodium sulfate and concentrated to give the crude product which was purified by column chromatography (50% EtOAC/Hexanes) to yield 11.87 g (88%) of AB.


3-[(6-Amino-hexanoyl)-ethoxycarbonylmethyl-amino]-propionic acid ethyl ester AC




embedded image


3-{Ethoxycarbonylmethyl-[6-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoyl]-amino}-propionic acid ethyl ester AB (11.5 g, 21.3 mmol) was dissolved in 20% piperidine in dimethylformamide at 0° C. The solution was continued stirring for 1 h. The reaction mixture was concentrated under vacuum, water was added to the residue, and the product was extracted with ethyl acetate. The crude product was purified by conversion into its hydrochloride salt.


3-({6-[17-(1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}ethoxycarbonylmethyl-amino)-propionic acid ethyl ester AD




embedded image


The hydrochloride salt of 3-[(6-Amino-hexanoyl)-ethoxycarbonylmethyl-amino]-propionic acid ethyl ester AC (4.7 g, 14.8 mmol) was taken up in dichloromethane. The suspension was cooled to 0° C. on ice. To the suspension diisopropylethylamine (3.87 g, 5.2 mL, 30 mmol) was added. To the resulting solution cholesteryl chloroformate (6.675 g, 14.8 mmol) was added. The reaction mixture was stirred overnight. The reaction mixture was diluted with dichloromethane and washed with 10% hydrochloric acid. The product was purified by flash chromatography (10.3 g, 92%).


1-{6-[17-(1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a] phenanthren-3-yloxycarbonylamino]-hexanoyl}-4-oxo-pyrrolidine-3-carboxylic acid ethyl ester AE




embedded image


Potassium t-butoxide (1.1 g, 9.8 mmol) was slurried in 30 mL of dry toluene. The mixture was cooled to 0*C on ice and 5 g (6.6 mmol) of diester AD was added slowly with stirring within 20 mins. The temperature was kept below 5° C. during the addition. The stirring was continued for 30 mins at 0° C. and 1 mL of glacial acetic acid was added, immediately followed by 4 g of NaH2PO4·H2O in 40 mL of water The resultant mixture was extracted twice with 100 mL of dichloromethane each and the combined organic extracts were washed twice with 10 mL of phosphate buffer each, dried, and evaporated to dryness. The residue was dissolved in 60 mL of toluene, cooled to 0° C. and extracted with three 50 mL portions of cold pH 9.5 carbonate buffer. The aqueous extracts were adjusted to pH 3 with phosphoric acid, and extracted with five 40 mL portions of chloroform which were combined, dried and evaporated to dryness. The residue was purified by column chromatography using 25% ethylacetate/hexane to afford 1.9 g of b-ketoester (39%).


[6-(3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-yl)-6-oxo-hexyl]-carbamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester AF




embedded image


Methanol (2 mL) was added dropwise over a period of 1 h to a refluxing mixture of b-ketoester AE (1.5 g, 2.2 mmol) and sodium borohydride (0.226 g, 6 mmol) in tetrahydrofuran (10 mL). Stirring was continued at reflux temperature for 1 h. After cooling to room temperature, 1 N HCl (12.5 mL) was added, the mixture was extracted with ethylacetate (3×40 mL). The combined ethylacetate layer was dried over anhydrous sodium sulfate and concentrated under vacuum to yield the product which was purified by column chromatography (10% MeOH/CHCl3) (89%).


(6-{3-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-pyrrolidin-1-yl}-6-oxo-hexyl)-carbamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester AG




embedded image


Diol AF (1.25 gm 1.994 mmol) was dried by evaporating with pyridine (2×5 mL) in vacuo. Anhydrous pyridine (10 mL) and 4,4′-dimethoxytritylchloride (0.724 g, 2.13 mmol) were added with stirring. The reaction was carried out at room temperature overnight. The reaction was quenched by the addition of methanol. The reaction mixture was concentrated under vacuum and to the residue dichloromethane (50 mL) was added. The organic layer was washed with 1M aqueous sodium bicarbonate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residual pyridine was removed by evaporating with toluene. The crude product was purified by column chromatography (2% MeOH/Chloroform, Rf=0.5 in 5% MeOH/CHCl3) (1.75 g, 95%).


Succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl 2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl) ester AH




embedded image


Compound AG (1.0 g, 1.05 mmol) was mixed with succinic anhydride (0.150 g, 1.5 mmol) and DMAP (0.073 g, 0.6 mmol) and dried in a vacuum at 40° C. overnight. The mixture was dissolved in anhydrous dichloroethane (3 mL), triethylamine (0.318 g, 0.440 mL, 3.15 mmol) was added and the solution was stirred at room temperature under argon atmosphere for 16 h. It was then diluted with dichloromethane (40 mL) and washed with ice cold aqueous citric acid (5 wt %, 30 mL) and water (2×20 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to dryness. The residue was used as such for the next step.


Cholesterol Derivatised CPG AI




embedded image


Succinate AH (0.254 g, 0.242 mmol) was dissolved in a mixture of dichloromethane/acetonitrile (3:2, 3 mL). To that solution DMAP (0.0296 g, 0.242 mmol) in acetonitrile (1.25 mL), 2,2′-Dithio-bis(5-nitropyridine) (0.075 g, 0.242 mmol) in acetonitrile/dichloroethane (3:1, 1.25 mL) were added successively. To the resulting solution triphenylphosphine (0.064 g, 0.242 mmol) in acetonitrile (0.6 ml) was added. The reaction mixture turned bright orange in color. The solution was agitated briefly using a wrist-action shaker (5 mins). Long chain alkyl amine-CPG (LCAA-CPG) (1.5 g, 61 mM) was added. The suspension was agitated for 2 h. The CPG was filtered through a sintered funnel and washed with acetonitrile, dichloromethane and ether successively. Unreacted amino groups were masked using acetic anhydride/pyridine. The achieved loading of the CPG was measured by taking UV measurement (37 mM/g).


The synthesis of siRNAs bearing a 5′-12-dodecanoic acid bisdecylamide group (herein referred to as “5′-C32-”) or a 5′-cholesteryl derivative group (herein referred to as “5′-Chol-”) was performed as described in WO 2004/065601, except that, for the cholesteryl derivative, the oxidation step was performed using the Beaucage reagent in order to introduce a phosphorothioate linkage at the 5′-end of the nucleic acid oligomer.


Nucleic acid sequences are represented below using standard nomenclature, and specifically the abbreviations of Table 1-2.


PCSK9 siRNA Screening in HuH7, HenG2, Hela and Primary Monkey Hepatocytes Discovers Highly Active Sequences


HuH-7 cells were obtained from JCRB Cell Bank (Japanese Collection of Research Bioresources) (Shinjuku, Japan, cat. No.: JCRBO403) Cells were cultured in Dulbecco's MEM (Biochrom AG, Berlin, Germany, cat. No. F0435) supplemented to contain 10% fetal calf serum (FCS) (Biochrom AG, Berlin, Germany, cat. No. S0115), Penicillin 100 U/ml, Streptomycin 100 μg/ml (Biochrom AG, Berlin, Germany, cat. No. A2213) and 2 mM L-Glutamin (Biochrom AG, Berlin, Germany, cat. No K0282) at 37° C. in an atmosphere with 5% CO2 in a humidified incubator (Heraeus HERAcell, Kendro Laboratory Products, Langenselbold, Germany). HepG2 and Hela cells were obtained from American Type Culture Collection (Rockville, Md., cat. No. HB-8065) and cultured in MEM (Gibco Invitrogen, Karlsruhe, Germany, cat. No. 21090-022) supplemented to contain 10% fetal calf serum (FCS) (Biochrom AG, Berlin, Germany, cat. No. S0115), Penicillin 100 U/ml, Streptomycin 100 μg/ml (Biochrom AG, Berlin, Germany, cat. No. A2213), 1× Non Essential Amino Acids (Biochrom AG, Berlin, Germany, cat. No. K-0293), and 1 mM Sodium Pyruvate (Biochrom AG, Berlin, Germany, cat. No. L-0473) at 37° C. in an atmosphere with 5% CO2 in a humidified incubator (Heraeus HERAcell, Kendro Laboratory Products, Langenselbold, Germany).


For transfection with siRNA, HuH7, HepG2, or Hela cells were seeded at a density of 2.0×104 cells/well in 96-well plates and transfected directly. Transfection of siRNA (30 nM for single dose screen) was carried out with lipofectamine 2000 (Invitrogen GmbH, Karlsruhe, Germany, cat. No. 11668-019) as described by the manufacturer.


24 hours after transfection HuH7 and HepG2 cells were lysed and PCSK9 mRNA levels were quantified with the Quantigene Explore Kit (Genosprectra, Dumbarton Circle Fremont, USA, cat. No. QG-000-02) according to the protocol. PCSK9 mRNA levels were normalized to GAP-DH mRNA. For each siRNA eight individual datapoints were collected. siRNA duplexes unrelated to PCSK9 gene were used as control. The activity of a given PCSK9 specific siRNA duplex was expressed as percent PCSK9 mRNA concentration in treated cells relative to PCSK9 mRNA concentration in cells treated with the control siRNA duplex.


Primary cynomolgus monkey hepatocytes (cryopreserved) were obtained from In vitro Technologies, Inc. (Baltimore, Md., USA, cat No M00305) and cultured in InVitroGRO CP Medium (cat No Z99029) at 37° C. in an atmosphere with 5% CO2 in a humidified incubator.


For transfection with siRNA, primary cynomolgus monkey cells were seeded on Collagen coated plates (Fisher Scientific, cat. No. 08-774-5) at a density of 3.5×104 cells/well in 96-well plates and transfected directly. Transfection of siRNA (eight 2-fold dilution series starting from 30 nM) in duplicates was carried out with lipofectamine 2000 (Invitrogen GmbH, Karlsruhe, Germany, cat. No. 11668-019) as described by the manufacturer.


16 hours after transfection medium was changed to fresh InVitroGRO CP Medium with Torpedo Antibiotic Mix (In vitro Technologies, Inc, cat. No Z99000) added.


24 hours after medium change primary cynomolgus monkey cells were lysed and PCSK9 mRNA levels were quantified with the Quantigene Explore Kit (Genosprectra, Dumbarton Circle Fremont, USA, cat. No. QG-000-02) according to the protocol. PCSK9 mRNA levels were normalized to GAPDH mRNA. Normalized PCSK9/GAPDH ratios were then compared to PCSK9/GAPDH ratio of lipofectamine 2000 only control.


Tables 1-2 (and FIG. 6) summarize the results and provides examples of in vitro screens in different cell lines at different doses. Silencing of PCSK9 transcript was expressed as percentage of remaining transcript at a given dose. Highly active sequences are those with less than 70% transcript remaining post treatment with a given siRNA at a dose less than or equal to 100 nm. Very active sequences are those that have less than 60% of transcript remaining after treatment with a dose. less than or equal to 100 nM. Active sequences are those that have less than 85% transcript remaining after treatment with a high dose (100 nM). Examples of active siRNA's were also screened in vivo in mouse in lipidoid formulations as described below. Active sequences in vitro were also generally active in vivo (See figure FIG. 6 example).


In Vivo Efficacy Screen of PCSK9 siRNAs


Formulation Procedure


The lipidoid LNP-01.4HCl (MW 1487) (FIG. 1), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) were used to prepare lipid-siRNA nanoparticles. Stock solutions of each in ethanol were prepared: LNP-01, 133 mg/mL; Cholesterol, 25 mg/mL, PEG-Ceramide C16, 100 mg/mL. LNP-01, Cholesterol, and PEG-Ceramide C16 stock solutions were then combined in a 42:48:10 molar ratio. Combined lipid solution was mixed rapidly with aqueous siRNA (in sodium acetate pH 5) such that the final ethanol concentration was 35-45% and the final sodium acetate concentration was 100-300 mM. Lipid-siRNA nanoparticles formed spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture was in some cases extruded through a polycarbonate membrane (100 nm cut-off) using a thermobarrel extruder (Lipex Extruder, Northern Lipids, Inc). In other cases, the extrusion step was omitted. Ethanol removal and simultaneous buffer exchange was accomplished by either dialysis or tangential flow filtration. Buffer was exchanged to phosphate buffered saline (PBS) pH 7.2.


Characterization of Formulations


Formulations prepared by either the standard or extrusion-free method are characterized in a similar manner. Formulations are first characterized by visual inspection. They should be whitish translucent solutions free from aggregates or sediment. Particle size and particle size distribution of lipid-nanoparticles are measured by dynamic light scattering using a Malvem Zetasizer Nano ZS (Malvem, USA). Particles should be 20-300 nm, and ideally, 40-100 nm in size. The particle size distribution should be unimodal. The total siRNA concentration in the formulation, as well as the entrapped fraction, is estimated using a dye exclusion assay. A sample of the formulated siRNA is incubated with the RNA-binding dye Ribogreen (Molecular Probes) in the presence or absence of a formulation disrupting surfactant, 0.5% Triton-X100. The total siRNA in the formulation is determined by the signal from the sample containing the surfactant, relative to a standard curve. The entrapped fraction is determined by subtracting the “free” siRNA content (as measured by the signal in the absence of surfactant) from the total siRNA content. Percent entrapped siRNA is typically >85%.


Bolus Dosing


Bolus dosing of formulated siRNAs in C57/BL6 mice (5/group, 8-10 weeks old, Charles River Laboratories, MA) was performed by tail vein injection using a 27 G needle. SiRNAs were formulated in LNP-01 (and then dialyzed against PBS) at 0.5 mg/ml concentration allowing the delivery of the 5 mg/kg dose in 10 μl/g body weight. Mice were kept under an infrared lamp for approximately 3 min prior to dosing to ease injection.


48 hour post dosing mice were sacrificed by CO2-asphyxiation. 0.2 ml blood was collected by retro-orbital bleeding and the liver was harvested and frozen in liquid nitrogen. Serum and livers were stored at −80° C.


Frozen livers were grinded using 6850 Freezer/Mill Cryogenic Grinder (SPEX CentriPrep, Inc) and powders stored at −80° C. until analysis.


PCSK9 mRNA levels were detected using the branched-DNA technology based kit from QuantiGene Reagent System (Genospectra) according to the protocol. 10-20 mg of frozen liver powders was lysed in 600 ul of 0.16 ug/ml Proteinase K (Epicentre, #MPRK092) in Tissue and Cell Lysis Solution (Epicentre, #MTC096H) at 65° C. for 3 hours. Then 10 ul of the lysates were added to 90 ul of Lysis Working Reagent (1 volume of stock Lysis Mixture in two volumes of water) and incubated at 52° C. overnight on Genospectra capture plates with probe sets specific to mouse PCSK9 and mouse GAPDH or cyclophilin B. Nucleic acid sequences for Capture Extender (CE), Label Extender (LE) and blocking (BL) probes were selected from the nucleic acid sequences of PCSK9, GAPDH and cyclophilin B with the help of the QuantiGene ProbeDesigner Software 2.0 (Genospectra, Fremont, Calif., USA, cat. No. QG-002-02). Chemo luminescence was read on a Victor2-Light (Perkin Elmer) as Relative light units. The ratio of PCSK9 mRNA to GAPDH or cyclophilin B mRNA in liver lysates was averaged over each treatment group and compared to a control group treated with PBS or a control group treated with an unrelated siRNA (blood coagulation factor VII).


Total serum cholesterol in mouse serum was measured using the StanBio Cholesterol LiquiColor kit (StanBio Laboratoriy, Boeme, Tex., USA) according to manufacturer's instructions. Measurements were taken on a Victor2 1420 Multilabel Counter (Perkin Elmer) at 495 nm.


EXAMPLES

32 PCSK9 siRNAs formulated in LNP-01 liposomes were tested in vivo in a mouse model. The experiment was performed at 5 mg/kg siRNA dose and at least 10 PCSK9 siRNAs showed more than 40% PCSK9 mRNA knock down compared to a control group treated with PBS, while control group treated with an unrelated siRNA (blood coagulation factor VII) had no effect (FIGS. 2-5). Silencing of PCSK9 transcript also coorelated with a lowering of cholesterol in these animals (FIGS. 4-5). In addition there was a strong coorelation between those molecules that were active in vitro and those active in vivo (FIG. 6). Sequences containing different chemical modifications were also screened in vitro (Tables 1 and 2) and in vivo. As an example, less modified sequences 9314 and 9318, and a more modified versions of that sequence 9314-(10792, 10793, and 10796); 9318-(10794, 10795, 10797) were tested both in vitro (In primary monkey hepatocytes) or in vivo (9314 and 10792) formulated in LNP-01. FIG. 7 (also see Tables 1 and 2) shows that the parent molecules 9314 and 9318 and the modified versions are all active in vitro. FIG. 8 as an example shows that both the parent 9314 and the more highly modified 10792 sequences are active in vivo displaying 50-60% silencing of endogenous PCSK9 in mice. FIG. 9 further exemplifies that activity of other chemically modified versions of the parents 9314 and 10792.


dsRNA Expression Vectors


In another aspect of the invention, PCSK9 specific dsRNA molecules that modulate PCSK9 gene expression activity are expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; Skillem, A., et al., International PCT Publication No. WO 00/22113, Conrad, International PCT Publication No. WO 00/22114, and Conrad, U.S. Pat. No. 6,054,299). These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be incorporated and inherited as a transgene integrated into the host genome. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad. Sci. USA (1995) 92:1292).


The individual strands of a dsRNA can be transcribed by promoters on two separate expression vectors and co-transfected into a target cell. Alternatively each individual strand of the dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In a preferred embodiment, a dsRNA is expressed as an inverted repeat joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.


The recombinant dsRNA expression vectors are generally DNA plasmids or viral vectors. dsRNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus (for a review, see Muzyczka, et al., Curr. Topics Micro. Immunol. (1992) 158:97-129)); adenovirus (see, for example, Berkner, et al., BioTechniques (1998) 6:616), Rosenfeld et al. (1991, Science 252:431-434), and Rosenfeld et al. (1992), Cell 68:143-155)); or alphavirus as well as others known in the art. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see, e.g., Eglitis, et al., Science (1985) 230:1395-1398; Danos and Mulligan, Proc. Natl. Acad. Sci. USA (1998) 85:6460-6464; Wilson et al., 1988, Proc. NatI. Acad. Sci. USA 85:3014-3018; Armentano et al., 1990, Proc. NatI. Acad. Sci. USA 87:61416145; Huber et al., 1991, Proc. NatI. Acad. Sci. USA 88:8039-8043; Ferry et al., 1991, Proc. NatI. Acad. Sci. USA 88:8377-8381; Chowdhury et al., 1991, Science 254:1802-1805; van Beusechem. et al., 1992, Proc. Nad. Acad. Sci. USA 89:7640-19; Kay et al., 1992, Human Gene Therapy 3:641-647; Dai et al., 1992, Proc. Natl. Acad. Sci. USA 89:10892-10895; Hwu et al., 1993, J. Immunol. 150:4104-4115; U.S. Pat. Nos. 4,868,116; 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573). Recombinant retroviral vectors capable of transducing and expressing genes inserted into the genome of a cell can be produced by transfecting the recombinant retroviral genome into suitable packaging cell lines such as PA317 and Psi-CRIP (Comette et al., 1991, Human Gene Therapy 2:5-10; Cone et al., 1984, Proc. Natl. Acad. Sci. USA 81:6349). Recombinant adenoviral vectors can be used to infect a wide variety of cells and tissues in susceptible hosts (e.g., rat, hamster, dog, and chimpanzee) (Hsu et al., 1992, J. Infectious Disease, 166:769), and also have the advantage of not requiring mitotically active cells for infection.


The promoter driving dsRNA expression in either a DNA plasmid or viral vector of the invention may be a eukaryotic RNA polymerase I (e.g. ribosomal RNA promoter), RNA polymerase II (e.g. CMV early promoter or actin promoter or U1 snRNA promoter) or generally RNA polymerase III promoter (e.g. U6 snRNA or 7SK RNA promoter) or a prokaryotic promoter, for example the T7 promoter, provided the expression plasmid also encodes T7 RNA polymerase required for transcription from a T7 promoter. The promoter can also direct transgene expression to the pancreas (see, e.g. the insulin regulatory sequence for pancreas (Bucchini et al., 1986, Proc. Natl. Acad. Sci. USA 83:2511-2515)).


In addition, expression of the transgene can be precisely regulated, for example, by using an inducible regulatory sequence and expression systems such as a regulatory sequence that is sensitive to certain physiological regulators, e.g., circulating glucose levels, or hormones (Docherty et al., 1994, FASEB J. 8:20-24). Such inducible expression systems, suitable for the control of transgene expression in cells or in mammals include regulation by ecdysone, by estrogen, progesterone, tetracycline, chemical inducers of dimerization, and isopropyl-beta-D1-thiogalactopyranoside (EPTG). A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the dsRNA transgene.


Generally, recombinant vectors capable of expressing dsRNA molecules are delivered as described below, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of dsRNA molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the dsRNAs bind to target RNA and modulate its function or expression. Delivery of dsRNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.


dsRNA expression DNA plasmids are typically transfected into target cells as a complex with cationic lipid carriers (e.g. Oligofectamine) or non-cationic lipid-based carriers (e.g. Transit-TKO™). Multiple lipid transfections for dsRNA-mediated knockdowns targeting different regions of a single PCSK9 gene or multiple PCSK9 genes over a period of a week or more are also contemplated by the invention. Successful introduction of the vectors of the invention into host cells can be monitored using various known methods. For example, transient transfection. can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection. of ex vivo cells can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (e.g., antibiotics and drugs), such as hygromycin B resistance.


The PCSK9 specific dsRNA molecules can also be inserted into vectors and used as gene therapy vectors for human patients. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.


Those skilled in the art are familiar with methods and compositions in addition to those specifically set out in the instant disclosure which will allow them to practice this invention to the full scope of the claims hereinafter appended.









TABLE 1







sequences












position







in human

SEQ

SEQ



access. #
Sense strand
ID
Antisense-strand
ID
Duplex


NM_174936
sequence (5′-3′)1
NO:
sequence (5′-3′)1
NO:
name





 2-20
AGCGACGUCGAGGCGCUCATT
   1
UGAGCGCCUCGACGUCGCUTT
   2
AD-15220





15-33
CGCUCAUGGUUGCAGGCGGTT
   3
CCGCCUGCAACCAUGAGCGTT
   4
AD-15275





16-34
GCUCAUGGUUGCAGGCGGGTT
   5
CCCGCCUGCAACCAUGAGCTT
   6
AD-15301





30-48
GCGGGCGCCGCCGUUCAGUTT
   7
ACUGAACGGCGGCGCCCGCTT
   8
AD-15276





31-49
CGGGCGCCGCCGUUCAGUUTT
   9
AACUGAACGGCGGCGCCCGTT
  10
AD-15302





32-50
GGGCGCCGCCGUUCAGUUCTT
  11
GAACUGAACGGCGGCGCCCTT
  12
AD-15303





40-58
CCGUUCAGUUCAGGGUCUGTT
  13
CAGACCCUGAACUGAACGGTT
  14
AD-15221





43-61
UUCAGUUCAGGGUCUGAGCTT
  15
GCUCAGACCCUGAACUGAATT
  16
AD-15413





 82-100
GUGAGACUGGCUCGGGCGGTT
  17
CCGCCCGAGCCAGUCUCACTT
  18
AD-15304





100-118
GGCCGGGACGCGUCGUUGCTT
  19
GCAACGACGCGUCCCGGCCTT
  20
AD-15305





101-119
GCCGGGACGCGUCGUUGCATT
  21
UGCAACGACGCGUCCCGGCTT
  22
AD-15306





102-120
CCGGGACGCGUCGUUGCAGTT
  23
CUGCAACGACGCGUCCCGGTT
  24
AD-15307





105-123
GGACGCGUCGUUGCAGCAGTT
  25
CUGCUGCAACGACGCGUCCTT
  26
AD-15277





135-153
UCCCAGCCAGGAUUCCGCGTsT
  27
CGCGGAAUCCUGGCUGGGATsT
  28
AD-9526





135-153
ucccAGccAGGAuuccGcGTsT
  29
CGCGGAAUCCUGGCUGGGATsT
  30
AD-9652





136-154
CCCAGCCAGGAUUCCGCGCTsT
  31
GCGCGGAAUCCUGGCUGGGTsT
  32
AD-9519





136-154
cccAGccAGGAuuccGcGcTsT
  33
GCGCGGAAUCCUGGCUGGGTsT
  34
AD-9645





138-156
CAGCCAGGAUUCCGCGCGCTsT
  35
GCGCGCGGAAUCCUGGCUGTsT
  36
AD-9523





138-156
cAGccAGGAuuccGcGcGcTsT
  37
GCGCGCGGAAUCCUGGCUGTsT
  38
AD-9649





185-203
AGCUCCUGCACAGUCCUCCTsT
  39
GGAGGACUGUGCAGGAGCUTsT
  40
AD-9569





185-203
AGcuccuGcAcAGuccuccTsT
  41
GGAGGACUGUGcAGGAGCUTsT
  42
AD-9695





205-223
CACCGCAAGGCUCAAGGCGTT
  43
CGCCUUGAGCCUUGCGGUGTT
  44
AD-15222





208-226
CGCAAGGCUCAAGGCGCCGTT
  45
CGGCGCCUUGAGCCUUGCGTT
  46
AD-15278





210-228
CAAGGCUCAAGGCGCCGCCTT
  47
GGCGGCGCCUUGAGCCUUGTT
  48
AD-15178





232-250
GUGGACCGCGCACGGCCUCTT
  49
GAGGCCGUGCGCGGUCCACTT
  50
AD-15308





233-251
UGGACCGCGCACGGCCUCUTT
  51
AGAGGCCGUGCGCGGUCCATT
  52
AD-15223





234-252
GGACCGCGCACGGCCUCUATT
  53
UAGAGGCCGUGCGCGGUCCTT
  54
AD-15309





235-253
GACCGCGCACGGCCUCUAGTT
  55
CUAGAGGCCGUGCGCGGUCTT
  56
AD-15279





236-254
ACCGCGCACGGCCUCUAGGTT
  57
CCUAGAGGCCGUGCGCGGUTT
  58
AD-15194





237-255
CCGCGCACGGCCUCUAGGUTT
  59
ACCUAGAGGCCGUGCGCGGTT
  60
AD-15310





238-256
CGCGCACGGCCUCUAGGUCTT
  61
GACCUAGAGGCCGUGCGCGTT
  62
AD-15311





239-257
GCGCACGGCCUCUAGGUCUTT
  63
AGACCUAGAGGCCGUGCGCTT
  64
AD-15392





240-258
CGCACGGCCUCUAGGUCUCTT
  65
GAGACCUAGAGGCCGUGCGTT
  66
AD-15312





248-266
CUCUAGGUCUCCUCGCCAGTT
  67
CUGGCGAGGAGACCUAGAGTT
  68
AD-15313





249-267
UCUAGGUCUCCUCGCCAGGTT
  69
CCUGGCGAGGAGACCUAGATT
  70
AD-15280





250-268
CUAGGUCUCCUCGCCAGGATT
  71
UCCUGGCGAGGAGACCUAGTT
  72
AD-15267





252-270
AGGUCUCCUCGCCAGGACATT
  73
UGUCCUGGCGAGGAGACCUTT
  74
AD-15314





258-276
CCUCGCCAGGACAGCAACCTT
  75
GGUUGCUGUCCUGGCGAGGTT
  76
AD-15315





300-318
CGUCAGCUCCAGGCGGUCCTsT
  77
GGACCGCCUGGAGCUGACGTsT
  78
AD-9624





300-318
cGucAGcuccAGGeGGuccTsT
  79
GGACCGCCUGGAGCUGACGTsT
  80
AD-9750





301-319
GUCAGCUCCAGGCGGUCCUTsT
  81
AGGACCGCCUGGAGCUGACTsT
  82
AD-9623





301-319
GucAGcuccAGaGGuccuTsT
  83
AGGACCGCCUGGAGCUGACTsT
  84
AD-9749





370-388
GGCGCCCGUGCGCAGGAGGTT
  85
CCUCCUGCGCACGGGCGCCTT
  86
AD-15384





408-426
GGAGCUGGUGCUAGCCUUGTsT
  87
CAAGGCUAGCACCAGCUCCTsT
  88
AD-9607





408-426
GGAGcuGGuGcuAGccuuGTsT
  89
cAAGGCuAGcACcAGCUCCTsT
  90
AD-9733





411-429
GCUGGUGCUAGCCUUGCGUTsT
  91
ACGCAAGGCUAGCACCAGCTsT
  92
AD-9524





411-429
GcuGGuGcuAGccuuGcGuTsT
  93
ACGcAAGGCuAGcACcAGCTsT
  94
AD-9650





412-430
CUGGUGCUAGCCUUGCGUUTsT
  95
AACGCAAGGCUAGCACCAGTsT
  96
AD-9520





412-430
CUGGUGCUAGCCUUGCGUUTsT
  97
AACGCAAGGCUAGCACCAGTsT
  98
AD-9520





412-430
cuGGuGcuAGccuuGcGuuTsT
  99
AACGcAAGGCuAGcACcAGTsT
 100
AD-9646





416-434
UGCUAGCCUUGCGUUCCGATsT
 101
UCGGAACGCAAGGCUAGCATsT
 102
AD-9608





416-434
uGcuAGccuuGcGuuccGATsT
 103
UCGGAACGcAAGGCuAGcATsT
 104
AD-9734





419-437
UAGCCUUGCGUUCCGAGGATsT
 105
UCCUCGGAACGCAAGGCUATsT
 106
AD-9546





419-437
uAGccuuGcGuuccGAGGATsT
 107
UCCUCGGAACGcAAGGCuATsT
 108
AD-9672





439-457
GACGGCCUGGCCGAAGCACTT
 109
GUGCUUCGGCCAGGCCGUCTT
 110
AD-15385





447-465
GGCCGAAGCACCCGAGCACTT
 111
GUGCUCGGGUGCUUCGGCCTT
 112
AD-15393





448-466
GCCGAAGCACCCGAGCACGTT
 113
CGUGCUCGGGUGCUUCGGCTT
 114
AD-15316





449-467
CCGAAGCACCCGAGCACGGTT
 115
CCGUGCUCGGGUGCUUCGGTT
 116
AD-15317





458-476
CCGAGCACGGAACCACAGCTT
 117
GCUGUGGUUCCGUGCUCGGTT
 118
AD-15318





484-502
CACCGCUGCGCCAAGGAUCTT
 119
GAUCCUUGGCGCAGCGGUGTT
 120
AD-15195





486-504
CCGCUGCGCCAAGGAUCCGTT
 121
CGGAUCCUUGGCGCAGCGGTT
 122
AD-15224





487-505
CGCUGCGCCAAGGAUCCGUTT
 123
ACGGAUCCUUGGCGCAGCGTT
 124
AD-15188





489-507
CUGCGCCAAGGAUCCGUGGTT
 125
CCACGGAUCCUUGGCGCAGTT
 126
AD-15225





500-518
AUCCGUGGAGGUUGCCUGGTT
 127
CCAGGCAACCUCCACGGAUTT
 128
AD-15281





509-527
GGUUGCCUGGCACCUACGUTT
 129
ACGUAGGUGCCAGGCAACCTT
 130
AD-15282





542-560
AGGAGACCCACCUCUCGCATT
 131
UGCGAGAGGUGGGUCUCCUTT
 132
AD-15319





543-561
GGAGACCCACCUCUCGCAGTT
 133
CUGCGAGAGGUGGGUCUCCTT
 134
AD-15226





544-562
GAGACCCACCUCUCGCAGUTT
 135
ACUGCGAGAGGUGGGUCUCTT
 136
AD-15271





549-567
CCACCUCUCGCAGUCAGAGTT
 137
CUCUGACUGCGAGAGGUGGTT
 138
AD-15283





552-570
CCUCUCGCAGUCAGAGCGCTT
 139
GCGCUCUGACUGCGAGAGGTT
 140
AD-15284





553-571
CUCUCGCAGUCAGAGCGCATT
 141
UGCGCUCUGACUGCGAGAGTT
 142
AD-15189





554-572
UCUCGCAGUCAGAGCGCACTT
 143
GUGCGCUCUGACUGCGAGATT
 144
AD-15227





555-573
CUCGCAGUCAGAGCGCACUTsT
 145
AGUGCGCUCUGACUGCGAGTsT
 146
AD-9547





555-573
cucGcAGucAGAGcGcAcuTsT
 147
AGUGCGCUCUGACUGCGAGTsT
 148
AD-9673





558-576
GCAGUCAGAGCGCACUGCCTsT
 149
GGCAGUGCGCUCUGACUGCTsT
 150
AD-9548





558-576
GcAGucAGAGcGcAcuGccTsT
 151
GGcAGUGCGCUCUGACUGCTsT
 152
AD-9674





606-624
GGGAUACCUCACCAAGAUCTsT
 153
GAUCUUGGUGAGGUAUCCCTsT
 154
AD-9529





606-624
GGGAuAccucAccAAGAucTsT
 155
GAUCUUGGUGAGGuAUCCCTsT
 156
AD-9655





659-677
UGGUGAAGAUGAGUGGCGATsT
 157
UCGCCACUCAUCUUCACCATsT
 158
AD-9605





659-677
uGGuGAAGAuGAGuGGcGATsT
 159
UCGCcACUcAUCUUcACcATsT
 160
AD-9731





663-681
GAAGAUGAGUGGCGACCUGTsT
 161
CAGGUCGCCACUCAUCUUCTsT
 162
AD-9596





663-681
GAAGAuGAGuGGcGAccuGTsT
 163
cAGGUCGCcACUcAUCUUCTsT
 164
AD-9722





704-722
CCCAUGUCGACUACAUCGATsT
 165
UCGAUGUAGUCGACAUGGGTsT
 166
AD-9583





704-722
cccAuGucGAcuAcAucGATsT
 167
UCGAUGuAGUCGAcAUGGGTsT
 168
AD-9709





718-736
AUCGAGGAGGACUCCUCUGTsT
 169
CAGAGGAGUCCUCCUCGAUTsT
 170
AD-9579





718-736
AucGAGGAGGAcuccucuGTsT
 171
cAGAGGAGUCCUCCUCGAUTsT
 172
AD-9705





758-776
GGAACCUGGAGCGGAUUACTT
 173
GUAAUCCGCUCCAGGUUCCTT
 174
AD-15394





759-777
GAACCUGGAGCGGAUUACCTT
 175
GGUAAUCCGCUCCAGGUUCTT
 176
AD-15196





760-778
AACCUGGAGCGGAUUACCCTT
 177
GGGUAAUCCGCUCCAGGUUTT
 178
AD-15197





777-795
CCCUCCACGGUACCGGGCGTT
 179
CGCCCGGUACCGUGGAGGGTT
 180
AD-15198





782-800
CACGGUACCGGGCGGAUGATsT
 181
UCAUCCGCCCGGUACCGUGTsT
 182
AD-9609





782-800
cAcGGuAccGGaGGAuGATsT
 183
UcAUCCGCCCGGuACCGUGTsT
 184
AD-9735





783-801
ACGGUACCGGGCGGAUGAATsT
 185
UUCAUCCGCCCGGUACCGUTsT
 186
AD-9537





783-801
AcGGuAccGGaGGAuGAATsT
 187
UUcAUCCGCCCGGuACCGUTsT
 188
AD-9663





784-802
CGGUACCGGGCGGAUGAAUTsT
 189
AUUCAUCCGCCCGGUACCGTsT
 190
AD-9528





784-802
cGGuAccGGGcGGAuGAAuTsT
 191
AUUcAUCCGCCCGGuACCGTsT
 192
AD-9654





785-803
GGUACCGGGCGGAUGAAUATsT
 193
UAUUCAUCCGCCCGGUACCTsT
 194
AD-9515





785-803
GGuAccGGaGGAuGAAuATsT
 195
uAUUcAUCCGCCCGGuACCTsT
 196
AD-9641





786-804
GUACCGGGCGGAUGAAUACTsT
 197
GUAUUCAUCCGCCCGGUACTsT
 198
AD-9514





786-804
GuAccGGGcGGAuGAAuAcTsT
 199
GuAUUcAUCCGCCCGGuACTsT
 200
AD-9640





788-806
ACCGGGCGGAUGAAUACCATsT
 201
UGGUAUUCAUCCGCCCGGUTsT
 202
AD-9530





788-806
AccGGGcGGAuGAAuAccATsT
 203
UGGuAUUcAUCCGCCCGGUTsT
 204
AD-9656





789-807
CCGGGCGGAUGAAUACCAGTsT
 205
CUGGUAUUCAUCCGCCCGGTsT
 206
AD-9538





789-807
ccGGaGGAuGAAuAccAGTsT
 207
CUGGuAUUcAUCCGCCCGGTsT
 208
AD-9664





825-843
CCUGGUGGAGGUGUAUCUCTsT
 209
GAGAUACACCUCCACCAGGTsT
 210
AD-9598





825-843
ccuGGuGGAGGuGuAucucTsT
 211
GAGAuAcACCUCcACcAGGTsT
 212
AD-9724





826-844
CUGGUGGAGGUGUAUCUCCTsT
 213
GGAGAUACACCUCCACCAGTsT
 214
AD-9625





826-844
cuGGuGGAGGuGuAucuccTsT
 215
GGAGAuAcACCUCcACcAGTsT
 216
AD-9751





827-845
UGGUGGAGGUGUAUCUCCUTsT
 217
AGGAGAUACACCUCCACCATsT
 218
AD-9556





827-845
uGGuGGAGGuGuAucuccuTsT
 219
AGGAGAuAcACCUCcACcATsT
 220
AD-9682





828-846
GGUGGAGGUGUAUCUCCUATsT
 221
UAGGAGAUACACCUCCACCTsT
 222
AD-9539





828-846
GGuGGAGGuGuAucuccuATsT
 223
uAGGAGAuAcACCUCcACCTsT
 224
AD-9665





831-849
GGAGGUGUAUCUCCUAGACTsT
 225
GUCUAGGAGAUACACCUCCTsT
 226
AD-9517





831-849
GGAGGuGuAucuccuAGAcTsT
 227
GUCuAGGAGAuAcACCUCCTsT
 228
AD-9643





833-851
AGGUGUAUCUCCUAGACACTsT
 229
GUGUCUAGGAGAUACACCUTsT
 230
AD-9610





833-851
AGGuGuAucuccuAGAcAcTsT
 231
GUGUCuAGGAGAuAcACCUTsT
 232
AD-9736





833-851
AfgGfuGfuAfuCfuCfcUfaG
 233
p-gUfgUfcUfaGfgAfgAfuA
 234
AD-14681



faCfaCfTsT

fcAfcCfuTsT







833-851
AGGUfGUfAUfCfUfCfCfUfA
 235
GUfGUfCfUfAGGAGAUfACfA
 236
AD-14691



GACfACfTsT

CfCfUfTsT







833-851
AgGuGuAuCuCcUaGaCaCTsT
 237
p-gUfgUfcUfaGfgAfgAfuA
 238
AD-14701





fcAfcCfuTsT







833-851
AgGuGuAuCuCcUaGaCaCTsT
 239
GUfGUfCfUfAGGAGAUfACfA
 240
AD-14711





CfCfUfTsT







833-851
AfgGfuGfuAfuCfuCfcUfaG
 241
GUGUCuaGGagAUACAccuTsT
 242
AD-14721



faCfaCfTsT









833-851
AGGUfGUfAUfCfUfCfCfUfA
 243
GUGUCuaGGagAUACAccuTsT
 244
AD-14731



GACfACfTsT









833-851
AgGuGuAuCuCcUaGaCaCTsT
 245
GUGUCuaGGagAUACAccuTsT
 246
AD-14741





833-851
GfcAfcCfcUfcAfuAfgGfcC
 247
p-uCfcAfgGfcCfuAfuGfaG
 248
AD-15087



fuGfgAfTsT

fgGfuGfcTsT







833-851
GCfACfCfCfUfCfAUfAGGCf
 249
UfCfCfAGGCfCfUfAUfGAGG
 250
AD-15097



CfUfGGATsT

GUfGCfTsT







833-851
GcAcCcUcAuAgGcCuGgATsT
 251
p-uCfcAfgGfcCfuAfuGfaG
 252
AD-15107





fgGfuGfcTsT







833-851
GcAcCcUcAuAgGcCuGgATsT
 253
UfCfCfAGGCfCfUfAUfGAGG
 254
AD-15117





GUfGCfTsT







833-851
GfcAfcCfcUfcAfuAfgGfcC
 255
UCCAGgcCUauGAGGGugcTsT
 256
AD-15127



fuGfgAfTsT









833-851
GCfACfCfCfUfCfAUfAGGCf
 257
UCCAGgcCUauGAGGGugcTsT
 258
AD-15137



CfUfGGATsT









833-851
GcAcCcUcAuAgGcCuGgATsT
 259
UCCAGgcCUauGAGGGugcTsT
 260
AD-15147





836-854
UGUAUCUCCUAGACACCAGTsT
 261
CUGGUGUCUAGGAGAUACATsT
 262
AD-9516





836-854
uGuAucuccuAGAcAccAGTsT
 263
CUGGUGUCuAGGAGAuAcATsT
 264
AD-9642





840-858
UCUCCUAGACACCAGCAUATsT
 265
UAUGCUGGUGUCUAGGAGATsT
 266
AD-9562





840-858
ucuccuAGAcAccAGcAuATsT
 267
uAUGCUGGUGUCuAGGAGATsT
 268
AD-9688





840-858
UfcUfcCfuAfgAfcAfcCfaG
 269
p-uAfuGfcUfgGfuGfuCfuA
 270
AD-14677



fcAfuAfTsT

fgGfaGfaTsT







840-858
UfCfUfCfCfUfAGACfACfCf
 271
UfAUfGCfUfGGUfGUfCfUfA
 272
AD-14687



AGCfAUfATsT

GGAGATsT







840-858
UcUcCuAgAcAcCaGcAuATsT
 273
p-uAfuGfcUfgGfuGfuCfuA
 274
AD-14697





fgGfaGfaTsT







840-858
UcUcCuAgAcAcCaGcAuATsT
 275
UfAUfGCfUfGGUfGUfCfUfA
 276
AD-14707





GGAGATsT







840-858
UfcUfcCfuAafAfcAfcCfaG
 277
UAUGCugGUguCUAGGagaTsT
 278
AD-14717



fcAfuAfTsT









840-858
UfCfUfCfCfUfAGACfACfCf
 279
UAUGCugGUguCUAGGagaTsT
 280
AD-14727



AGCfAUfATsT









840-858
UcUcCuAgAcAcCaGcAuATsT
 281
UAUGCugGUguCUAGGagaTsT
 282
AD-14737





840-858
AfgGfcCfuGfgAfgUfuUfaU
 283
p-cCfgAfaUfaAfaCfuCfcA
 284
AD-15083



fuCfgGfTsT

fgGfcCfuTsT







840-858
AGGCfCfUfGGAGUfUfUfAUf
 285
CfCfGAAUfAAACfUfCfCfAG
 286
AD-15093



UfCfGGTsT

GCfCfUfTsT







840-858
AgGcCuGgAgUuUaUuCgGTsT
 287
p-cCfgAfaUfaAfaCfuCfcA
 288
AD-15103





fgGfcCfuTsT







840-858
AgGcCuGgAgUuUaUuCgGTsT
 289
CfCfGAAUfAAACfUfCfCfAG
 290
AD-15113





GCfCfUfTsT







840-858
AfgGfcCfuGfgAfgUfuUfaU
 291
CCGAAuaAAcuCCAGGccuTsT
 292
AD-15123



fuCfgGfTsT









840-858
AGGCfCfUfGGAGUfUfUfAUf
 293
CCGAAuaAAcuCCAGGccuTsT
 294
AD-15133



UfCfGGTsT









840-858
AgGcCuGgAgUuUaUuCgGTsT
 295
CCGAAuaAAcuCCAGGccuTsT
 296
AD-15143





841-859
CUCCUAGACACCAGCAUACTsT
 297
GUAUGCUGGUGUCUAGGAGTsT
 298
AD-9521





841-859
cuccuAGAcAccAGcAuAcTsT
 299
GuAUGCUGGUGUCuAGGAGTsT
 300
AD-9647





842-860
UCCUAGACACCAGCAUACATsT
 301
UGUAUGCUGGUGUCUAGGATsT
 302
AD-9611





842-860
uccuAGAcAccAGcAuAcATsT
 303
UGuAUGCUGGUGUCuAGGATsT
 304
AD-9737





843-861
CCUAGACACCAGCAUACAGTsT
 305
CUGUAUGCUGGUGUCUAGGTsT
 306
AD-9592





843-861
ccuAGAcAccAGcAuAcAGTsT
 307
CUGuAUGCUGGUGUCuAGGTsT
 308
AD-9718





847-865
GACACCAGCAUACAGAGUGTsT
 309
CACUCUGUAUGCUGGUGUCTsT
 310
AD-9561





847-865
GAcAccAGcAuAcAGAGuGTsT
 311
cACUCUGuAUGCUGGUGUCTsT
 312
AD-9687





855-873
CAUACAGAGUGACCACCGGTsT
 313
CCGGUGGUCACUCUGUAUGTsT
 314
AD-9636





855-873
cAuAcAGAGuGAccAccGGTsT
 315
CCGGUGGUcACUCUGuAUGTsT
 316
AD-9762





860-878
AGAGUGACCACCGGGAAAUTsT
 317
AUUUCCCGGUGGUCACUCUTsT
 318
AD-9540





860-878
AGAGuGAccAccGGGAAAuTsT
 319
AUUUCCCGGUGGUcACUCUTsT
 320
AD-9666





861-879
GAGUGACCACCGGGAAAUCTsT
 321
GAUUUCCCGGUGGUCACUCTsT
 322
AD-9535





861-879
GAGuGAccAccGGGAAAucTsT
 323
GAUUUCCCGGUGGUcACUCTsT
 324
AD-9661





863-881
GUGACCACCGGGAAAUCGATsT
 325
UCGAUUUCCCGGUGGUCACTsT
 326
AD-9559





863-881
GuGAccAccGGGAAAucGATsT
 327
UCGAUUUCCCGGUGGUcACTsT
 328
AD-9685





865-883
GACCACCGGGAAAUCGAGGTsT
 329
CCUCGAUUUCCCGGUGGUCTsT
 330
AD-9533





865-883
GAccAccGGGAAAucGAGGTsT
 331
CCUCGAUUUCCCGGUGGUCTsT
 332
AD-9659





866-884
ACCACCGGGAAAUCGAGGGTsT
 333
CCCUCGAUUUCCCGGUGGUTsT
 334
AD-9612





866-884
AccAccGGGAAAucGAGGGTsT
 335
CCCUCGAUUUCCCGGUGGUTsT
 336
AD-9738





867-885
CCACCGGGAAAUCGAGGGCTsT
 337
GCCCUCGAUUUCCCGGUGGTsT
 338
AD-9557





867-885
ccAccGGGAAAucGAGGGcTsT
 339
GCCCUCGAUUUCCCGGUGGTsT
 340
AD-9683





875-893
AAAUCGAGGGCAGGGUCAUTsT
 341
AUGACCCUGCCCUCGAUUUTsT
 342
AD-9531





875-893
AAAucGAGGGcAGGGucAuTsT
 343
AUGACCCUGCCCUCGAUUUTsT
 344
AD-9657





875-893
AfaAfuCfgAfgGfgCfaGfgG
 345
p-aUfgAfcCfcUfgCfcCfuC
 346
AD-14673



fuCfaUfTsT

fgAfuUfuTsT







875-893
AAAUfCfGAGGGCfAGGGUfCf
 347
AUfGACfCfCfUfGCfCfCfUf
 348
AD-14683



AUfTsT

CfGAUfUfUfTsT







875-893
AaAuCgAgGgCaGgGuCaUTsT
 349
p-aUfgAfcCfcUfgCfcCfuC
 350
AD-14693





fgAfuUfuTsT







875-893
AaAuCgAgGgCaGgGuCaUTsT
 351
AUfGACfCfCfUfGCfCfCfUf
 352
AD-14703





CfGAUfUfUfTsT







875-893
AfaAfuCfgAfgGfgCfaGfgG
 353
AUGACccUGccCUCGAuuuTsT
 354
AD-14713



fuCfaUfTsT









875-893
AAAUfCfGAGGGCfAGGGUfCf
 355
AUGACccUGccCUCGAuuuTsT
 356
AD-14723



AUfTsT









875-893
AaAuCgAgGgCaGgGuCaUTsT
 357
AUGACccUGccCUCGAuuuTsT
 358
AD-14733





875-893
CfgGfcAfcCfcUfcAfuAfgG
 359
p-cAfgGfcCfuAfuGfaGfgG
 360
AD-15079



fcCfuGfTsT

fuGfcCfgTsT







875-893
CfGGCfACfCfCfUfCfAUfAG
 361
CfAGGCfCfUfAUfGAGGGUfG
 362
AD-15089



GCfCfUfGTsT

CfCfGTsT







875-893
CgGcAcCcUcAuAgGcCuGTsT
 363
p-cAfgGfcCfuAfuGfaGfgG
 364
AD-15099





fuGfcCfgTsT







875-893
CgGcAcCcUcAuAgGcCuGTsT
 365
CfAGGCfCfUfAUfGAGGGUfG
 366
AD-15109





CfCfGTsT







875-893
CfgGfcAfcCfcUfcAfuAfgG
 367
CAGGCcuAUgaGGGUGccgTsT
 368
AD-15119



fcCfuGfTsT









875-893
CfGGCfACfCfCfUfCfAUfAG
 369
CAGGCcuAUgaGGGUGccgTsT
 370
AD-15129



GCfCfUfGTsT









875-893
CgGcAcCcUcAuAgGcCuGTsT
 371
CAGGCcuAUgaGGGUGccgTsT
 372
AD-15139





877-895
AUCGAGGGCAGGGUCAUGGTsT
 373
CCAUGACCCUGCCCUCGAUTsT
 374
AD-9542





877-895
AucGAGGGcAGGGucAuGGTsT
 375
CcAUGACCCUGCCCUCGAUTsT
 376
AD-9668





878-896
cGAGGGcAGGGucAuGGucTsT
 377
GACcAUGACCCUGCCCUCGTsT
 378
AD-9739





880-898
GAGGGCAGGGUCAUGGUCATsT
 379
UGACCAUGACCCUGCCCUCTsT
 380
AD-9637





880-898
GAGGGcAGGGucAuGGucATsT
 381
UGACcAUGACCCUGCCCUCTsT
 382
AD-9763





882-900
GGGCAGGGUCAUGGUCACCTsT
 383
GGUGACCAUGACCCUGCCCTsT
 384
AD-9630





882-900
GGGcAGGGucAuGGucAccTsT
 385
GGUGACcAUGACCCUGCCCTsT
 386
AD-9756





885-903
CAGGGUCAUGGUCACCGACTsT
 387
GUCGGUGACCAUGACCCUGTsT
 388
AD-9593





885-903
cAGGGucAuGGucAccGAcTsT
 389
GUCGGUGACcAUGACCCUGTsT
 390
AD-9719





886-904
AGGGUCAUGGUCACCGACUTsT
 391
AGUCGGUGACCAUGACCCUTsT
 392
AD-9601





886-904
AGGGucAuGGucAccGAcuTsT
 393
AGUCGGUGACcAUGACCCUTsT
 394
AD-9727





892-910
AUGGUCACCGACUUCGAGATsT
 395
UCUCGAAGUCGGUGACCAUTsT
 396
AD-9573





892-910
AuGGucAccGAcuucGAGATsT
 397
UCUCGAAGUCGGUGACcAUTsT
 398
AD-9699





899-917
CCGACUUCGAGAAUGUGCCTT
 399
GGCACAUUCUCGAAGUCGGTT
 400
AD-15228





921-939
GGAGGACGGGACCCGCUUCTT
 401
GAAGCGGGUCCCGUCCUCCTT
 402
AD-15395





 993-1011
CAGCGGCCGGGAUGCCGGCTsT
 403
GCCGGCAUCCCGGCCGCUGTsT
 404
AD-9602





 993-1011
cAaGGccGGGAuGccGGcTsT
 405
GCCGGcAUCCCGGCCGCUGTsT
 406
AD-9728





1020-1038
GGGUGCCAGCAUGCGCAGCTT
 407
GCUGCGCAUGCUGGCACCCTT
 408
AD-15386





1038-1056
CCUGCGCGUGCUCAACUGCTsT
 409
GCAGUUGAGCACGCGCAGGTsT
 410
AD-9580





1038-1056
ccuGcGcGuGcucAAcuGcTsT
 411
GcAGUUGAGcACGCGcAGGTsT
 412
AD-9706





1040-1058
UGCGCGUGCUCAACUGCCATsT
 413
UGGCAGUUGAGCACGCGCATsT
 414
AD-9581





1040-1058
uGcGcGuGcucAAcuGccATsT
 415
UGGcAGUUGAGcACGCGcATsT
 416
AD-9707





1042-1060
CGCGUGCUCAACUGCCAAGTsT
 417
CUUGGCAGUUGAGCACGCGTsT
 418
AD-9543





1042-1060
cGcGuGcucAAcuGccAAGTsT
 419
CUUGGcAGUUGAGcACGCGTsT
 420
AD-9669





1053-1071
CUGCCAAGGGAAGGGCACGTsT
 421
CGUGCCCUUCCCUUGGCAGTsT
 422
AD-9574





1053-1071
cuGccAAGGGAAGGGcAcGTsT
 423
CGUGCCCUUCCCUUGGcAGTsT
 424
AD-9700





1057-1075
CAAGGGAAGGGCACGGUUATT
 425
UAACCGUGCCCUUCCCUUGTT
 426
AD-15320





1058-1076
AAGGGAAGGGCACGGUUAGTT
 427
CUAACCGUGCCCUUCCCUUTT
 428
AD-15321





1059-1077
AGGGAAGGGCACGGUUAGCTT
 429
GCUAACCGUGCCCUUCCCUTT
 430
AD-15199





1060-1078
GGGAAGGGCACGGUUAGCGTT
 431
CGCUAACCGUGCCCUUCCCTT
 432
AD-15167





1061-1079
GGAAGGGCACGGUUAGCGGTT
 433
CCGCUAACCGUGCCCUUCCTT
 434
AD-15164





1062-1080
GAAGGGCACGGUUAGCGGCTT
 435
GCCGCUAACCGUGCCCUUCTT
 436
AD-15166





1063-1081
AAGGGCACGGUUAGCGGCATT
 437
UGCCGCUAACCGUGCCCUUTT
 438
AD-15322





1064-1082
AGGGCACGGUUAGCGGCACTT
 439
GUGCCGCUAACCGUGCCCUTT
 440
AD-15200





1068-1086
CACGGUUAGCGGCACCCUCTT
 441
GAGGGUGCCGCUAACCGUGTT
 442
AD-15213





1069-1087
ACGGUUAGCGGCACCCUCATT
 443
UGAGGGUGCCGCUAACCGUTT
 444
AD-15229





1072-1090
GUUAGCGGCACCCUCAUAGTT
 445
CUAUGAGGGUGCCGCUAACTT
 446
AD-15215





1073-1091
UUAGCGGCACCCUCAUAGGTT
 447
CCUAUGAGGGUGCCGCUAATT
 448
AD-15214





1076-1094
GCGGCACCCUCAUAGGCCUTsT
 449
AGGCCUAUGAGGGUGCCGCTsT
 450
AD-9315





1079-1097
GCACCCUCAUAGGCCUGGATsT
 451
UCCAGGCCUAUGAGGGUGCTsT
 452
AD-9326





1085-1103
UCAUAGGCCUGGAGUUUAUTsT
 453
AUAAACUCCAGGCCUAUGATsT
 454
AD-9318





1090-1108
GGCCUGGAGUUUAUUCGGATsT
 455
UCCGAAUAAACUCCAGGCCTsT
 456
AD-9323





1091-1109
GCCUGGAGUUUAUUCGGAATsT
 457
UUCCGAAUAAACUCCAGGCTsT
 458
AD-9314





1091-1109
GccuGGAGuuuAuucGGAATsT
 459
UUCCGAAuAAACUCcAGGCTsT
 460
AD-10792





1091-1109
GccuGGAGuuuAuucGGAATsT
 461
UUCCGAAUAACUCCAGGCTsT
 462
AD-10796





1093-1111
CUGGAGUUUAUUCGGAAAATsT
 463
UUUUCCGAAUAAACUCCAGTsT
 464
AD-9638





1093-1111
cuGGAGuuuAuucGGAAAATsT
 465
UUUUCCGAAuAAACUCcAGTsT
 466
AD-9764





1095-1113
GGAGUUUAUUCGGAAAAGCTsT
 467
GCUUUUCCGAAUAAACUCCTsT
 468
AD-9525





1095-1113
GGAGuuuAuucGGAAAAGcTsT
 469
GCUUUUCCGAAuAAACUCCTsT
 470
AD-9651





1096-1114
GAGUUUAUUCGGAAAAGCCTsT
 471
GGCUUUUCCGAAUAAACUCTsT
 472
AD-9560





1096-1114
GAGuuuAuucGGAAAAGccTsT
 473
GGCUUUUCCGAAuAAACUCTsT
 474
AD-9686





1100-1118
UUAUUCGGAAAAGCCAGCUTsT
 475
AGCUGGCUUUUCCGAAUAATsT
 476
AD-9536





1100-1118
uuAuucGGAAAAGccAGcuTsT
 477
AGCUGGCUUUUCCGAAuAATsT
 478
AD-9662





1154-1172
CCCUGGCGGGUGGGUACAGTsT
 479
CUGUACCCACCCGCCAGGGTsT
 480
AD-9584





1154-1172
cccuGaGGGuGGGuAcAGTsT
 481
CUGuACCcACCCGCcAGGGTsT
 482
AD-9710





1155-1173
CCUGGCGGGUGGGUACAGCTT
 483
GCUGUACCCACCCGCCAGGTT
 484
AD-15323





1157-1175
UGGCGGGUGGGUACAGCCGTsT
 485
CGGCUGUACCCACCCGCCATsT
 486
AD-9551





1157-1175
uGaGGGuGGGuAcAGccGTsT
 487
CGGCUGuACCcACCCGCcATsT
 488
AD-9677





1158-1176
GGCGGGUGGGUACAGCCGCTT
 489
GCGGCUGUACCCACCCGCCTT
 490
AD-15230





1162-1180
GGUGGGUACAGCCGCGUCCTT
 491
GGACGCGGCUGUACCCACCTT
 492
AD-15231





1164-1182
UGGGUACAGCCGCGUCCUCTT
 493
GAGGACGCGGCUGUACCCATT
 494
AD-15285





1172-1190
GCCGCGUCCUCAACGCCGCTT
 495
GCGGCGUUGAGGACGCGGCTT
 496
AD-15396





1173-1191
CCGCGUCCUCAACGCCGCCTT
 497
GGCGGCGUUGAGGACGCGGTT
 498
AD-15397





1216-1234
GUCGUGCUGGUCACCGCUGTsT
 499
CAGCGGUGACCAGCACGACTsT
 500
AD-9600





1216-1234
GucGuGcuGGucAccGcuGTsT
 501
cAGCGGUGACcAGcACGACTsT
 502
AD-9726





1217-1235
UCGUGCUGGUCACCGCUGCTsT
 503
GCAGCGGUGACCAGCACGATsT
 504
AD-9606





1217-1235
ucGuGcuGGucAccGcuGcTsT
 505
GcAGCGGUGACcAGcACGATsT
 506
AD-9732





1223-1241
UGGUCACCGCUGCCGGCAATsT
 507
UUGCCGGCAGCGGUGACCATsT
 508
AD-9633





1223-1241
uGGucAccGcuGccGGcAATsT
 509
UUGCCGGcAGCGGUGACcATsT
 510
AD-9759





1224-1242
GGUCACCGCUGCCGGCAACTsT
 511
GUUGCCGGCAGCGGUGACCTsT
 512
AD-9588





1224-1242
GGucAccGcuGccGGcAAcTsT
 513
GUUGCCGGcAGCGGUGACCTsT
 514
AD-9714





1227-1245
CACCGCUGCCGGCAACUUCTsT
 515
GAAGUUGCCGGCAGCGGUGTsT
 516
AD-9589





1227-1245
cAccGcuGccGGcAAcuucTsT
 517
GAAGUUGCCGGcAGCGGUGTsT
 518
AD-9715





1229-1247
CCGCUGCCGGCAACUUCCGTsT
 519
CGGAAGUUGCCGGCAGCGGTsT
 520
AD-9575





1229-1247
ccGcuGccGGcAAcuuccGTsT
 521
CGGAAGUUGCCGGcAGCGGTsT
 522
AD-9701





1230-1248
CGCUGCCGGCAACUUCCGGTsT
 523
CCGGAAGUUGCCGGCAGCGTsT
 524
AD-9563





1230-1248
cGcuGccGGcAAcuuccGGTsT
 525
CCGGAAGUUGCCGGcAGCGTsT
 526
AD-9689





1231-1249
GCUGCCGGCAACUUCCGGGTsT
 527
CCCGGAAGUUGCCGGCAGCTsT
 528
AD-9594





1231-1249
GcuGccGGcAAcuuccGGGTsT
 529
CCCGGAAGUUGCCGGcAGCTsT
 530
AD-9720





1236-1254
CGGCAACUUCCGGGACGAUTsT
 531
AUCGUCCCGGAAGUUGCCGTsT
 532
AD-9585





1236-1254
cGGcAAcuuccGGGAcGAuTsT
 533
AUCGUCCCGGAAGUUGCCGTsT
 534
AD-9711





1237-1255
GGCAACUUCCGGGACGAUGTsT
 535
CAUCGUCCCGGAAGUUGCCTsT
 536
AD-9614





1237-1255
GGcAAcuuccGGGAcGAuGTsT
 537
cAUCGUCCCGGAAGUUGCCTsT
 538
AD-9740





1243-1261
UUCCGGGACGAUGCCUGCCTsT
 539
GGCAGGCAUCGUCCCGGAATsT
 540
AD-9615





1243-1261
uuccGGGAcGAuGccuGccTsT
 541
GGcAGGcAUCGUCCCGGAATsT
 542
AD-9741





1248-1266
GGACGAUGCCUGCCUCUACTsT
 543
GUAGAGGCAGGCAUCGUCCTsT
 544
AD-9534





1248-1266
GGACGAUGCCUGCCUCUACTsT
 545
GUAGAGGCAGGCAUCGUCCTsT
 546
AD-9534





1248-1266
GGAcGAuGccuGccucuAcTsT
 547
GuAGAGGcAGGcAUCGUCCTsT
 548
AD-9660





1279-1297
GCUCCCGAGGUCAUCACAGTT
 549
CUGUGAUGACCUCGGGAGCTT
 550
AD-15324





1280-1298
CUCCCGAGGUCAUCACAGUTT
 551
ACUGUGAUGACCUCGGGAGTT
 552
AD-15232





1281-1299
UCCCGAGGUCAUCACAGUUTT
 553
AACUGUGAUGACCUCGGGATT
 554
AD-15233





1314-1332
CCAAGACCAGCCGGUGACCTT
 555
GGUCACCGGCUGGUCUUGGTT
 556
AD-15234





1315-1333
CAAGACCAGCCGGUGACCCTT
 557
GGGUCACCGGCUGGUCUUGTT
 558
AD-15286





1348-1366
ACCAACUUUGGCCGCUGUGTsT
 559
CACAGCGGCCAAAGUUGGUTsT
 560
AD-9590





1348-1366
AccAAcuuuGGccGcuGuGTsT
 561
cAcAGCGGCcAAAGUUGGUTsT
 562
AD-9716





1350-1368
CAACUUUGGCCGCUGUGUGTsT
 563
CACACAGCGGCCAAAGUUGTsT
 564
AD-9632





1350-1368
cAAcuuuGGccGcuGuGuGTsT
 565
cAcAcAGCGGCcAAAGUUGTsT
 566
AD-9758





1360-1378
CGCUGUGUGGACCUCUUUGTsT
 567
CAAAGAGGUCCACACAGCGTsT
 568
AD-9567





1360-1378
cGcuGuGuGGAccucuuuGTsT
 569
cAAAGAGGUCcAcAcAGCGTsT
 570
AD-9693





1390-1408
GACAUCAUUGGUGCCUCCATsT
 571
UGGAGGCACCAAUGAUGUCTsT
 572
AD-9586





1390-1408
GAcAucAuuGGuGccuccATsT
 573
UGGAGGcACcAAUGAUGUCTsT
 574
AD-9712





1394-1412
UCAUUGGUGCCUCCAGCGATsT
 575
UCGCUGGAGGCACCAAUGATsT
 576
AD-9564





1394-1412
ucAuuGGuGccuccAGcGATsT
 577
UCGCUGGAGGcACcAAUGATsT
 578
AD-9690





1417-1435
AGCACCUGCUUUGUGUCACTsT
 579
GUGACACAAAGCAGGUGCUTsT
 580
AD-9616





1417-1435
AGcAccuGcuuuGuGucAcTsT
 581
GUGAcAcAAAGcAGGUGCUTsT
 582
AD-9742





1433-1451
CACAGAGUGGGACAUCACATT
 583
UGUGAUGUCCCACUCUGUGTT
 584
AD-15398





1486-1504
AUGCUGUCUGCCGAGCCGGTsT
 585
CCGGCUCGGCAGACAGCAUTsT
 586
AD-9617





1486-1504
AuGcuGucuGccGAGccGGTsT
 587
CCGGCUCGGcAGAcAGcAUTsT
 588
AD-9743





1491-1509
GUCUGCCGAGCCGGAGCUCTsT
 589
GAGCUCCGGCUCGGCAGACTsT
 590
AD-9635





1491-1509
GucuGccGAGccGGAGcucTsT
 591
GAGCUCCGGCUCGGcAGACTsT
 592
AD-9761





1521-1539
GUUGAGGCAGAGACUGAUCTsT
 593
GAUCAGUCUCUGCCUCAACTsT
 594
AD-9568





1521-1539
GuuGAGGcAGAGAcuGAucTsT
 595
GAUcAGUCUCUGCCUcAACTsT
 596
AD-9694





1527-1545
GCAGAGACUGAUCCACUUCTsT
 597
GAAGUGGAUCAGUCUCUGCTsT
 598
AD-9576





1527-1545
GcAGAGAcuGAuccAcuucTsT
 599
GAAGUGGAUcAGUCUCUGCTsT
 600
AD-9702





1529-1547
AGAGACUGAUCCACUUCUCTsT
 601
GAGAAGUGGAUCAGUCUCUTsT
 602
AD-9627





1529-1547
AGAGAcuGAuccAcuucucTsT
 603
GAGAAGUGGAUcAGUCUCUTsT
 604
AD-9753





1543-1561
UUCUCUGCCAAAGAUGUCATsT
 605
UGACAUCUUUGGCAGAGAATsT
 606
AD-9628





1543-1561
uucucuGccAAAGAuGucATsT
 607
UGAcAUCUUUGGcAGAGAATsT
 608
AD-9754





1545-1563
CUCUGCCAAAGAUGUCAUCTsT
 609
GAUGACAUCUUUGGCAGAGTsT
 610
AD-9631





1545-1563
cucuGccAAAGAuGucAucTsT
 611
GAUGAcAUCUUUGGcAGAGTsT
 612
AD-9757





1580-1598
CUGAGGACCAGCGGGUACUTsT
 613
AGUACCCGCUGGUCCUCAGTsT
 614
AD-9595





1580-1598
cuGAGGAccAaGGGuAcuTsT
 615
AGuACCCGCUGGUCCUcAGTsT
 616
AD-9721





1581-1599
UGAGGACCAGCGGGUACUGTsT
 617
CAGUACCCGCUGGUCCUCATsT
 618
AD-9544





1581-1599
uGAGGAccAaGGGuAcuGTsT
 619
cAGuACCCGCUGGUCCUcATsT
 620
AD-9670





1666-1684
ACUGUAUGGUCAGCACACUTT
 621
AGUGUGCUGACCAUACAGUTT
 622
AD-15235





1668-1686
UGUAUGGUCAGCACACUCGTT
 623
CGAGUGUGCUGACCAUACATT
 624
AD-15236





1669-1687
GUAUGGUCAGCACACUCGGTT
 625
CCGAGUGUGCUGACCAUACTT
 626
AD-15168





1697-1715
GGAUGGCCACAGCCGUCGCTT
 627
GCGACGGCUGUGGCCAUCCTT
 628
AD-15174





1698-1716
GAUGGCCACAGCCGUCGCCTT
 629
GGCGACGGCUGUGGCCAUCTT
 630
AD-15325





1806-1824
CAAGCUGGUCUGCCGGGCCTT
 631
GGCCCGGCAGACCAGCUUGTT
 632
AD-15326





1815-1833
CUGCCGGGCCCACAACGCUTsT
 633
AGCGUUGUGGGCCCGGCAGTsT
 634
AD-9570





1815-1833
cuGccGGGcccAcAAcGcuTsT
 635
AGCGUUGUGGGCCCGGcAGTsT
 636
AD-9696





1816-1834
UGCCGGGCCCACAACGCUUTsT
 637
AAGCGUUGUGGGCCCGGCATsT
 638
AD-9566





1816-1834
uGccGGGcccAcAAcGcuuTsT
 639
AAGCGUUGUGGGCCCGGcATsT
 640
AD-9692





1818-1836
CCGGGCCCACAACGCUUUUTsT
 641
AAAAGCGUUGUGGGCCCGGTsT
 642
AD-9532





1818-1836
ccGGGcccAcAAcGcuuuuTsT
 643
AAAAGCGUUGUGGGCCCGGTsT
 644
AD-9658





1820-1838
GGGCCCACAACGCUUUUGGTsT
 645
CCAAAAGCGUUGUGGGCCCTsT
 646
AD-9549





1820-1838
GGGcccAcAAcGcuuuuGGTsT
 647
CcAAAAGCGUUGUGGGCCCTsT
 648
AD-9675





1840-1858
GGUGAGGGUGUCUACGCCATsT
 649
UGGCGUAGACACCCUCACCTsT
 650
AD-9541





1840-1858
GGuGAGGGuGucuAcGccATsT
 651
UGGCGuAGAcACCCUcACCTsT
 652
AD-9667





1843-1861
GAGGGUGUCUACGCCAUUGTsT
 653
CAAUGGCGUAGACACCCUCTsT
 654
AD-9550





1843-1861
GAGGGuGucuAcGccAuuGTsT
 655
cAAUGGCGuAGAcACCCUCTsT
 656
AD-9676





1861-1879
GCCAGGUGCUGCCUGCUACTsT
 657
GUAGCAGGCAGCACCUGGCTsT
 658
AD-9571





1861-1879
GccAGGuGcuGccuGcuAcTsT
 659
GuAGcAGGcAGcACCUGGCTsT
 660
AD-9697





1862-1880
CCAGGUGCUGCCUGCUACCTsT
 661
GGUAGCAGGCAGCACCUGGTsT
 662
AD-9572





1862-1880
ccAGGuGcuGccuGcuAccTsT
 663
GGuAGcAGGcAGcACCUGGTsT
 664
AD-9698





2008-2026
ACCCACAAGCCGCCUGUGCTT
 665
GCACAGGCGGCUUGUGGGUTT
 666
AD-15327





2023-2041
GUGCUGAGGCCACGAGGUCTsT
 667
GACCUCGUGGCCUCAGCACTsT
 668
AD-9639





2023-2041
GuGcuGAGGccAcGAGGucTsT
 669
GACCUCGUGGCCUcAGcACTsT
 670
AD-9765





2024-2042
UGCUGAGGCCACGAGGUCATsT
 671
UGACCUCGUGGCCUCAGCATsT
 672
AD-9518





2024-2042
UGCUGAGGCCACGAGGUCATsT
 673
UGACCUCGUGGCCUCAGCATsT
 674
AD-9518





2024-2042
uGcuGAGGccAcGAGGucATsT
 675
UGACCUCGUGGCCUcAGcATsT
 676
AD-9644





2024-2042
UfgCfuGfaGfgCfcAfcGfaG
 677
p-uGfaCfcUfcGfuGfgCfcU
 678
AD-14672



fgUfcAfTsT

fcAfgCfaTsT







2024-2042
UfGCfUfGAGGCfCfACfGAGG
 679
UfGACfCfUfCfGUfGGCfCfU
 680
AD-14682



UfCfATsT

fCfAGCfATsT







2024-2042
UgCuGaGgCcAcGaGgUcATsT
 681
p-uGfaCfcUfcGfuGfgCfcU
 682
AD-14692





fcAfgCfaTsT







2024-2042
UgCuGaGgCcAcGaGgUcATsT
 683
UfGACfCfUfCfGUfGGCfCfU
 684
AD-14702





fCfAGCfATsT







2024-2042
UfgCfuGfaGfgCfcAfcGfaG
 685
UGACCucGUggCCUCAgcaTsT
 686
AD-14712



fgUfcAfTsT









2024-2042
UfGCfUfGAGGCfCfACfGAGG
 687
UGACCucGUggCCUCAgcaTsT
 688
AD-14722



UfCfATsT









2024-2042
UgCuGaGgCcAcGaGgUcATsT
 689
UGACCucGUggCCUCAgcaTsT
 690
AD-14732





2024-2042
GfuGfgUfcAfgCfgGfcCfgG
 691
p-cAfuCfcCfgGfcCfgCfuG
 692
AD-15078



fgAfuGfTsT

faCfcAfcTsT







2024-2042
GUfGGUfCfAGCfGGCfCfGGG
 693
CfAUfCfCfCfGGCfCfGCfUf
 694
AD-15088



AUfGTsT

GACfCfACfTsT







2024-2042
GuGgUcAgCgGcCgGgAuGTsT
 695
p-cAfuCfcCfgGfcCfgCfuG
 696
AD-15098





faCfcAfcTsT







2024-2042
GuGgUcAgCgGcCgGgAuGTsT
 697
CfAUfCfCfCfGGCfCfGCfUf
 698
AD-15108





GACfCfACfTsT







2024-2042
GfuGfgUfcAfgCfgGfcCfgG
 699
CAUCCcgGCcgCUGACcacTsT
 700
AD-15118



fgAfuGfTsT









2024-2042
GUfGGUfCfAGCfGGCfCfGGG
 701
CAUCCcgGCcgCUGACcacTsT
 702
AD-15128



AUfGTsT









2024-2042
GuGgUcAgCgGcCgGgAuGTsT
 703
CAUCCcgGCcgCUGACcacTsT
 704
AD-15138





2030-2048
GGCCACGAGGUCAGCCCAATT
 705
UUGGGCUGACCUCGUGGCCTT
 706
AD-15237





2035-2053
CGAGGUCAGCCCAACCAGUTT
 707
ACUGGUUGGGCUGACCUCGTT
 708
AD-15287





2039-2057
GUCAGCCCAACCAGUGCGUTT
 709
ACGCACUGGUUGGGCUGACTT
 710
AD-15238





2041-2059
CAGCCCAACCAGUGCGUGGTT
 711
CCACGCACUGGUUGGGCUGTT
 712
AD-15328





2062-2080
CACAGGGAGGCCAGCAUCCTT
 713
GGAUGCUGGCCUCCCUGUGTT
 714
AD-15399





2072-2090
CCAGCAUCCACGCUUCCUGTsT
 715
CAGGAAGCGUGGAUGCUGGTsT
 716
AD-9582





2072-2090
ccAGcAuccAcGcuuccuGTsT
 717
cAGGAAGCGUGGAUGCUGGTsT
 718
AD-9708





2118-2136
AGUCAAGGAGCAUGGAAUCTsT
 719
GAUUCCAUGCUCCUUGACUTsT
 720
AD-9545





2118-2136
AGucAAGGAGcAuGGAAucTsT
 721
GAUUCcAUGCUCCUUGACUTsT
 722
AD-9671





2118-2136
AfgUfcAfaGfgAfgCfaUfgG
 723
p-gAfuUfcCfaUfgCfuCfcU
 724
AD-14674



faAfuCfTsT

fuGfaCfuTsT







2118-2136
AGUfCfAAGGAGCfAUfGGAAU
 725
GAUfUfCfCfAUfGCfUfCfCf
 726
AD-14684



fCfTsT

UfUfGACfUfTsT







2118-2136
AgUcAaGgAgCaUgGaAuCTsT
 727
p-gAfuUfcCfaUfgCfuCfcU
 728
AD-14694





fuGfaCfuTsT







2118-2136
AgUcAaGgAgCaUgGaAuCTsT
 729
GAUfUfCfCfAUfGCfUfCfCf
 730
AD-14704





UfUfGACfUfTsT







2118-2136
AfgUfcAfaGfgAfgCfaUfgG
 731
GAUUCcaUGcuCCUUGacuTsT
 732
AD-14714



faAfuCfTsT









2118-2136
AGUfCfAAGGAGCfAUfGGAAU
 733
GAUUCcaUGcuCCUUGacuTsT
 734
AD-14724



fCfTsT









2118-2136
AgUcAaGgAgCaUgGaAuCTsT
 735
GAUUCcaUGcuCCUUGacuTsT
 736
AD-14734





2118-2136
GfcGfgCfaCfcCfuCfaUfaG
 737
p-aGfgCfcUfaUfgAfgGfgU
 738
AD-15080



fgCfcUfTsT

fgCfcGfcTsT







2118-2136
GCfGGCfACfCfCfUfCfAUfA
 739
AGGCfCfUfAUfGAGGGUfGCf
 740
AD-15090



GGCfCfUfTsT

CfGCfTsT







2118-2136
GeGgCaCcCuCaUaGgCcUTsT
 741
p-aGfgCfcUfaUfgAfgGfgU
 742
AD-15100





fgCfcGfcTsT







2118-2136
GeGgCaCcCuCaUaGgCcUTsT
 743
AGGCfCfUfAUfGAGGGUfGCf
 744
AD-15110





CfGCfTsT







2118-2136
GfcGfgCfaCfcCfuCfaUfaG
 745
AGGCCuaUGagGGUGCcgcTsT
 746
AD-15120



fgCfcUfTsT









2118-2136
GCfGGCfACfCfCfUfCfAUfA
 747
AGGCCuaUGagGGUGCcgcTsT
 748
AD-15130



GGCfCfUfTsT









2118-2136
GeGgCaCcCuCaUaGgCcUTsT
 749
AGGCCuaUGagGGUGCcgcTsT
 750
AD-15140





2122-2140
AAGGAGCAUGGAAUCCCGGTsT
 751
CCGGGAUUCCAUGCUCCUUTsT
 752
AD-9522





2122-2140
AAGGAGcAuGGAAucceGGTsT
 753
CCGGGAUUCcAUGCUCCUUTsT
 754
AD-9648





2123-2141
AGGAGCAUGGAAUCCCGGCTsT
 755
GCCGGGAUUCCAUGCUCCUTsT
 756
AD-9552





2123-2141
AGGAGcAuGGAAucceGGcTsT
 757
GCCGGGAUUCcAUGCUCCUTsT
 758
AD-9678





2125-2143
GAGCAUGGAAUCCCGGCCCTsT
 759
GGGCCGGGAUUCCAUGCUCTsT
 760
AD-9618





2125-2143
GAGcAuGGAAucceGGcccTsT
 761
GGGCCGGGAUUCcAUGCUCTsT
 762
AD-9744





2230-2248
GCCUACGCCGUAGACAACATT
 763
UGUUGUCUACGGCGUAGGCTT
 764
AD-15239





2231-2249
CCUACGCCGUAGACAACACTT
 765
GUGUUGUCUACGGCGUAGGTT
 766
AD-15212





2232-2250
CUACGCCGUAGACAACACGTT
 767
CGUGUUGUCUACGGCGUAGTT
 768
AD-15240





2233-2251
UACGCCGUAGACAACACGUTT
 769
ACGUGUUGUCUACGGCGUATT
 770
AD-15177





2235-2253
CGCCGUAGACAACACGUGUTT
 771
ACACGUGUUGUCUACGGCGTT
 772
AD-15179





2236-2254
GCCGUAGACAACACGUGUGTT
 773
CACACGUGUUGUCUACGGCTT
 774
AD-15180





2237-2255
CCGUAGACAACACGUGUGUTT
 775
ACACACGUGUUGUCUACGGTT
 776
AD-15241





2238-2256
CGUAGACAACACGUGUGUATT
 777
UACACACGUGUUGUCUACGTT
 778
AD-15268





2240-2258
UAGACAACACGUGUGUAGUTT
 779
ACUACACACGUGUUGUCUATT
 780
AD-15242





2241-2259
AGACAACACGUGUGUAGUCTT
 781
GACUACACACGUGUUGUCUTT
 782
AD-15216





2242-2260
GACAACACGUGUGUAGUCATT
 783
UGACUACACACGUGUUGUCTT
 784
AD-15176





2243-2261
ACAACACGUGUGUAGUCAGTT
 785
CUGACUACACACGUGUUGUTT
 786
AD-15181





2244-2262
CAACACGUGUGUAGUCAGGTT
 787
CCUGACUACACACGUGUUGTT
 788
AD-15243





2247-2265
CACGUGUGUAGUCAGGAGCTT
 789
GCUCCUGACUACACACGUGTT
 790
AD-15182





2248-2266
ACGUGUGUAGUCAGGAGCCTT
 791
GGCUCCUGACUACACACGUTT
 792
AD-15244





2249-2267
CGUGUGUAGUCAGGAGCCGTT
 793
CGGCUCCUGACUACACACGTT
 794
AD-15387





2251-2269
UGUGUAGUCAGGAGCCGGGTT
 795
CCCGGCUCCUGACUACACATT
 796
AD-15245





2257-2275
GUCAGGAGCCGGGACGUCATsT
 797
UGACGUCCCGGCUCCUGACTsT
 798
AD-9555





2257-2275
GucAGGAGccGGGAcGucATsT
 799
UGACGUCCCGGCUCCUGACTsT
 800
AD-9681





2258-2276
UCAGGAGCCGGGACGUCAGTsT
 801
CUGACGUCCCGGCUCCUGATsT
 802
AD-9619





2258-2276
ucAGGAGccGGGAcGucAGTsT
 803
CUGACGUCCCGGCUCCUGATsT
 804
AD-9745





2259-2277
CAGGAGCCGGGACGUCAGCTsT
 805
GCUGACGUCCCGGCUCCUGTsT
 806
AD-9620





2259-2277
cAGGAGccGGGAcGucAGcTsT
 807
GCUGACGUCCCGGCUCCUGTsT
 808
AD-9746





2263-2281
AGCCGGGACGUCAGCACUATT
 809
UAGUGCUGACGUCCCGGCUTT
 810
AD-15288





2265-2283
CCGGGACGUCAGCACUACATT
 811
UGUAGUGCUGACGUCCCGGTT
 812
AD-15246





2303-2321
CCGUGACAGCCGUUGCCAUTT
 813
AUGGCAACGGCUGUCACGGTT
 814
AD-15289





2317-2335
GCCAUCUGCUGCCGGAGCCTsT
 815
GGCUCCGGCAGCAGAUGGCTsT
 816
AD-9324





2375-2393
CCCAUCCCAGGAUGGGUGUTT
 817
ACACCCAUCCUGGGAUGGGTT
 818
AD-15329





2377-2395
CAUCCCAGGAUGGGUGUCUTT
 819
AGACACCCAUCCUGGGAUGTT
 820
AD-15330





2420-2438
AGCUUUAAAAUGGUUCCGATT
 821
UCGGAACCAUUUUAAAGCUTT
 822
AD-15169





2421-2439
GCUUUAAAAUGGUUCCGACTT
 823
GUCGGAACCAUUUUAAAGCTT
 824
AD-15201





2422-2440
CUUUAAAAUGGUUCCGACUTT
 825
AGUCGGAACCAUUUUAAAGTT
 826
AD-15331





2423-2441
UUUAAAAUGGUUCCGACUUTT
 827
AAGUCGGAACCAUUUUAAATT
 828
AD-15190





2424-2442
UUAAAAUGGUUCCGACUUGTT
 829
CAAGUCGGAACCAUUUUAATT
 830
AD-15247





2425-2443
UAAAAUGGUUCCGACUUGUTT
 831
ACAAGUCGGAACCAUUUUATT
 832
AD-15248





2426-2444
AAAAUGGUUCCGACUUGUCTT
 833
GACAAGUCGGAACCAUUUUTT
 834
AD-15175





2427-2445
AAAUGGUUCCGACUUGUCCTT
 835
GGACAAGUCGGAACCAUUUTT
 836
AD-15249





2428-2446
AAUGGUUCCGACUUGUCCCTT
 837
GGGACAAGUCGGAACCAUUTT
 838
AD-15250





2431-2449
GGUUCCGACUUGUCCCUCUTT
 839
AGAGGGACAAGUCGGAACCTT
 840
AD-15400





2457-2475
CUCCAUGGCCUGGCACGAGTT
 841
CUCGUGCCAGGCCAUGGAGTT
 842
AD-15332





2459-2477
CCAUGGCCUGGCACGAGGGTT
 843
CCCUCGUGCCAGGCCAUGGTT
 844
AD-15388





2545-2563
GAACUCACUCACUCUGGGUTT
 845
ACCCAGAGUGAGUGAGUUCTT
 846
AD-15333





2549-2567
UCACUCACUCUGGGUGCCUTT
 847
AGGCACCCAGAGUGAGUGATT
 848
AD-15334





2616-2634
UUUCACCAUUCAAACAGGUTT
 849
ACCUGUUUGAAUGGUGAAATT
 850
AD-15335





2622-2640
CAUUCAAACAGGUCGAGCUTT
 851
AGCUCGACCUGUUUGAAUGTT
 852
AD-15183





2623-2641
AUUCAAACAGGUCGAGCUGTT
 853
CAGCUCGACCUGUUUGAAUTT
 854
AD-15202





2624-2642
UUCAAACAGGUCGAGCUGUTT
 855
ACAGCUCGACCUGUUUGAATT
 856
AD-15203





2625-2643
UCAAACAGGUCGAGCUGUGTT
 857
CACAGCUCGACCUGUUUGATT
 858
AD-15272





2626-2644
CAAACAGGUCGAGCUGUGCTT
 859
GCACAGCUCGACCUGUUUGTT
 860
AD-15217





2627-2645
AAACAGGUCGAGCUGUGCUTT
 861
AGCACAGCUCGACCUGUUUTT
 862
AD-15290





2628-2646
AACAGGUCGAGCUGUGCUCTT
 863
GAGCACAGCUCGACCUGUUTT
 864
AD-15218





2630-2648
CAGGUCGAGCUGUGCUCGGTT
 865
CCGAGCACAGCUCGACCUGTT
 866
AD-15389





2631-2649
AGGUCGAGCUGUGCUCGGGTT
 867
CCCGAGCACAGCUCGACCUTT
 868
AD-15336





2633-2651
GUCGAGCUGUGCUCGGGUGTT
 869
CACCCGAGCACAGCUCGACTT
 870
AD-15337





2634-2652
UCGAGCUGUGCUCGGGUGCTT
 871
GCACCCGAGCACAGCUCGATT
 872
AD-15191





2657-2675
AGCUGCUCCCAAUGUGCCGTT
 873
CGGCACAUUGGGAGCAGCUTT
 874
AD-15390





2658-2676
GCUGCUCCCAAUGUGCCGATT
 875
UCGGCACAUUGGGAGCAGCTT
 876
AD-15338





2660-2678
UGCUCCCAAUGUGCCGAUGTT
 877
CAUCGGCACAUUGGGAGCATT
 878
AD-15204





2663-2681
UCCCAAUGUGCCGAUGUCCTT
 879
GGACAUCGGCACAUUGGGATT
 880
AD-15251





2665-2683
CCAAUGUGCCGAUGUCCGUTT
 881
ACGGACAUCGGCACAUUGGTT
 882
AD-15205





2666-2684
CAAUGUGCCGAUGUCCGUGTT
 883
CACGGACAUCGGCACAUUGTT
 884
AD-15171





2667-2685
AAUGUGCCGAUGUCCGUGGTT
 885
CCACGGACAUCGGCACAUUTT
 886
AD-15252





2673-2691
CCGAUGUCCGUGGGCAGAATT
 887
UUCUGCCCACGGACAUCGGTT
 888
AD-15339





2675-2693
GAUGUCCGUGGGCAGAAUGTT
 889
CAUUCUGCCCACGGACAUCTT
 890
AD-15253





2678-2696
GUCCGUGGGCAGAAUGACUTT
 891
AGUCAUUCUGCCCACGGACTT
 892
AD-15340





2679-2697
UCCGUGGGCAGAAUGACUUTT
 893
AAGUCAUUCUGCCCACGGATT
 894
AD-15291





2683-2701
UGGGCAGAAUGACUUUUAUTT
 895
AUAAAAGUCAUUCUGCCCATT
 896
AD-15341





2694-2712
ACUUUUAUUGAGCUCUUGUTT
 897
ACAAGAGCUCAAUAAAAGUTT
 898
AD-15401





2700-2718
AUUGAGCUCUUGUUCCGUGTT
 899
CACGGAACAAGAGCUCAAUTT
 900
AD-15342





2704-2722
AGCUCUUGUUCCGUGCCAGTT
 901
CUGGCACGGAACAAGAGCUTT
 902
AD-15343





2705-2723
GCUCUUGUUCCGUGCCAGGTT
 903
CCUGGCACGGAACAAGAGCTT
 904
AD-15292





2710-2728
UGUUCCGUGCCAGGCAUUCTT
 905
GAAUGCCUGGCACGGAACATT
 906
AD-15344





2711-2729
GUUCCGUGCCAGGCAUUCATT
 907
UGAAUGCCUGGCACGGAACTT
 908
AD-15254





2712-2730
UUCCGUGCCAGGCAUUCAATT
 909
UUGAAUGCCUGGCACGGAATT
 910
AD-15345





2715-2733
CGUGCCAGGCAUUCAAUCCTT
 911
GGAUUGAAUGCCUGGCACGTT
 912
AD-15206





2716-2734
GUGCCAGGCAUUCAAUCCUTT
 913
AGGAUUGAAUGCCUGGCACTT
 914
AD-15346





2728-2746
CAAUCCUCAGGUCUCCACCTT
 915
GGUGGAGACCUGAGGAUUGTT
 916
AD-15347





2743-2761
CACCAAGGAGGCAGGAUUCTsT
 917
GAAUCCUGCCUCCUUGGUGTsT
 918
AD-9577





2743-2761
cAccAAGGAGGcAGGAuucTsT
 919
GAAUCCUGCCUCCUUGGUGTsT
 920
AD-9703





2743-2761
CfaCfcAfaGfgAfgGfcAfgG
 921
p-gAfaUfcCfuGfcCfuCfcU
 922
AD-14678



faUfuCfTsT

fuGfgUfgTsT







2743-2761
CfACfCfAAGGAGGCfAGGAUf
 923
GAAUfCfCfUfGCfCfUfCfCf
 924
AD-14688



UfCfTsT

UfUfGGUfGTsT







2743-2761
CaCcAaGgAgGcAgGaUuCTsT
 925
p-gAfaUfcCfuGfcCfuCfcU
 926
AD-14698





fuGfgUfgTsT







2743-2761
CaCcAaGgAgGcAgGaUuCTsT
 927
GAAUfCfCfUfGCfCfUfCfCf
 928
AD-14708





UfUfGGUfGTsT







2743-2761
CfaCfcAfaGfgAfgGfcAfgG
 929
GAAUCcuGCcuCCUUGgugTsT
 930
AD-14718



faUfuCfTsT









2743-2761
CfACfCfAAGGAGGCfAGGAUf
 931
GAAUCcuGCcuCCUUGgugTsT
 932
AD-14728



UfCfTsT









2743-2761
CaCcAaGgAgGcAgGaUuCTsT
 933
GAAUCcuGCcuCCUUGgugTsT
 934
AD-14738





2743-2761
GfgCfcUfgGfaGfuUfuAfuU
 935
p-uCfcGfaAfuAfaAfcUfcC
 936
AD-15084



fcGfgAfTsT

faGfgCfcTsT







2743-2761
GGCfCfUfGGAGUfUfUfAUfU
 937
UfCfCfGAAUfAAACfUfCfCf
 938
AD-15094



fCfGGATsT

AGGCfCfTsT







2743-2761
GgCcUgGaGuUuAuUcGgATsT
 939
p-uCfcGfaAfuAfaAfcUfcC
 940
AD-15104





faGfgCfcTsT







2743-2761
GgCcUgGaGuUuAuUcGgATsT
 941
UfCfCfGAAUfAAACfUfCfCf
 942
AD-15114





AGGCfCfTsT







2743-2761
GfgCfcUfgGfaGfuUfuAfuU
 943
UCCGAauAAacUCCAGgccTsT
 944
AD-15124



fcGfgAfTsT









2743-2761
GGCfCfUfGGAGUfUfUfAUfU
 945
UCCGAauAAacUCCAGgccTsT
 946
AD-15134



fCfGGATsT









2743-2761
GgCcUgGaGuUuAuUcGgATsT
 947
UCCGAauAAacUCCAGgccTsT
 948
AD-15144





2753-2771
GCAGGAUUCUUCCCAUGGATT
 949
UCCAUGGGAAGAAUCCUGCTT
 950
AD-15391





2794-2812
UGCAGGGACAAACAUCGUUTT
 951
AACGAUGUUUGUCCCUGCATT
 952
AD-15348





2795-2813
GCAGGGACAAACAUCGUUGTT
 953
CAACGAUGUUUGUCCCUGCTT
 954
AD-15349





2797-2815
AGGGACAAACAUCGUUGGGTT
 955
CCCAACGAUGUUUGUCCCUTT
 956
AD-15170





2841-2859
CCCUCAUCUCCAGCUAACUTT
 957
AGUUAGCUGGAGAUGAGGGTT
 958
AD-15350





2845-2863
CAUCUCCAGCUAACUGUGGTT
 959
CCACAGUUAGCUGGAGAUGTT
 960
AD-15402





2878-2896
GCUCCCUGAUUAAUGGAGGTT
 961
CCUCCAUUAAUCAGGGAGCTT
 962
AD-15293





2881-2899
CCCUGAUUAAUGGAGGCUUTT
 963
AAGCCUCCAUUAAUCAGGGTT
 964
AD-15351





2882-2900
CCUGAUUAAUGGAGGCUUATT
 965
UAAGCCUCCAUUAAUCAGGTT
 966
AD-15403





2884-2902
UGAUUAAUGGAGGCUUAGCTT
 967
GCUAAGCCUCCAUUAAUCATT
 968
AD-15404





2885-2903
GAUUAAUGGAGGCUUAGCUTT
 969
AGCUAAGCCUCCAUUAAUCTT
 970
AD-15207





2886-2904
AUUAAUGGAGGCUUAGCUUTT
 971
AAGCUAAGCCUCCAUUAAUTT
 972
AD-15352





2887-2905
UUAAUGGAGGCUUAGCUUUTT
 973
AAAGCUAAGCCUCCAUUAATT
 974
AD-15255





2903-2921
UUUCUGGAUGGCAUCUAGCTsT
 975
GCUAGAUGCCAUCCAGAAATsT
 976
AD-9603





2903-2921
uuucuGGAuGGcAucuAGcTsT
 977
GCuAGAUGCcAUCcAGAAATsT
 978
AD-9729





2904-2922
UUCUGGAUGGCAUCUAGCCTsT
 979
GGCUAGAUGCCAUCCAGAATsT
 980
AD-9599





2904-2922
uucuGGAuGGcAucuAGccTsT
 981
GGCuAGAUGCcAUCcAGAATsT
 982
AD-9725





2905-2923
UCUGGAUGGCAUCUAGCCATsT
 983
UGGCUAGAUGCCAUCCAGATsT
 984
AD-9621





2905-2923
ucuGGAuGGcAucuAGccATsT
 985
UGGCuAGAUGCcAUCcAGATsT
 986
AD-9747





2925-2943
AGGCUGGAGACAGGUGCGCTT
 987
GCGCACCUGUCUCCAGCCUTT
 988
AD-15405





2926-2944
GGCUGGAGACAGGUGCGCCTT
 989
GGCGCACCUGUCUCCAGCCTT
 990
AD-15353





2927-2945
GCUGGAGACAGGUGCGCCCTT
 991
GGGCGCACCUGUCUCCAGCTT
 992
AD-15354





2972-2990
UUCCUGAGCCACCUUUACUTT
 993
AGUAAAGGUGGCUCAGGAATT
 994
AD-15406





2973-2991
UCCUGAGCCACCUUUACUCTT
 995
GAGUAAAGGUGGCUCAGGATT
 996
AD-15407





2974-2992
CCUGAGCCACCUUUACUCUTT
 997
AGAGUAAAGGUGGCUCAGGTT
 998
AD-15355





2976-2994
UGAGCCACCUUUACUCUGCTT
 999
GCAGAGUAAAGGUGGCUCATT
1000
AD-15356





2978-2996
AGCCACCUUUACUCUGCUCTT
1001
GAGCAGAGUAAAGGUGGCUTT
1002
AD-15357





2981-2999
CACCUUUACUCUGCUCUAUTT
1003
AUAGAGCAGAGUAAAGGUGTT
1004
AD-15269





2987-3005
UACUCUGCUCUAUGCCAGGTsT
1005
CCUGGCAUAGAGCAGAGUATsT
1006
AD-9565





2987-3005
uAcucuGcucuAuGccAGGTsT
1007
CCUGGcAuAGAGcAGAGuATsT
1008
AD-9691





2998-3016
AUGCCAGGCUGUGCUAGCATT
1009
UGCUAGCACAGCCUGGCAUTT
1010
AD-15358





3003-3021
AGGCUGUGCUAGCAACACCTT
1011
GGUGUUGCUAGCACAGCCUTT
1012
AD-15359





3006-3024
CUGUGCUAGCAACACCCAATT
1013
UUGGGUGUUGCUAGCACAGTT
1014
AD-15360





3010-3028
GCUAGCAACACCCAAAGGUTT
1015
ACCUUUGGGUGUUGCUAGCTT
1016
AD-15219





3038-3056
GGAGCCAUCACCUAGGACUTT
1017
AGUCCUAGGUGAUGGCUCCTT
1018
AD-15361





3046-3064
CACCUAGGACUGACUCGGCTT
1019
GCCGAGUCAGUCCUAGGUGTT
1020
AD-15273





3051-3069
AGGACUGACUCGGCAGUGUTT
1021
ACACUGCCGAGUCAGUCCUTT
1022
AD-15362





3052-3070
GGACUGACUCGGCAGUGUGTT
1023
CACACUGCCGAGUCAGUCCTT
1024
AD-15192





3074-3092
UGGUGCAUGCACUGUCUCATT
1025
UGAGACAGUGCAUGCACCATT
1026
AD-15256





3080-3098
AUGCACUGUCUCAGCCAACTT
1027
GUUGGCUGAGACAGUGCAUTT
1028
AD-15363





3085-3103
CUGUCUCAGCCAACCCGCUTT
1029
AGCGGGUUGGCUGAGACAGTT
1030
AD-15364





3089-3107
CUCAGCCAACCCGCUCCACTsT
1031
GUGGAGCGGGUUGGCUGAGTsT
1032
AD-9604





3089-3107
cucAGccAAcccGcuccAcTsT
1033
GUGGAGCGGGUUGGCUGAGTsT
1034
AD-9730





3093-3111
GCCAACCCGCUCCACUACCTsT
1035
GGUAGUGGAGCGGGUUGGCTsT
1036
AD-9527





3093-3111
GccAAcccGcuccAcuAccTsT
1037
GGuAGUGGAGCGGGUUGGCTsT
1038
AD-9653





3096-3114
AACCCGCUCCACUACCCGGTT
1039
CCGGGUAGUGGAGCGGGUUTT
1040
AD-15365





3099-3117
CCGCUCCACUACCCGGCAGTT
1041
CUGCCGGGUAGUGGAGCGGTT
1042
AD-15294





3107-3125
CUACCCGGCAGGGUACACATT
1043
UGUGUACCCUGCCGGGUAGTT
1044
AD-15173





3108-3126
UACCCGGCAGGGUACACAUTT
1045
AUGUGUACCCUGCCGGGUATT
1046
AD-15366





3109-3127
ACCCGGCAGGGUACACAUUTT
1047
AAUGUGUACCCUGCCGGGUTT
1048
AD-15367





3110-3128
CCCGGCAGGGUACACAUUCTT
1049
GAAUGUGUACCCUGCCGGGTT
1050
AD-15257





3112-3130
CGGCAGGGUACACAUUCGCTT
1051
GCGAAUGUGUACCCUGCCGTT
1052
AD-15184





3114-3132
GCAGGGUACACAUUCGCACTT
1053
GUGCGAAUGUGUACCCUGCTT
1054
AD-15185





3115-3133
CAGGGUACACAUUCGCACCTT
1055
GGUGCGAAUGUGUACCCUGTT
1056
AD-15258





3116-3134
AGGGUACACAUUCGCACCCTT
1057
GGGUGCGAAUGUGUACCCUTT
1058
AD-15186





3196-3214
GGAACUGAGCCAGAAACGCTT
1059
GCGUUUCUGGCUCAGUUCCTT
1060
AD-15274





3197-3215
GAACUGAGCCAGAAACGCATT
1061
UGCGUUUCUGGCUCAGUUCTT
1062
AD-15368





3198-3216
AACUGAGCCAGAAACGCAGTT
1063
CUGCGUUUCUGGCUCAGUUTT
1064
AD-15369





3201-3219
UGAGCCAGAAACGCAGAUUTT
1065
AAUCUGCGUUUCUGGCUCATT
1066
AD-15370





3207-3225
AGAAACGCAGAUUGGGCUGTT
1067
CAGCCCAAUCUGCGUUUCUTT
1068
AD-15259





3210-3228
AACGCAGAUUGGGCUGGCUTT
1069
AGCCAGCCCAAUCUGCGUUTT
1070
AD-15408





3233-3251
AGCCAAGCCUCUUCUUACUTsT
1071
AGUAAGAAGAGGCUUGGCUTsT
1072
AD-9597





3233-3251
AGccAAGccucuucuuAcuTsT
1073
AGuAAGAAGAGGCUUGGCUTsT
1074
AD-9723





3233-3251
AfgCfcAfaGfcCfuCfuUfcU
1075
p-aGfuAfaGfaAfgAfgGfcU
1076
AD-14680



fuAfcUfTsT

fuGfgCfuTsT







3233-3251
AGCfCfAAGCfCfUfCfUfUfC
1077
AGUfAAGAAGAGGCfUfUfGGC
1078
AD-14690



fUfUfACfUfTsT

fUfTsT







3233-3251
AgCcAaGcCuCuUcUuAcUTsT
1079
p-aGfuAfaGfaAfgAfgGfcU
1080
AD-14700





fuGfgCfuTsT







3233-3251
AgCcAaGcCuCuUcUuAcUTsT
1081
AGUfAAGAAGAGGCfUfUfGGC
1082
AD-14710





fUfTsT







3233-3251
AfgCfcAfaGfcCfuCfuUfcU
1083
AGUAAgaAGagGCUUGgcuTsT
1084
AD-14720



fuAfcUfTsT









3233-3251
AGCfCfAAGCfCfUfCfUfUfC
1085
AGUAAgaAGagGCUUGgcuTsT
1086
AD-14730



fUfUfACfUfTsT









3233-3251
AgCcAaGcCuCuUcUuAcUTsT
1087
AGUAAgaAGagGCUUGgcuTsT
1088
AD-14740





3233-3251
UfgGfuUfcCfcUfgAfgGfaC
1089
p-gCfuGfgUfcCfuCfaGfgG
1090
AD-15086



fcAfgCfTsT

faAfcCfaTsT







3233-3251
UfGGUfUfCfCfCfUfGAGGAC
1091
GCfUfGGUfCfCfUfCfAGGGA
1092
AD-15096



fCfAGCfTsT

ACfCfATsT







3233-3251
UgGuUcCcUgAgGaCcAgCTsT
1093
p-gCfuGfgUfcCfuCfaGfgG
1094
AD-15106





faAfcCfaTsT







3233-3251
UgGuUcCcUgAgGaCcAgCTsT
1095
GCfUfGGUfCfCfUfCfAGGGA
1096
AD-15116





ACfCfATsT







3233-3251
UfgGfuUfcCfcUfgAfgGfaC
1097
GCUGGucCUcaGGGAAccaTsT
1098
AD-15126



fcAfgCfTsT









3233-3251
UfGGUfUfCfCfCfUfGAGGAC
1099
GCUGGucCUcaGGGAAccaTsT
1100
AD-15136



fCfAGCfTsT









3233-3251
UgGuUcCcUgAgGaCcAgCTsT
1101
GCUGGucCUcaGGGAAccaTsT
1102
AD-15146





3242-3260
UCUUCUUACUUCACCCGGCTT
1103
GCCGGGUGAAGUAAGAAGATT
1104
AD-15260





3243-3261
CUUCUUACUUCACCCGGCUTT
1105
AGCCGGGUGAAGUAAGAAGTT
1106
AD-15371





3244-3262
UUCUUACUUCACCCGGCUGTT
1107
CAGCCGGGUGAAGUAAGAATT
1108
AD-15372





3262-3280
GGGCUCCUCAUUUUUACGGTT
1109
CCGUAAAAAUGAGGAGCCCTT
1110
AD-15172





3263-3281
GGCUCCUCAUUUUUACGGGTT
1111
CCCGUAAAAAUGAGGAGCCTT
1112
AD-15295





3264-3282
GCUCCUCAUUUUUACGGGUTT
1113
ACCCGUAAAAAUGAGGAGCTT
1114
AD-15373





3265-3283
CUCCUCAUUUUUACGGGUATT
1115
UACCCGUAAAAAUGAGGAGTT
1116
AD-15163





3266-3284
UCCUCAUUUUUACGGGUAATT
1117
UUACCCGUAAAAAUGAGGATT
1118
AD-15165





3267-3285
CCUCAUUUUUACGGGUAACTT
1119
GUUACCCGUAAAAAUGAGGTT
1120
AD-15374





3268-3286
CUCAUUUUUACGGGUAACATT
1121
UGUUACCCGUAAAAAUGAGTT
1122
AD-15296





3270-3288
CAUUUUUACGGGUAACAGUTT
1123
ACUGUUACCCGUAAAAAUGTT
1124
AD-15261





3271-3289
AUUUUUACGGGUAACAGUGTT
1125
CACUGUUACCCGUAAAAAUTT
1126
AD-15375





3274-3292
UUUACGGGUAACAGUGAGGTT
1127
CCUCACUGUUACCCGUAAATT
1128
AD-15262





3308-3326
CAGACCAGGAAGCUCGGUGTT
1129
CACCGAGCUUCCUGGUCUGTT
1130
AD-15376





3310-3328
GACCAGGAAGCUCGGUGAGTT
1131
CUCACCGAGCUUCCUGGUCTT
1132
AD-15377





3312-3330
CCAGGAAGCUCGGUGAGUGTT
1133
CACUCACCGAGCUUCCUGGTT
1134
AD-15409





3315-3333
GGAAGCUCGGUGAGUGAUGTT
1135
CAUCACUCACCGAGCUUCCTT
1136
AD-15378





3324-3342
GUGAGUGAUGGCAGAACGATT
1137
UCGUUCUGCCAUCACUCACTT
1138
AD-15410





3326-3344
GAGUGAUGGCAGAACGAUGTT
1139
CAUCGUUCUGCCAUCACUCTT
1140
AD-15379





3330-3348
GAUGGCAGAACGAUGCCUGTT
1141
CAGGCAUCGUUCUGCCAUCTT
1142
AD-15187





3336-3354
AGAACGAUGCCUGCAGGCATT
1143
UGCCUGCAGGCAUCGUUCUTT
1144
AD-15263





3339-3357
ACGAUGCCUGCAGGCAUGGTT
1145
CCAUGCCUGCAGGCAUCGUTT
1146
AD-15264





3348-3366
GCAGGCAUGGAACUUUUUCTT
1147
GAAAAAGUUCCAUGCCUGCTT
1148
AD-15297





3356-3374
GGAACUUUUUCCGUUAUCATT
1149
UGAUAACGGAAAAAGUUCCTT
1150
AD-15208





3357-3375
GAACUUUUUCCGUUAUCACTT
1151
GUGAUAACGGAAAAAGUUCTT
1152
AD-15209





3358-3376
AACUUUUUCCGUUAUCACCTT
1153
GGUGAUAACGGAAAAAGUUTT
1154
AD-15193





3370-3388
UAUCACCCAGGCCUGAUUCTT
1155
GAAUCAGGCCUGGGUGAUATT
1156
AD-15380





3378-3396
AGGCCUGAUUCACUGGCCUTT
1157
AGGCCAGUGAAUCAGGCCUTT
1158
AD-15298





3383-3401
UGAUUCACUGGCCUGGCGGTT
1159
CCGCCAGGCCAGUGAAUCATT
1160
AD-15299





3385-3403
AUUCACUGGCCUGGCGGAGTT
1161
CUCCGCCAGGCCAGUGAAUTT
1162
AD-15265





3406-3424
GCUUCUAAGGCAUGGUCGGTT
1163
CCGACCAUGCCUUAGAAGCTT
1164
AD-15381





3407-3425
CUUCUAAGGCAUGGUCGGGTT
1165
CCCGACCAUGCCUUAGAAGTT
1166
AD-15210





3429-3447
GAGGGCCAACAACUGUCCCTT
1167
GGGACAGUUGUUGGCCCUCTT
1168
AD-15270





3440-3458
ACUGUCCCUCCUUGAGCACTsT
1169
GUGCUCAAGGAGGGACAGUTsT
1170
AD-9591





3440-3458
AcuGucccuccuuGAGcAcTsT
1171
GUGCUcAAGGAGGGAcAGUTsT
1172
AD-9717





3441-3459
CUGUCCCUCCUUGAGCACCTsT
1173
GGUGCUCAAGGAGGGACAGTsT
1174
AD-9622





3441-3459
cuGucccuccuuGAGcAccTsT
1175
GGUGCUcAAGGAGGGAcAGTsT
1176
AD-9748





3480-3498
ACAUUUAUCUUUUGGGUCUTsT
1177
AGACCCAAAAGAUAAAUGUTsT
1178
AD-9587





3480-3498
AcAuuuAucuuuuGGGucuTsT
1179
AGACCcAAAAGAuAAAUGUTsT
1180
AD-9713





3480-3498
AfcAfuUfuAfuCfuUfuUfgG
1181
p-aGfaCfcCfaAfaAfgAfuA
1182
AD-14679



fgUfcUfTsT

faAfuGfuTsT







3480-3498
ACfAUfUfUfAUfCfUfUfUfU
1183
AGACfCfCfAAAAGAUfAAAUf
1184
AD-14689



fGGGUfCfUfTsT

GUfTsT







3480-3498
AcAuUuAuCuUuUgGgUcUTsT
1185
p-aGfaCfcCfaAfaAfgAfuA
1186
AD-14699





faAfuGfuTsT







3480-3498
AcAuUuAuCuUuUgGgUcUTsT
1187
AGACfCfCfAAAAGAUfAAAUf
1188
AD-14709





GUfTsT







3480-3498
AfcAfuUfuAfuCfuUfuUfgG
1189
AGACCcaAAagAUAAAuguTsT
1190
AD-14719



fgUfcUfTsT









3480-3498
ACfAUfUfUfAUfCfUfUfUfU
1191
AGACCcaAAagAUAAAuguTsT
1192
AD-14729



fGGGUfCfUfTsT









3480-3498
AcAuUuAuCuUuUgGgUcUTsT
1193
AGACCcaAAagAUAAAuguTsT
1194
AD-14739





3480-3498
GfcCfaUfcUfgCfuGfcCfgG
1195
p-gGfcUfcCfgGfcAfgCfaG
1196
AD-15085



faGfcCfTsT

faUfgGfcTsT







3480-3498
GCfCfAUfCfUfGCfUfGCfCf
1197
GGCfUfCfCfGGCfAGCfAGAU
1198
AD-15095



GGAGCfCfTsT

fGGCfTsT







3480-3498
GcCaUcUgCuGcCgGaGcCTsT
1199
p-gGfcUfcCfgGfcAfgCfaG
1200
AD-15105





faUfgGfcTsT







3480-3498
GcCaUcUgCuGcCgGaGcCTsT
1201
GGCfUfCfCfGGCfAGCfAGAU
1202
AD-15115





fGGCfTsT







3480-3498
GfcCfaUfcUfgCfuGfcCfgG
1203
GGCUCauGCagCAGAUggcTsT
1204
AD-15125



faGfcCfTsT









3480-3498
GCfCfAUfCfUfGCfUfGCfCf
1205
GGCUCauGCagCAGAUggcTsT
1206
AD-15135



GGAGCfCfTsT









3480-3498
GcCaUcUgCuGcCgGaGcCTsT
1207
GGCUCauGCagCAGAUggcTsT
1208
AD-15145





3481-3499
CAUUUAUCUUUUGGGUCUGTsT
1209
CAGACCCAAAAGAUAAAUGTsT
1210
AD-9578





3481-3499
cAuuuAucuuuuGGGucuGTsT
1211
cAGACCcAAAAGAuAAAUGTsT
1212
AD-9704





3485-3503
UAUCUUUUGGGUCUGUCCUTsT
1213
AGGACAGACCCAAAAGAUATsT
1214
AD-9558





3485-3503
uAucuuuuGGGucuGuccuTsT
1215
AGGAcAGACCcAAAAGAuATsT
1216
AD-9684





3504-3522
CUCUGUUGCCUUUUUACAGTsT
1217
CUGUAAAAAGGCAACAGAGTsT
1218
AD-9634





3504-3522
cucuGuuGccuuuuuAcAGTsT
1219
CUGuAAAAAGGcAAcAGAGTsT
1220
AD-9760





3512-3530
CCUUUUUACAGCCAACUUUTT
1221
AAAGUUGGCUGUAAAAAGGTT
1222
AD-15411





3521-3539
AGCCAACUUUUCUAGACCUTT
1223
AGGUCUAGAAAAGUUGGCUTT
1224
AD-15266





3526-3544
ACUUUUCUAGACCUGUUUUTT
1225
AAAACAGGUCUAGAAAAGUTT
1226
AD-15382





3530-3548
UUCUAGACCUGUUUUGCUUTsT
1227
AAGCAAAACAGGUCUAGAATsT
1228
AD-9554





3530-3548
uucuAGAccuGuuuuGcuuTsT
1229
AAGcAAAAcAGGUCuAGAATsT
1230
AD-9680





3530-3548
UfuCfuAfgAfcCfuGfuUfuU
1231
p-aAfgCfaAfaAfcAfgGfuC
1232
AD-14676



fgCfuUfTsT

fuAfgAfaTsT







3530-3548
UfUfCfUfAGACfCfUfGUfUf
1233
AAGCfAAAACfAGGUfCfUfAG
1234
AD-14686



UfUfGCfUfUfTsT

AATsT







3530-3548
UuCuAgAcCuGuUuUgCuUTsT
1235
p-aAfgCfaAfaAfcAfgGfuC
1236
AD-14696





fuAfgAfaTsT







3530-3548
UuCuAgAcCuGuUuUgCuUTsT
1237
AAGCfAAAACfAGGUfCfUfAG
1238
AD-14706





AATsT







3530-3548
UfuCfuAfgAfcCfuGfuUfuU
1239
AAGcAaaACagGUCUAgaaTsT
1240
AD-14716



ffCfuUfTsT









3530-3548
UfUfCfUfAGACfCfUfGUfUf
1241
AAGcAaaACagGUCUAgaaTsT
1242
AD-14726



UfUfGCfUfUfTsT









3530-3548
UuCuAgAcCuGuUuUgCuUTsT
1243
AAGcAaaACagGUCUAgaaTsT
1244
AD-14736





3530-3548
CfaUfaGfgCfcUfgGfaGfuU
1245
p-aAfuAfaAfcUfcCfaGfgC
1246
AD-15082



fuAfuUfTsT

fcUfaUfgTsT







3530-3548
CfAUfAGGCfCfUfGGAGUfUf
1247
AAUfAAACfUfCfCfAGGCfCf
1248
AD-15092



UfAUfUfTsT

UfAUfGTsT







3530-3548
CaUaGgCcUgGaGuUuAuUTsT
1249
p-aAfuAfaAfcUfcCfaGfgC
1250
AD-15102





fcUfaUfgTsT







3530-3548
CaUaGgCcUgGaGuUuAuUTsT
1251
AAUfAAACfUfCfCfAGGCfCf
1252
AD-15112





UfAUfGTsT







3530-3548
CfaUfaGfgCfcUfgGfaGfuU
1253
AAUAAacUCcaGGCCUaugTsT
1254
AD-15122



fuAfuUfTsT









3530-3548
CfAUfAGGCfCfUfGGAGUfUf
1255
AAUAAacUCcaGGCCUaugTsT
1256
AD-15132



UfAUfUfTsT









3530-3548
CaUaGgCcUgGaGuUuAuUTsT
1257
AAUAAacUCcaGGCCUaugTsT
1258
AD-15142





3531-3549
UCUAGACCUGUUUUGCUUUTsT
1259
AAAGCAAAACAGGUCUAGATsT
1260
AD-9553





3531-3549
ucuAGAccuGuuuuGcuuuTsT
1261
AAAGcAAAAcAGGUCuAGATsT
1262
AD-9679





3531-3549
UfcUfaGfaCfcUfgUfuUfuG
1263
p-aAfaGfcAfaAfaCfaGfgU
1264
AD-14675



fcUfuUfTsT

fcUfaGfaTsT







3531-3549
UfCfUfAGACfCfUfGUfUfUf
1265
AAAGCfAAAACfAGGUfCfUfA
1266
AD-14685



UfGCfUfUfUfTsT

GATsT







3531-3549
UcUaGaCcUgUuUuGcUuUTsT
1267
p-aAfaGfcAfaAfaCfaGfgU
1268
AD-14695





fcUfaGfaTsT







3531-3549
UcUaGaCcUgUuUuGcUuUTsT
1269
AAAGCfAAAACfAGGUfCfUfA
1270
AD-14705





GATsT







3531-3549
UfcUfaGfaCfcUfgUfuUfuG
1271
AAAGCaaAAcaGGUCUagaTsT
1272
AD-14715



fcUfuUfTsT









3531-3549
UfCfUfAGACfCfUfGUfUfUf
1273
AAAGCaaAAcaGGUCUagaTsT
1274
AD-14725



UfGCfUfUfUfTsT









3531-3549
UcUaGaCcUgUuUuGcUuUTsT
1275
AAAGCaaAAcaGGUCUagaTsT
1276
AD-14735





3531-3549
UfcAfuAfgGfcCfuGfgAfgU
1277
p-aUfaAfaCfuCfcAfgGfcC
1278
AD-15081



fuUfaUfTsT

fuAfuGfaTsT







3531-3549
UfCfAUfAGGCfCfUfGGAGUf
1279
AUfAAACfUfCfCfAGGCfCfU
1280
AD-15091



UfUfAUfTsT

fAUfGATsT







3531-3549
UcAuAgGcCuGgAgUuUaUTsT
1281
p-aUfaAfaCfuCfcAfgGfcC
1282
AD-15101





fuAfuGfaTsT







3531-3549
UcAuAgGcCuGgAgUuUaUTsT
1283
AUfAAACfUfCfCfAGGCfCfU
1284
AD-15111





fAUfGATsT







3531-3549
UfcAfuAfgGfcCfuGfgAfgU
1285
AUAAAcuCCagGCCUAugaTsT
1286
AD-15121



fuUfaUfTsT









3531-3549
UfCfAUfAGGCfCfUfGGAGUf
1287
AUAAAcuCCagGCCUAugaTsT
1288
AD-15131



UfUfAUfTsT









3531-3549
UcAuAgGcCuGgAgUuUaUTsT
1289
AUAAAcuCCagGCCUAugaTsT
1290
AD-15141





3557-3575
UGAAGAUAUUUAUUCUGGGTsT
1291
CCCAGAAUAAAUAUCUUCATsT
1292
AD-9626





3557-3575
uGAAGAuAuuuAuucuGGGTsT
1293
CCcAGAAuAAAuAUCUUcATsT
1294
AD-9752





3570-3588
UCUGGGUUUUGUAGCAUUUTsT
1295
AAAUGCUACAAAACCCAGATsT
1296
AD-9629





3570-3588
ucuGGGuuuuGuAGcAuuuTsT
1297
AAAUGCuAcAAAACCcAGATsT
1298
AD-9755





3613-3631
AUAAAAACAAACAAACGUUTT
1299
AACGUUUGUUUGUUUUUAUTT
1300
AD-15412





3617-3635
AAACAAACAAACGUUGUCCTT
1301
GGACAACGUUUGUUUGUUUTT
1302
AD-15211





3618-3636
AACAAACAAACGUUGUCCUTT
1303
AGGACAACGUUUGUUUGUUTT
1304
AD-15300






1U, C, A, G: corresponding ribonucleotide; T: deoxythymidine; u, c, a, g: corresponding 2′-O-methyl ribonucleotide; Uf, Cf, Af, Gf: corresponding 2′-deoxy-2′-fluoro ribonucleotide; where nucleotides are written in sequence, they are connected by 3′-5′ phosphodiester groups; nucleotides with interjected “s” are connected by 3′-O-5′-O phosphorothiodiester groups; unless denoted by prefix “p-”, oligonucleotides are devoid of a 5′-phosphate group on the 5′-most nucleotide; all oligonucleotides bear 3′-OH on the 3′-most nucleotide














TABLE 1







data













IC50 in





Cynomolgous



Mean percent remaining mRNA transcript
IC50 in
monkey



at siRNA concentration/in cell type
HepG2
Hepatocyte













Duplex name
100 nM/HepG2
30 nM/HepG2
3 nM/HepG2
30 nM/Hela
[nM]
[nM]s
















AD-15220



35




AD-15275



56


AD-15301



70


AD-15276



42


AD-15302



32


AD-15303



37


AD-15221



30


AD-15413



61


AD-15304



70


AD-15305



36


AD-15306



20


AD-15307



38


AD-15277



50


AD-9526
74
89


AD-9652

97


AD-9519

78


AD-9645

66


AD-9523

55


AD-9649

60


AD-9569

112


AD-9695

102


AD-15222



75


AD-15278



78


AD-15178



83


AD-15308



84


AD-15223



67


AD-15309



34


AD-15279



44


AD-15194



63


AD-15310



42


AD-15311



30


AD-15392



18


AD-15312



21


AD-15313



19


AD-15280



81


AD-15267



82


AD-15314



32


AD-15315



74


AD-9624

94


AD-9750

96


AD-9623
43
66


AD-9749

105


AD-15384



48


AD-9607

32
28

0.20


AD-9733

78
73


AD-9524

23
28

0.07


AD-9650

91
90


AD-9520

23
32


AD-9520

23


AD-9646

97
108


AD-9608

37


AD-9734

91


AD-9546

32


AD-9672

57


AD-15385



54


AD-15393



31


AD-15316



37


AD-15317



37


AD-15318



63


AD-15195



45


AD-15224



57


AD-15188



42


AD-15225



51


AD-15281



89


AD-15282



75


AD-15319



61


AD-15226



56


AD-15271



25


AD-15283



25


AD-15284



64


AD-15189



17


AD-15227



62


AD-9547

31
29

0.20


AD-9673

56
57


AD-9548

54
60


AD-9674

36
57


AD-9529

60


AD-9655

140


AD-9605

27
31

0.27


AD-9731

31
31

0.32


AD-9596

37


AD-9722

76


AD-9583

42


AD-9709

104


AD-9579

113


AD-9705

81


AD-15394



32


AD-15196



72


AD-15197



85


AD-15198



71


AD-9609
66
71


AD-9735

115


AD-9537

145


AD-9663

102


AD-9528

113


AD-9654

107


AD-9515

49


AD-9641

92


AD-9514

57


AD-9640

89


AD-9530

75


AD-9656

77


AD-9538
79
80


AD-9664

53


AD-9598
69
83


AD-9724

127


AD-9625
58
88


AD-9751

60


AD-9556

46


AD-9682

38


AD-9539
56
63


AD-9665

83


AD-9517

36


AD-9643

40


AD-9610

36
34

0.04


AD-9736

22
29

0.04


AD-14681



33


AD-14691



27


AD-14701



32


AD-14711



33


AD-14721



22


AD-14731



21


AD-14741



22


AD-15087



37


AD-15097



51


AD-15107



26


AD-15117



28


AD-15127



33


AD-15137



54


AD-15147



52


AD-9516

94


AD-9642

105


AD-9562

46
51


AD-9688

26
34

4.20


AD-14677



38


AD-14687



52


AD-14697



35


AD-14707



58


AD-14717



42


AD-14727



50


AD-14737



32


AD-15083



16


AD-15093



24


AD-15103



11


AD-15113



34


AD-15123



19


AD-15133



15


AD-15143



16


AD-9521

50


AD-9647

62


AD-9611

48


AD-9737

68


AD-9592
46
55


AD-9718

78


AD-9561

64


AD-9687

84


AD-9636

42
41

2.10


AD-9762

9
28

0.40


AD-9540

45


AD-9666

81


AD-9535
48
73


AD-9661

83


AD-9559

35


AD-9685

77


AD-9533

100


AD-9659

88


AD-9612

122


AD-9738

83


AD-9557
75
96


AD-9683

48


AD-9531

31
32

0.53


AD-9657

23
29

0.66


AD-14673



81


AD-14683



56


AD-14693



56


AD-14703



68


AD-14713



55


AD-14723



24


AD-14733



34


AD-15079



85


AD-15089



54


AD-15099



70


AD-15109



67


AD-15119



67


AD-15129



57


AD-15139



69


AD-9542

160


AD-9668

92


AD-9739

109


AD-9637
56
83


AD-9763

79


AD-9630

82


AD-9756

63


AD-9593

55


AD-9719

115


AD-9601

111


AD-9727

118


AD-9573

36
42

1.60


AD-9699

32
36

2.50


AD-15228



26


AD-15395



53


AD-9602

126


AD-9728

94


AD-15386



45


AD-9580

112


AD-9706

86


AD-9581

35


AD-9707

81


AD-9543

51


AD-9669

97


AD-9574

74


AD-9700


AD-15320



26


AD-15321



34


AD-15199



64


AD-15167



86


AD-15164



41


AD-15166



43


AD-15322



64


AD-15200



46


AD-15213



27


AD-15229



44


AD-15215



49


AD-15214



101


AD-9315

15
32

0.98


AD-9326

35
51


AD-9318

14
37

0.40


AD-9323

14
33


AD-9314

11
22

0.04


AD-10792




0.10
0.10


AD-10796




0.1
0.1


AD-9638

101


AD-9764

112


AD-9525

53


AD-9651

58


AD-9560

97


AD-9686

111


AD-9536

157


AD-9662

81


AD-9584
52
68


AD-9710

111


AD-15323



62


AD-9551

91


AD-9677

62


AD-15230



52


AD-15231



25


AD-15285



36


AD-15396



27


AD-15397



56


AD-9600

112


AD-9726

95


AD-9606

107


AD-9732

105


AD-9633
56
75


AD-9759

111


AD-9588

66


AD-9714

106


AD-9589
67
85


AD-9715

113


AD-9575

120


AD-9701

100


AD-9563

103


AD-9689

81


AD-9594
80
95


AD-9720

92


AD-9585

83


AD-9711

122


AD-9614

100


AD-9740

198


AD-9615

116


AD-9741

130


AD-9534

32
30


AD-9534

32


AD-9660

89
79


AD-15324



46


AD-15232



19


AD-15233



25


AD-15234



59


AD-15286



109


AD-9590

122


AD-9716

114


AD-9632

34


AD-9758

96


AD-9567

41


AD-9693

50


AD-9586
81
104


AD-9712

107


AD-9564

120


AD-9690

92


AD-9616
74
84


AD-9742

127


AD-15398



24


AD-9617

111


AD-9743

104


AD-9635
73
90


AD-9761

83


AD-9568

76


AD-9694

52


AD-9576

47


AD-9702

79


AD-9627

69


AD-9753

127


AD-9628

141


AD-9754

89


AD-9631

80


AD-9757

78


AD-9595

31
32


AD-9721

87
70


AD-9544

68


AD-9670

67


AD-15235



25


AD-15236



73


AD-15168



100


AD-15174



92


AD-15325



81


AD-15326



65


AD-9570
35
42


AD-9696

77


AD-9566

38


AD-9692

78


AD-9532

100


AD-9658

102


AD-9549

50


AD-9675

78


AD-9541

43


AD-9667

73


AD-9550

36


AD-9676

100


AD-9571

27
32


AD-9697

74
89


AD-9572
47
53


AD-9698

73


AD-15327



82


AD-9639

30
35


AD-9765

82
74


AD-9518

31
35

0.60


AD-9518

31


AD-9644

35
37

2.60


AD-14672



26


AD-14682



27


AD-14692



22


AD-14702



19


AD-14712



25


AD-14722



18


AD-14732



32


AD-15078



86


AD-15088



97


AD-15098



74


AD-15108



67


AD-15118



76


AD-15128



86


AD-15138



74


AD-15237



30


AD-15287



30


AD-15238



36


AD-15328



35


AD-15399



47


AD-9582

37


AD-9708

81


AD-9545

31
43


AD-9671

15
33

2.50


AD-14674



16


AD-14684



26


AD-14694



18


AD-14704



27


AD-14714



20


AD-14724



18


AD-14734



18


AD-15080



29


AD-15090



23


AD-15100



26


AD-15110



23


AD-15120



20


AD-15130



20


AD-15140



19


AD-9522

59


AD-9648

78


AD-9552

80


AD-9678

76


AD-9618

90


AD-9744

91


AD-15239



38


AD-15212



19


AD-15240



43


AD-15177



59


AD-15179



13


AD-15180



15


AD-15241



14


AD-15268



42


AD-15242



21


AD-15216



28


AD-15176



35


AD-15181



35


AD-15243



22


AD-15182



42


AD-15244



31


AD-15387



23


AD-15245



18


AD-9555

34


AD-9681

55


AD-9619
42
61


AD-9745

56


AD-9620
44
77


AD-9746

89


AD-15288



19


AD-15246



16


AD-15289



37


AD-9324

59
67


AD-15329



103


AD-15330



62


AD-15169



22


AD-15201



6


AD-15331



14


AD-15190



47


AD-15247



61


AD-15248



22


AD-15175



45


AD-15249



51


AD-15250



96


AD-15400



12


AD-15332



22


AD-15388



30


AD-15333



20


AD-15334



96


AD-15335



75


AD-15183



16


AD-15202



41


AD-15203



39


AD-15272



49


AD-15217



16


AD-15290



15


AD-15218



13


AD-15389



13


AD-15336



40


AD-15337



19


AD-15191



33


AD-15390



25


AD-15338



9


AD-15204



33


AD-15251



76


AD-15205



14


AD-15171



16


AD-15252



58


AD-15339



20


AD-15253



15


AD-15340



18


AD-15291



17


AD-15341



11


AD-15401



13


AD-15342



30


AD-15343



21


AD-15292



16


AD-15344



20


AD-15254



18


AD-15345



18


AD-15206



15


AD-15346



16


AD-15347



62


AD-9577

33
31


AD-9703

17
26


AD-14678



22


AD-14688



23


AD-14698



23


AD-14708



14


AD-14718



31


AD-14728



25


AD-14738



31


AD-15084



19


AD-15094



11


AD-15104



16


AD-15114



15


AD-15124



11


AD-15134



12


AD-15144



9


AD-15391



7


AD-15348



13


AD-15349



8


AD-15170



40


AD-15350



14


AD-15402



27


AD-15293



27


AD-15351



14


AD-15403



11


AD-15404



38


AD-15207



15


AD-15352



23


AD-15255



31


AD-9603

123


AD-9729

56


AD-9599

139


AD-9725

38


AD-9621

77


AD-9747

63


AD-15405



32


AD-15353



39


AD-15354



49


AD-15406



35


AD-15407



39


AD-15355



18


AD-15356



50


AD-15357



54


AD-15269



23


AD-9565

74


AD-9691

49


AD-15358



12


AD-15359



24


AD-15360



13


AD-15219



19


AD-15361



24


AD-15273



36


AD-15362



31


AD-15192



20


AD-15256



19


AD-15363



33


AD-15364



24


AD-9604
35
49


AD-9730

85


AD-9527

45


AD-9653

86


AD-15365



62


AD-15294



30


AD-15173



12


AD-15366



21


AD-15367



11


AD-15257



18


AD-15184



50


AD-15185



12


AD-15258



73


AD-15186



36


AD-15274



19


AD-15368



7


AD-15369



17


AD-15370



19


AD-15259



38


AD-15408



52


AD-9597

23
21

0.04


AD-9723

12
26


AD-14680



15


AD-14690



18


AD-14700



15


AD-14710



15


AD-14720



18


AD-14730



18


AD-14740



17


AD-15086



85


AD-15096



70


AD-15106



71


AD-15116



73


AD-15126



71


AD-15136



56


AD-15146



72


AD-15260



79


AD-15371



24


AD-15372



52


AD-15172



27


AD-15295



22


AD-15373



11


AD-15163



18


AD-15165



13


AD-15374



23


AD-15296



13


AD-15261



20


AD-15375



90


AD-15262



72


AD-15376



14


AD-15377



19


AD-15409



17


AD-15378



18


AD-15410



8


AD-15379



11


AD-15187



36


AD-15263



18


AD-15264



75


AD-15297



21


AD-15208



6


AD-15209



28


AD-15193



131


AD-15380



88


AD-15298



43


AD-15299



99


AD-15265



95


AD-15381



18


AD-15210



40


AD-15270



83


AD-9591
75
95


AD-9717

105


AD-9622

94


AD-9748

103


AD-9587

63
49


AD-9713

22
25


AD-14679



19


AD-14689



24


AD-14699



19


AD-14709



21


AD-14719



24


AD-14729



23


AD-14739



24


AD-15085



74


AD-15095



60


AD-15105



33


AD-15115



30


AD-15125



54


AD-15135



51


AD-15145



49


AD-9578
49
61


AD-9704

111


AD-9558

66


AD-9684

63


AD-9634

29
30


AD-9760

14
27


AD-15411



5


AD-15266



23


AD-15382



12


AD-9554

23
24


AD-9680

12
22

0.10
0.10


AD-14676



12


AD-14686



13


AD-14696



12


AD-14706



18


AD-14716



17


AD-14726



16


AD-14736



9


AD-15082



27


AD-15092



28


AD-15102



19


AD-15112



17


AD-15122



56


AD-15132



39


AD-15142



46


AD-9553

27
22

0.02


AD-9679

17
21


AD-14675



11


AD-14685



19


AD-14695



12


AD-14705



16


AD-14715



19


AD-14725



19


AD-14735



19


AD-15081



30


AD-15091



16


AD-15101



16


AD-15111



11


AD-15121



19


AD-15131



17


AD-15141



18


AD-9626

97
68


AD-9752

28
33


AD-9629

23
24


AD-9755

28
29


AD-15412



21


AD-15211



73


AD-15300



41




















TABLE 2







SEQ

SEQ


Duplex
Sense strand
ID
Antisense-strand
ID


number
sequence (5′-3′)1
NO:
sequence (5′-3′)1
NO:







AD-10792
GccuGGAGuuuAuucGGAATsT
1305
UUCCGAAuAAACUCcAGGCTsT
1306





AD-10793
GccuGGAGuuuAuucGGAATsT
1307
uUcCGAAuAAACUccAGGCTsT
1308





AD-10796
GccuGGAGuuuAuucGGAATsT
1309
UUCCGAAUAAACUCCAGGCTsT
1310





AD-12038
GccuGGAGuuuAuucGGAATsT
1311
uUCCGAAUAAACUCCAGGCTsT
1312





AD-12039
GccuGGAGuuuAuucGGAATsT
1313
UuCCGAAUAAACUCCAGGCTsT
1314





AD-12040
GccuGGAGuuuAuucGGAATsT
1315
UUcCGAAUAAACUCCAGGCTsT
1316





AD-12041
GccuGGAGuuuAuucGGAATsT
1317
UUCcGAAUAAACUCCAGGCTsT
1318





AD-12042
GCCUGGAGUUUAUUCGGAATsT
1319
uUCCGAAUAAACUCCAGGCTsT
1320





AD-12043
GCCUGGAGUUUAUUCGGAATsT
1321
UuCCGAAUAAACUCCAGGCTsT
1322





AD-12044
GCCUGGAGUUUAUUCGGAATsT
1323
UUcCGAAUAAACUCCAGGCTsT
1324





AD-12045
GCCUGGAGUUUAUUCGGAATsT
1325
UUCcGAAUAAACUCCAGGCTsT
1326





AD-12046
GccuGGAGuuuAuucGGAA
1327
UUCCGAAUAAACUCCAGGCscsu
1328





AD-12047
GccuGGAGuuuAuucGGAAA
1329
UUUCCGAAUAAACUCCAGGCscsu
1330





AD-12048
GccuGGAGuuuAuucGGAAAA
1331
UUUUCCGAAUAAACUCCAGGCscsu
1332





AD-12049
GccuGGAGuuuAuucGGAAAAG
1333
CUUUUCCGAAUAAACUCCAGGCscsu
1334





AD-12050
GccuGGAGuuuAuucGGAATTab
1335
UUCCGAAUAAACUCCAGGCTTab
1336





AD-12051
GccuGGAGuuuAuucGGAAATTab
1337
UUUCCGAAuAAACUCCAGGCTTab
1338





AD-12052
GccuGGAGuuuAuucGGAAAATTab
1339
UUUUCCGAAUAAACUCCAGGCTTab
1340





AD-12053
GccuGGAGuuuAuucGGAAAAGTTab
1341
CUUUUCCGAAUAAACUCCAGGCTTab
1342





AD-12054
GCCUGGAGUUUAUUCGGAATsT
1343
UUCCGAAUAAACUCCAGGCscsu
1344





AD-12055
GccuGGAGuuuAuucGGAATsT
1345
UUCCGAAUAAACUCCAGGCscsu
1346





AD-12056
GcCuGgAgUuUaUuCgGaA
1347
UUCCGAAUAAACUCCAGGCTTab
1348





AD-12057
GcCuGgAgUuUaUuCgGaA
1349
UUCCGAAUAAACUCCAGGCTsT
1350





AD-12058
GcCuGgAgUuUaUuCgGaA
1351
UUCCGAAuAAACUCcAGGCTsT
1352





AD-12059
GcCuGgAgUuUaUuCgGaA
1353
uUcCGAAuAAACUccAGGCTsT
1354





AD-12060
GcCuGgAgUuUaUuCgGaA
1355
UUCCGaaUAaaCUCCAggc
1356





AD-12061
GcCuGgnAgUuUaUuCgGaATsT
1357
UUCCGaaUAaaCUCCAggcTsT
1358





AD-12062
GcCuGgAgUuUaUuCgGaATTab
1359
UUCCGaaUAaaCUCCAggcTTab
1360





AD-12063
GcCuGgAgUuUaUuCgGaA
1361
UUCCGaaUAaaCUCCAggcscsu
1362





AD-12064
GcCuGgnAgUuUaUuCgGaATsT
1363
UUCCGAAuAAACUCcAGGCTsT
1364





AD-12065
GcCuGgAgUuUaUuCgGaATTab
1365
UUCCGAAuAAACUCcAGGCTTab
1366





AD-12066
GcCuGgAgUuUaUuCgGaA
1367
UUCCGAAuAAACUCcAGGCscsu
1368





AD-12067
GcCuGgnAgUuUaUuCgGaATsT
1369
UUCCGAAUAAACUCCAGGCTsT
1370





AD-12068
GcCuGgAgUuUaUuCgGaATTab
1371
UUCCGAAUAAACUCCAGGCTTab
1372





AD-12069
GcCuGgAgUuUaUuCgGaA
1373
UUCCGAAUAAACUCCAGGCscsu
1374





AD-12338
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1375
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfc
1376





AD-12339
GcCuGgAgUuUaUuCgGaA
1377
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfc
1378





AD-12340
GccuGGAGuuuAuucGGAA
1379
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfc
1380





AD-12341
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTsT
1381
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcTsT
1382





AD-12342
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTsT
1383
UUCCGAAuAAACUCcAGGCTsT
1384





AD-12343
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTsT
1385
uUcCGAAuAAACUccAGGCTsT
1386





AD-12344
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTsT
1387
UUCCGAAUAAACUCCAGGCTsT
1388





AD-12345
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTsT
1389
UUCCGAAUAAACUCCAGGCscsu
1390





AD-12346
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTsT
1391
UUCCGaaUAaaCUCCAggcscsu
1392





AD-12347
GCCUGGAGUUUAUUCGGAATsT
1393
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcTsT
1394





AD-12348
GccuGGAGuuuAuucGGAATsT
1395
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcTsT
1396





AD-12349
GcCuGgnAgUuUaUuCgGaATsT
1397
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcTsT
1398





AD-12350
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTTab
1399
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcTTab
1400





AD-12351
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1401
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcsCfsu
1402





AD-12352
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1403
UUCCGaaUAaaCUCCAggcscsu
1404





AD-12354
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1405
UUCCGAAUAAACUCCAGGCscsu
1406





AD-12355
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1407
UUCCGAAuAAACUCcAGGCTsT
1408





AD-12356
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1409
uUcCGAAuAAACUccAGGCTsT
1410





AD-12357
GmocCmouGmogAm02gUmouUmoaUmouC
1411
UUCCGaaUAaaCUCCAggc
1412



mogGmoaA








AD-12358
GmocCmouGmogAm02gUmouUmoaUmouC
1413
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfc
1414



mogGmoaA








AD-12359
GmocCmouGmogAm02gUmouUmoaUmouC
1415
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcsCfsu
1416



mogGmoaA








AD-12360
GmocCmouGmogAm02gUmouUmoaUmouC
1417
UUCCGAAUAAACUCCAGGCscsu
1418



mogGmoaA








AD-12361
GmocCmouGmogAm02gUmouUmoaUmouC
1419
UUCCGAAuAAACUCcAGGCTsT
1420



mogGmoaA








AD-12362
GmocCmouGmogAm02gUmouUmoaUmouC
1421
uUcCGAAuAAACUccAGGCTsT
1422



mogGmoaA








AD-12363
GmocCmouGmogAm02gUmouUmoaUmouC
1423
UUCCGaaUAaaCUCCAggcscsu
1424



mogGmoaA








AD-12364
GmocCmouGmogAmogUmouUmoaUmouCm
1425
UUCCGaaUAaaCUCCAggcTsT
1426



ogGmoaATsT








AD-12365
GmocCmouGmogAmogUmouUmoaUmouCm
1427
UUCCGAAuAAACUCcAGGCTsT
1428



ogGmoaATsT








AD-12366
GmocCmouGmogAmogUmouUmoaUmouCm
1429
UUCCGAAUAAACUCCAGGCTsT
1430



ogGmoaATsT








AD-12367
GmocmocmouGGAGmoumoumouAmoumou
1431
UUCCGaaUAaaCUCCAggcTsT
1432



mocGGAATsT








AD-12368
GmocmocmouGGAGmoumoumouAmoumou
1433
UUCCGAAuAAACUCcAGGCTsT
1434



mocGGAATsT








AD-12369
GmocmocmouGGAGmoumoumouAmoumou
1435
UUCCGAAUAAACUCCAGGCTsT
1436



mocGGAATsT








AD-12370
GmocmocmouGGAGmoumoumouAmoumou
1437
P-UfaCfCfGAAUfAAACfUfCfCfAGGCfTsT
1438



mocGGAATsT








AD-12371
GmocmocmouGGAGmoumoumouAmoumou
1439
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1440



mocGGAATsT








AD-12372
GmocmocmouGGAGmoumoumouAmoumou
1441
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcsCfsu
1442



mocGGAATsT








AD-12373
GmocmocmouGGAGmoumoumouAmoumou
1443
UUCCGAAUAAACUCCAGGCTsT
1444



mocGGAATsT








AD-12374
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1445
UfUfCfCfGAAUfAAACfUfCfCfAGGCfTsT
1446





AD-12375
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1447
UUCCGAAUAAACUCCAGGCTsT
1448





AD-12377
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1449
uUcCGAAuAAACUccAGGCTsT
1450





AD-12378
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1451
UUCCGaaUAaaCUCCAggcscsu
1452





AD-12379
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1453
UUCCGAAUAAACUCCAGGCscsu
1454





AD-12380
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1455
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcsCfsu
1456





AD-12381
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1457
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcTsT
1458





AD-12382
GCfCfUfGGAGUfUfUfAUfUfCfGGAATsT
1459
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfTsT
1460





AD-12383
GCCUGGAGUUUAUUCGGAATsT
1461
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfTsT
1462





AD-12384
GccuGGAGuuuAuucGGAATsT
1463
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfTsT
1464





AD-12385
GcCuGgnAgUuUaUuCgGaATsT
1465
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfTsT
1466





AD-12386
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1467
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfTsT
1468





AD-12387
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1469
UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1470





AD-12388
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1471
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfc
1472





AD-12389
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1473
P-uUfcCfgAfaUfaAfaCfuCfcAfgGfcsCfsu
1474





AD-12390
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1475
UUCCGAAUAAACUCCAGGCscsu
1476





AD-12391
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1477
UUCCGaaUAaaCUCCAggc
1478





AD-12392
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1479
UUCCGAAUAAACUCCAGGCTsT
1480





AD-12393
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1481
UUCCGAAuAAACUCcAGGCTsT
1482





AD-12394
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1483
uUcCGAAuAAACUccAGGCTsT
1484





AD-12395
GmocCmouGmogAmogUmouUmoaUmouCm
1485
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1486



ogGmoaATsT








AD-12396
GmocCmouGmogAm02gUmouUmoaUmouC
1487
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1488



mogGmoaA








AD-12397
GfcCfuGfgAfgUfuUfaUfuCfgGfaAf
1489
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1490





AD-12398
GfcCfuGfgAfgUfuUfaUfuCfgGfaAfTsT
1491
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1492





AD-12399
GcCuGgnAgUuUaUuCgGaATsT
1493
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1494





AD-12400
GCCUGGAGUUUAUUCGGAATsT
1495
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1496





AD-12401
GccuGGAGuuuAuucGGAATsT
1497
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1498





AD-12402
GccuGGAGuuuAuucGGAA
1499
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1500





AD-12403
GCfCfUfGGAGGUfUfUfAUfUfCfGGAA
1501
P-UfUfCfCfGAAUfAAACfUfCfCfAGGCfsCfsUf
1502





AD-9314
GCCUGGAGUUUAUUCGGAATsT
1503
UUCCGAAUAAACUCCAGGCTsT
1504






1U, C, A, G: corresponding ribonucleotide; T: deoxythymidine; u, c, a, g: corresponding 2′-O-methyl ribonucleotide; Uf, Cf, Af, Gf: corresponding 2′-deoxy-2′-fluoro ribonucleotide; moc, mou, mog, moa: corresponding 2′-MOE nucleotide; where nucleotides are written in sequence, they are connected by 3′-5′ phosphodiester groups; ab: 3′-terminal abasic nucleotide; nucleotides with interjected “s” are connected by 3′-O-5′-O phosphorothiodiester groups; unless denoted by prefix “p-”, oligonucleotides are devoid of a 5′-phosphate group on the 5′-most nucleotide; all oligonucleotides bear 3′-OH on the 3′-most nucleotide

















TABLE 2








Remaining mRNA




in % of controls



Duplex
at siRNA conc.



number
of 30 nM



















AD-10792
15



AD-10793
32



AD-10796
13



AD-12038
13



AD-12039
29



AD-12040
10



AD-12041
11



AD-12042
12



AD-12043
13



AD-12044
7



AD-12045
8



AD-12046
13



AD-12047
17



AD-12048
43



AD-12049
34



AD-12050
16



AD-12051
31



AD-12052
81



AD-12053
46



AD-12054
8



AD-12055
13



AD-12056
11



AD-12057
8



AD-12058
9



AD-12059
23



AD-12060
10



AD-12061
7



AD-12062
10



AD-12063
19



AD-12064
15



AD-12065
16



AD-12066
20



AD-12067
17



AD-12068
18



AD-12069
13



AD-12338
15



AD-12339
14



AD-12340
19



AD-12341
12



AD-12342
13



AD-12343
24



AD-12344
9



AD-12345
12



AD-12346
13



AD-12347
11



AD-12348
8



AD-12349
11



AD-12350
17



AD-12351
11



AD-12352
11



AD-12354
11



AD-12355
9



AD-12356
25



AD-12357
56



AD-12358
29



AD-12359
30



AD-12360
15



AD-12361
20



AD-12362
51



AD-12363
11



AD-12364
25



AD-12365
18



AD-12366
23



AD-12367
42



AD-12368
40



AD-12369
26



AD-12370
68



AD-12371
60



AD-12372
60



AD-12373
55



AD-12374
9



AD-12375
16



AD-12377
88



AD-12378
6



AD-12379
6



AD-12380
8



AD-12381
10



AD-12382
7



AD-12383
7



AD-12377
88



AD-12378
6



AD-12379
6



AD-12380
8



AD-12381
10



AD-12382
7



AD-12383
7



AD-12384
8



AD-12385
8



AD-12386
11



AD-12387
13



AD-12388
19



AD-12389
16



AD-12390
17



AD-12391
21



AD-12392
28



AD-12393
17



AD-12394
75



AD-12395
55



AD-12396
59



AD-12397
20



AD-12398
11



AD-12399
13



AD-12400
12



AD-12401
13



AD-12402
14



AD-12403
4



AD-9314
9









Claims
  • 1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of a human proprotein convertase subtilisin kexin 9 (PCSK9) gene in a cell, wherein the dsRNA comprises a sense strand and an antisense strand complementary to at least 15contiguous nucleotides of a PCSK9 gene and comprises a duplex structure between 15 and 30base pairs in length, wherein the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:457.
  • 2. The dsRNA of claim 1 comprising a duplex structure between 19 and 21 base pairs in length.
  • 3. The dsRNA of claim 1, consisting of a sense strand comprising the nucleotide sequence of SEQ ID NO:457 and an antisense strand comprising the nucleotide sequence of SEQ ID NO:458.
  • 4. The dsRNA of claim 1, wherein the sense strand and antisense comprises a terminal 3′ sequence TsT, wherein the terminal thymine comprises a 3′-O-5′-O phosphorothiodiester as indicated by a lower case “s”.
  • 5. The dsRNA of claim 1, wherein the dsRNA comprises at least one modified nucleotide.
  • 6. The dsRNA of claim 1, wherein the dsRNA comprises at least one 2′-O-methyl modified nucleotide and at least one nucleotide comprising a 5′-phosphorothioate group.
  • 7. The of dsRNA of claim 1, wherein the dsRNA comprises at least one modified nucleotide, wherein the modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified-nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a nucleotide comprising a 5′-phosphorothioate group, a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, and a non-natural base comprising nucleotide.
  • 8. A cell comprising the dsRNA of claim 1.
  • 9. A pharmaceutical composition comprising the dsRNA of claim 1 and a pharmaceutically acceptable carrier.
  • 10. A composition comprising the dsRNA of claim 1 and a lipid formulation.
  • 11. A composition comprising the dsRNA of claim 1 and a lipid formulation, wherein the lipid formulation comprises a cationic lipid comprising ND-98.
  • 12. A vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of the dsRNA of claim 1.
  • 13. A cell comprising the vector of claim 12.
  • 14. The dsRNA of claim 1, wherein contacting a cell in vitro with 30 nM or less of the dsRNA and maintaining the cell for a time sufficient to obtain degradation of a mRNA transcript of a PCSK9 gene, inhibits expression of the PCSK9 gene in the cell.
  • 15. The dsRNA of claim 1, wherein contacting HepG2 cells expressing the PCSK9 gene in vitro with the dsRNA and maintaining the cells for a time sufficient to obtain degradation of a mRNA transcript of a PCSK9 gene, inhibits expression of the PCSK9 gene in the cell by at least 20%.
  • 16. The dsRNA of claim 1, wherein administering the dsRNA to an animal decreases total serum cholesterol in the animal.
  • 17. A method for inhibiting expression of a proprotein convertase subtilisin kexin 9 (PCSK9) gene in a cell comprising contacting the cell with the dsRNA of claim 1 and maintaining the cell for a time sufficient to obtain degradation of a mRNA transcript of a PCSK9 gene, thereby inhibiting expression of the PCSK9 gene in the cell.
  • 18. A method of treating or managing pathological processes which can be mediated by down regulating expression of a proprotein convertase subtilisin kexin 9 (PCSK9) gene comprising administering to a patient in need of such treatment or management a therapeutically effective amount of the dsRNA of claim 1.
  • 19. A method of treating a proprotein convertase subtilisin kexin 9(PCSK9) gene-associated disorder comprising administering to a patient in need of such treatment, a therapeutically effective amount of the dsRNA of claim 1.
  • 20. The composition of claim 1, wherein the dsRNA is selected from the group consisting of the dsRNA comprising sense strand SEQ ID NO 1305(GccuGGAGuuuAuucGGAATsT) and antisense strand SEQ ID NO 1306(UUCCGAAuAAACUCcAGGCTsT), or the dsRNA comprising sense strand SEQ ID NO 1307(GccuGGAGuuuAuucGGAATsT) and antisense strand SEQ ID NO 1308(uUcCGAAuAAACUccAGGCTsT), or dsRNA comprising sense strand SEQ ID NO 1309(GccuGGAGuuuAuucGGAATsT) and antisense strand SEQ ID NO 1310(UUCCGAAUAAACUCCAGGCTsT), wherein each strand is modified to include a 2′-O-methyl ribonucleotide as indicated by a lower case letter “c” or “u” and a 3′-O -5′-O phosphorothiodiester as indicated by a lower case letter “s”.
  • 21. A cell comprising the dsRNA of claim 3.
  • 22. A pharmaceutical composition comprising the dsRNA of claim 3 and a pharmaceutically acceptable carrier.
  • 23. A composition comprising the dsRNA of claim 3 and a lipid formulation.
  • 24. A composition comprising the dsRNA of claim 3 and a lipid formulation, wherein the lipid formulation comprises a cationic lipid comprising ND-98.
  • 25. A method for inhibiting expression of a proprotein convertase subtilisin kexin 9 (PCSK9) gene in a cell comprising contacting the cell with the dsRNA of claim 3 and maintaining the cell for a time sufficient to obtain degradation of a mRNA transcript of a PCSK9 gene, thereby inhibiting expression of the PCSK9 gene in the cell.
  • 26. A method of treating or managing pathological processes which can be mediated by down regulating expression of a proprotein convertase subtilisin kexin 9 (PCSK9) gene comprising administering to a patient in need of such treatment or management a therapeutically effective amount of the dsRNA of claim 3.
  • 27. A method of treating a proprotein convertase subtilisin kexin 9 (PCSK9) gene-associated disorder comprising administering to a patient in need of such treatment, a therapeutically effective amount of the dsRNA of claim 3.
  • 28. A cell comprising the dsRNA of claim 20.
  • 29. A pharmaceutical composition comprising the dsRNA of claim 20 and a pharmaceutically acceptable carrier.
  • 30. A composition comprising the dsRNA of claim 20 and a lipid formulation.
  • 31. A composition comprising the dsRNA of claim 20 and a lipid formulation, wherein the lipid formulation comprises a cationic lipid comprising ND-98.
  • 32. A method for inhibiting expression of a proprotein convertase subtilisin kexin 9 (PCSK9) gene in a cell comprising contacting the cell with the dsRNA of claim 20 and maintaining the cell for a time sufficient to obtain degradation of a mRNA transcript of a PCSK9 gene, thereby inhibiting expression of the PCSK9 gene in the cell.
  • 33. A method of treating or managing pathological processes which can be mediated by down regulating expression of a proprotein convertase subtilisin kexin 9 (PCSK9) gene comprising administering to a patient in need of such treatment or management a therapeutically effective amount of the dsRNA of claim 20.
  • 34. A method of treating a proprotein convertase subtilisin kexin 9 (PCSK9) gene-associated disorder comprising administering to a patient in need of such treatment, a therapeutically effective amount of the dsRNA of claim 20.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/330,923 filed Jul. 14, 2014 (allowed), which is a continuation of U.S. application Ser. No. 13/472,438, filed May 15, 2012, now U.S. Pat. No. 8,809,292 issued Aug. 19, 2014, which is a continuation of U.S. application Ser. No. 12/554,231, filed Sep. 4, 2009, now U.S. Pat. No. 8,222,222, issued on Jul. 17, 2012, which is a divisional of U.S. application Ser. No. 11/746,864, filed May 10, 2007, now U.S. Pat. No. 7,605,251, issued on Oct. 20, 2009, which claims the benefit of and priority to U.S. Provisional Application No. 60/799,458, filed May 11, 2006; U.S. Provisional Application No. 60/817,203, filed Jun. 27, 2006; U.S. Provisional Application No. 60/840,089, filed Aug. 25, 2006; U.S. Provisional Application No. 60/829,914, filed Oct. 18, 2006; and U.S. Provisional Application No. 60/901,134, filed Feb. 13, 2007. The contents of all of these applications are hereby incorporated by reference in their entirety.

US Referenced Citations (43)
Number Name Date Kind
6054299 Conrad Apr 2000 A
6271359 Norris et al. Aug 2001 B1
7427605 Davis et al. Sep 2008 B2
7605251 Tan et al. Oct 2009 B2
7718629 Bumcrot et al. May 2010 B2
8222222 Tan et al. Jul 2012 B2
8273869 Fitzgerald et al. Sep 2012 B2
8563528 Straarup et al. Oct 2013 B2
8598139 Fitzgerald et al. Dec 2013 B2
20030143732 Fosnaugh et al. Jul 2003 A1
20030170891 McSwiggen Sep 2003 A1
20030229037 Massing et al. Dec 2003 A1
20040009216 Rodrigueza et al. Jan 2004 A1
20040259247 Tuschl et al. Dec 2004 A1
20060008910 MacLachlan et al. Jan 2006 A1
20060083780 Heyes et al. Apr 2006 A1
20060240093 MacLachlan et al. Oct 2006 A1
20060263435 Davis et al. Nov 2006 A1
20070004664 McSwiggen et al. Jan 2007 A1
20070031844 Khvorova et al. Feb 2007 A1
20070135372 MacLachlan et al. Jun 2007 A1
20070173473 McSwiggen et al. Jul 2007 A1
20070281899 Bumcrot et al. Dec 2007 A1
20080188675 Chen et al. Aug 2008 A1
20080249040 McSwiggen et al. Oct 2008 A1
20080253960 Zheng et al. Oct 2008 A1
20080306015 Khvorova et al. Dec 2008 A1
20090023215 Jessee et al. Jan 2009 A1
20090023673 Manoharan et al. Jan 2009 A1
20090142352 Jackson et al. Jun 2009 A1
20090149403 MacLachlan et al. Jun 2009 A1
20090291131 MacLachlan et al. Nov 2009 A1
20100010066 Fitzgerald et al. Jan 2010 A1
20100120893 Sah et al. May 2010 A1
20100130588 Yaworski et al. May 2010 A1
20100144834 Freier et al. Jun 2010 A1
20100168206 Gollob et al. Jul 2010 A1
20100324120 Chen et al. Dec 2010 A1
20110015250 Bumcrot et al. Jan 2011 A1
20110015252 Fitzgerald et al. Jan 2011 A1
20110065644 Xie et al. Mar 2011 A1
20120244207 Fitzgerald et al. Sep 2012 A1
20130035371 Fitzgerald et al. Feb 2013 A1
Foreign Referenced Citations (33)
Number Date Country
10100586 Nov 2002 DE
1 471 152 Oct 2004 EP
WO 9640964 Dec 1996 WO
WO 9932619 Jul 1999 WO
WO 9953050 Oct 1999 WO
WO 9961631 Dec 1999 WO
WO 0022113 Apr 2000 WO
WO 0022114 Apr 2000 WO
WO 0044895 Aug 2000 WO
WO 03070918 Aug 2003 WO
WO 2004065601 Aug 2004 WO
WO 2004080406 Sep 2004 WO
WO 2004090108 Oct 2004 WO
WO 2005014782 Feb 2005 WO
WO 2005120152 Dec 2005 WO
WO 2007012191 Feb 2007 WO
WO 2007056861 May 2007 WO
WO 2007115168 Oct 2007 WO
WO 2007134161 Nov 2007 WO
WO 2008011431 Jan 2008 WO
WO 2008042973 Apr 2008 WO
WO 2008109472 Sep 2008 WO
WO 2008109472 Sep 2008 WO
WO 2009086558 Jul 2009 WO
WO 2009111658 Sep 2009 WO
WO 2009127060 Oct 2009 WO
WO 2009134487 Nov 2009 WO
WO 2010054406 May 2010 WO
WO 2010088537 Aug 2010 WO
WO 2010129709 Nov 2010 WO
WO 2010144740 Dec 2010 WO
WO 2010147992 Dec 2010 WO
WO 2010148013 Dec 2010 WO
Non-Patent Literature Citations (111)
Entry
U.S. Office Action, U.S. Appl. No. 13/882,473, dated Oct. 16, 2015, seven pages.
U.S. Office Action, U.S. Appl. No. 14/058,052, dated Sep. 4, 2015, 15 pages.
Abifadel et al., “Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia”, Nature Genetics, 2003, vol. 34, pp. 154-156.
Agrawal S., et al., “Antisense oligonucleotides: towards clinical trials.” Trends in Biotechnology. 14: 376-87. Oct. 1996.
Akdim et al., “Antisense apolipoprotein B therapy: where do we stand?” Curr. Opin. Lipidol. 18:397-400, 2007.
Basak, A., “Inhibitors of Proprotein Convertases,” Journal of Molecular Medicine, 2002, vol. 83, pp. 844-855.
Bass, B., “The short answer,” Nature, May 24, 2001, pp. 428-429, vol. 411.
Benjannet, S. et al., “NARC-1/PCSK9 and Its Natural Mutants: Zymogen Cleavage and Effects on the Low Density Lipoprotein (LDL) Receptor and LDL Cholesterol,” Journal of Biological Chemistry, Nov. 19, 2004, pp. 48865-48875, vol. 279, No. 47.
Bergeron et al., “Subtilase-Like Pro-Protein Convertases: from Molecular Specificity to Therapeutic Applications,” Journal of Molecular Endocrinology, 2000, vol. 24, pp. 1-22.
Betteridge, D.J., et al., “Treatment of familial hypercholesterolemia. United Kingdom lipid clinics study or pravastatin and cholestyramine,” BMJ, May 23, 1992, pp. 1335-1338, vol. 304.
Chinese Office Action, Chinese Application No. 201310491236.5, Dec. 3, 2014, 9 pages (with concise explanation of relevance).
Cohen et al, “Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Mutations in PCSK9,” Nature Genetics, 2005, vol. 37, pp. 161-165.
Cohen et al., “Molecular Mechanisms of Autosomal Recessive Hypercholesterolemia,” Current Opinion in Lipidology, 2003, vol. 14, pp. 121-127.
Cohen et al., “Sequence Variations in PCSK9, Low LDL, and Protection Against Coronary Heart Disease,” New England Journal of Medicine, 2006, vol. 354, pp. 1264-1272.
Couture et al., “Anti-gene Therapy: The Use of Ribozymes to Inhibit Gene Function,” TIG, 1996, vol. 12, pp. 510-515.
Downward, “Science, Medicine, and the Future RNA Interference,” BMJ, vol. 328, pp. 1245-1248, 2004.
Dubuc et al., “Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, Journal of the American Heart Association, 2004, vol. 24, pp. 1454-1459.
Dubuc et al., Arteriosclerosis, Thrombosis, and Vascular Biology, Journal of the American Heart Association, 2004, 24, pp. 1454-1459.
Elbashir, S., et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,” Methods, 2002, pp. 199-213, vol. 26.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S., et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila melanogaster Embryo Lysate”, The EMBO Journal, 2001, pp. 6877-6888, vol. 20, No. 23.
Elbashir, S., et al., “RNA Interference is Mediated by 21-and 22 Nucleotide RNAs,” Genes & Development, 2001, pp. 188-200, vol. 15.
European Extended Search Report, European Application No. 11837272.1, dated Apr. 8, 2015, 7 pages.
European Extended Search Report, European Application No. 14173646.2, dated Jan. 14, 2015, 5 pages.
European Search Report, European Patent Application No. EP 09015323.0, dated Apr. 28, 2010, 7 Pages.
Examination Report for Australia Patent Application No. 572666, dated Jun. 1, 2010, 9 pages.
Examination Report for Australia Patent Application No. 572666, dated Sep. 21, 2010, 2 pages.
Examination Report for Australian Patent Application No. 2010241357, dated Aug. 8, 2012, 4 pages.
Examination Report for New Zealand Patent Application No. 587616, dated Dec. 20, 2011 2 pages.
Examination Report for New Zealand Patent Application No. 587616, dated Sep. 1, 2010, 2 pages.
Examination Report dated Dec. 20, 2011 for New Zealand Patent Application No. NZ 587616, 2 pages.
Extended European Search Report, European Patent Application No. 07762085.4, dated Sep. 25, 2009, 11 pages.
Extended European Search Report, European Patent Application No. 09015323.0, dated Apr. 28, 2010, 7 pages.
Extended European Search Report, European Patent Application No. 09739290.6, dated May 7, 2012, 11 pages.
Fire, A., “RNA-triggered Gene Silencing,” Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.
Fire, A., et al., “Potent and Specific Genetic Interference by Double Stranded RNA in Caenorhabditis elegans,” Nature, Feb. 19, 1998, pp. 806-811, vol. 391.
First Examination Report for India Patent Application No. IN 6166/CHENP/2008, Mar. 8, 2013, 2 Pages.
First Office Action for Chinese Patent Application No. CN 2007820024854.1, dated Jun. 27, 2011, 7 pages.
Fitzgerald et al., “Abstract 583: RNAi Therapeutics for the Lowering of Cholesterol,” Circulation, 2007, p. II.sub.-105, vol. 116.
Frank-Kamenetsky, M. et al., “Therapeutic RNAi Targeting PCSK9 Acutely Lowers Plasma Cholesterol in Rodents and LDL Cholesterol in Nonhuman Primates,” Proceedings of the National Academy of Sciences, Aug. 19, 2008, pp. 11915-11920, vol. 105, No. 33.
Gassman et al., “Maintenance of an Extrachromosomal Plasmid Vector in Mouse Embryonic Stem Cells,” Proc. Natl. Acad, Sci., 1995, vol. 92, pp. 1292-1296.
Genbank Accession No. Nm.sub.-174936. Homo sapiens proprotein convertase subtilisin/kexin type 9 (PCSK9), mRNA. Sep. 30, 2007, p. 1-5.
Gensberg, K., “Subtilisin-related serine proteases in the mammalian constitutive secretory pathway,” 1998, Semin. Cell Dev. Biol., vol. 9, pp. 11-17.
Graham et al., “Antisense Inhibition of Proprotein Convertase Subtilism/Kexin Type 9 Reduces Serum LDL in Hyperlipidemix Mice”, Journal of Lipid Research, 2007, vol. 48, pp. 767-769.
Harborth, J., et al., “Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing,” Antisense & Nucleic Acid Drug Development, Apr. 1, 2003, pp. 83-105, vol. 13, No. 2.
Heyes, J., et al., “Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids,” Journal of Controlled Release, 2005, pp. 276-287, vol. 107.
Hornung, V., et al., “Sequence-specific potent induction of IFN-.alpha. By short interfering RNA in plasmacytoid dendritic cells throughTLR7,” Nature Medicine, Mar. 2005, pp. 263-270, vol. 11, No. 3.
Horton, J., et al., “Molecular biology of PCSK9: its role in LDL metabolism,” Trends in Biochemical Sciences 32(2):71-77, 2006.
Japanese Patent Office, Notice of Reasons for Rejection, Japanese Patent Application No. 2009/510173, dated Nov. 14, 2012, 15 Pages.
Judge, A.D., et al., “Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice,” The Journal of Clinical Investigation, vol. 119, No. 3, pp. 661-673, Mar. 2009.
Korean Intellectual Property Office, Notice of Preliminary Rejection, Korean Patent Application No. 10-2010-7013424, dated Nov. 10, 2012, 11 Pages.
Lagace et al., “Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice,” J Clin Invest. 116:2995-3005, 2006.
Lalanne, F., et al., “Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells,” Journal of Lipid Research, vol. 46, No. 6, pp. 1312-1319, Jun. 2005.
Leren, “Mutations in the PCSK9 Gene in Norwegian Subjects with Autosomal Dominant Hypercholesterolemia,” Clinical Genetics, 2004, vol. 65, pp. 419-422.
Li et al., “Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells,” Phar. Research, 1998, vol. 15, pp. 1540-1545.
Li, H. et al., “Recent Patents on PCSK9: a New Target for Treating Hypercholesterolemia,” Recent Patents on DNA & Gene Sequences, Nov. 1, 2009, pp. 201-212, vol. 3, No. 3.
Love et al., “Lipid-like materials for low-dose, in vivo gene silencing,” PNAS, Feb. 2, 2010, pp. 1864-1869, vol. 107, No. 5.
Lu et al., “Delivering siRNA in Vivo for Functional Genomics and Novel Therapeutics in RNA Interference Technology”, Cambridge, Appasani, 2005, pp. 303-317.
Manoharan, “Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action,” Antisense & Nucleic Acid Drug Development, 2002, vol. 12, pp. 103-128.
Maxwell et al., “Adenoviral-Mediated Expression of Pcsk9 in Mice Results in a Low-Density LipoProtein Receptor Knockout Phenotype,” Proc. Acad. Sci. USA, 2004, vol. 101, pp. 7100-7105.
Maxwell et al., “Novel Putative SREBP and LXR Target Genes Identified by Microarray Analysis in Liver of Cholesterol-Fed Mice,” Journal of Lipid Research, 2003, vol. 44, pp. 2109-2119.
Morrissey et al., “Potent and Persistent in Vivo Anti-HBV Activity of Chemically Modified siRNAs,” Nature Biotechnology, 2005, vol. 23, pp. 1002-1007.
NM 153565, NCBI, 2006, pp. 1-4.
NM 174936, NCBI, 2006, pp. 1-5.
NM 199253, NCBI, 2006, pp. 1-4.
Notice of Preliminary Rejection for Korea Patent Application No. 10-2008-7030164, dated Aug. 13, 2010, 11 pages.
Office Action for Canada Patent Application No. CA 2,651,839, dated Sep. 6, 2011, 3 pages.
Official Action for Eurasian Patent Application No. 200870528, dated Oct. 4, 2010, 3 pages.
Park et al., “Post-Transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver,” Journal of Biological Chemistry, 2004, vol. 279, pp. 50630-50638.
PCT International Search Report and Written Opinion, PCT/US2007/068655, dated Oct. 29, 2007, 15 pages.
PCT International Search Report and Written Opinion, PCT/US2009/032743, Dec. 10, 2009, 10 Pages.
PCT International Search Report and Written Opinion, PCT/US2010/038679, dated Aug. 30, 2010, 9 Pages.
PCT International Search Report and Written Opinion, PCT/US2010/038707, dated Dec. 16, 2010, 18 Pages.
PCT International Search Report and Written Opinion, PCT/US2010/047726, dated Dec. 13, 2010, 18 Pages.
PCT International Search Report and Written Opinion, PCT/US2011/058682, dated May 25, 2012, 13 pages.
PCT Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, PCT/US2009/032743, dated Sep. 17, 2009, 2 Pages.
PCT Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, PCT/US2010/038707, dated Oct. 14, 2010, 2 pages.
Rader et al., “Monogenic Hypercholesterolemia: New Insights in Pathogenesis and Treatment,” Journal of Clinical Investigation, 2003, vol. 111, pp. 1795-1803.
Rashid et al., “Decreased Plasma Cholesterol and Hypersensitivity to Statins in Mice Lacking Pcsk9,” PNAS, 2005, vol. 102, pp. 5374-5379.
Reynolds et al., “Rational siRNA design for RNA interference,” Nature Biotechnology, 2004, vol. 22, No. 3, pp. 326-330.
Robbins, M., et al., “Stable expression of shRNAs in human CD34.sup.+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro,” Nature Biotechnology, May 2006, pp. 566-571, vol. 24, No. 5.
Rose, S., et al., “Functional polarity is introduced by Dicer processing of short substrate RNAs,” Nucleic Acids Research, 2005, pp. 4140-4156, vol. 33, No. 13.
Samarsky et al., “RNAi in Drug development: Practical Considerations in RNA Interference Technology,” Cambridge, Appasani, 2005, pp. 384-395.
Sauer et al., “An Apolipoprotein E-Derived Peptide Mediates Uptake of Sterically Stabilized Liposomes into Brain Capillary Endothelial Cells,” Biochemistry, 2005, pp. 2021-2029, vol. 44.
Search Report and Written Opinion for Singaporean Patent Application No. 201103340-4, dated Jul. 6, 2012, 2 pages.
Seidah et al., “Proprotein and Prohormone Convertases: A Family of Subtilases Generating Diverse Bioactive Polypeptides,” Brain Research, 1999, vol. 848, pp. 45-62.
Semple et al., “Rational design of cationic lipids for siRNA delivery,” Nature Biotechnology 28(2):172-178, Feb. 2010.
Shioji et al., “Genetic Variants in PCSK9 Affect the Cholesterol Level in Japanese,” J. Hum Genet, 2004, vol. 49, pp. 109-114.
Supplementary European Search Report, EP 07762085, dated Sep. 25, 2009, 11 Pages.
Taylor et al., “Curbing Activation:proprotein Convertases in Homeostasis and Pathology,” FASEB, vol. 17, pp. 1215-1227, 2003.
Templeton et al., “Improved DNA: Liposome Complexes for Increased Systemic Delivery and Gene Expression,” Nature Biotechnology, 1997, vol. 15, pp. 647-652.
Timms et al., “A Mutation in PCSK9 Causing Autosomal-Dominant Hypercholesterolemia in a Utah Pedigree,” Humm Genet, 2004, vol. 114, pp. 349-353.
Tuschl, T., “Expanding small RNA interference,” Nature Biotechnology, vol. 20:446-448 (2002).
Tuschl, T., “Mammalian RNA Interference,” RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.
Tuschl, T., “RNA Interference and Small Interfering RNAs,” Chembiochem, 2001, vol. 2, pp. 239-245.
Tuschl, T., et al., “Functional genomics: RNA sets the standard,” Nature, Jan. 2003, vol. 421, pp. 220-221.
Tuschl, T., et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.
Tuschl, T., et al., “Targeted mRNA Degradation by Double-Stranded RNA in Vitro,” Genes & Development, 1999, pp. 3191-3197, vol. 13.
U.S. Office Action, U.S. Appl. No. 11/746,864, dated Mar. 26, 2008, 18 pages.
U.S. Office Action, U.S. Appl. No. 12/478,452, dated Mar. 25, 2011, 16 Pages.
U.S. Office Action, U.S. Appl. No. 12/554,231, dated Aug. 30, 2011, 12 pages.
U.S. Office Action, U.S. Appl. No. 12/816,207, dated Jul. 25, 2011, 13 Pages.
U.S. Office Action, U.S. Appl. No. 12/900,430, dated Apr. 20, 2012, 17 pages.
U.S. Office Action, U.S. Appl. No. 13/245,730, dated Jul. 20, 2012, 21 pages.
U.S. Office Action, U.S. Appl. No. 13/245,730, dated Mar. 1, 2013, 13 pages.
U.S. Office Action, U.S. Appl. No. 13/472,438, dated Nov. 7, 2013, 10 pages.
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
Weil et al., “Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells,” Biotechniques 33(6):1244-1248, 2002.
Yang et al., “Evidence that Processed Small dsRNAs May Mediate Sequence-Specific mRNA Degradation During RNAi in Drosophila Embryos,” Current Biology, 2000, vol. 10, pp. 1191-1200.
Zhou et al., “Proteolytic Processing in the Secretory Pathway,” Journal of Biological Chemistry, 1999, vol. 274, pp. 20745-20748.
Zimmerman et al., “RNAi-mediated gene silencing in non-human primates,” Nature, May 4, 2006, pp. 111-114, with supplementary information, vol. 441.
Related Publications (1)
Number Date Country
20160348117 A1 Dec 2016 US
Provisional Applications (5)
Number Date Country
60799458 May 2006 US
60817203 Jun 2006 US
60840089 Aug 2006 US
60829914 Oct 2006 US
60901134 Feb 2007 US
Divisions (1)
Number Date Country
Parent 11746864 May 2007 US
Child 12554231 US
Continuations (3)
Number Date Country
Parent 14330923 Jul 2014 US
Child 15005933 US
Parent 13472438 May 2012 US
Child 14330923 US
Parent 12554231 Sep 2009 US
Child 13472438 US